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ABSTRACT  
Dietary Restriction (DR), defined as reduced food intake without malnutrition, was 
first described nearly a century ago to extend lifespan in rats. Since then, DR has been 
extensively studied, in a multitude of organisms, and evidence supports that DR increases 
lifespan and confers protection against age-associated diseases such as hypertension, 
ischemia of the limbs, heart or brain.  
Angiogenesis, the formation of new blood vessels by endothelial cells (EC), is crucial 
for the protection and recovery from blood vessel occlusion. Hypoxia is the best understood 
pro-angiogenic trigger, but therapies targeting this pathway have largely failed to 
demonstrate long-term benefits. 
Here, we hypothesized that a nutrient-based pathway regulates angiogenesis 
independent of hypoxia. We found that dietary sulfur amino acid restriction (methionine and 
cysteine) promoted VEGF expression and capillary growth in skeletal muscle of mice 
independent of hypoxia or the transcription factor HIF1α, instead requiring the amino acid-
sensing translation initiation factor eIF2α kinase GCN2 and the transcription factor ATF4. 
GCN2/ATF4 activation increased cystathionine-γ-lyase expression and pro-angiogenic 
hydrogen sulfide (H2S) production. In human EC, H2S boosted glycolytic ATP production by 
inhibiting mitochondrial electron transport, and was required for angiogenesis triggered by 
amino acid deprivation, exercise or local VEGF overexpression.  
H2S is an endogenously produced gas with broad protective effects on the vascular 
system, and can be measured in blood serum. Using a cohort of patients undergoing 
vascular surgery (for advanced occlusive disease) and matched healthy patients, we found 
that healthy patients had the highest serum H2S production. Importantly, among patients 
that underwent surgery for vascular disease, the percentage of survival in the low H2S 
(defined as < median) was lower compared to high H2S (defined as > median) suggesting 
that it may serve as an easily quantified measure with biological significance with regards to 
vascular health.  
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RESUME 
 La restriction alimentaire (RA), définie comme une réduction des apports 
alimentaires sans malnutrition, fut décrite il y a près d'un siècle. Depuis, la RA a été étudiée 
dans une multitude d'organismes, démontrant que la RA permet d’augmenter l’espérance de 
vie et de protéger contre les maladies associées à l'âge telles que l'hypertension, l'ischémie 
cardiaque, cérébrale et des membres inférieurs. 
 L'angiogenèse, soit la formation de nouveaux vaisseaux sanguins par les cellules 
endothéliales (EC), protège et facilite la récupération lors d’une occlusion vasculaire 
(ischémie). L'hypoxie est le stimulus pro-angiogénique le plus étudié; cependant, les 
thérapies ciblant cette voie ont à l’heure actuelle largement échouées. Nous avons donc émis 
l'hypothèse qu'une voie indépendante, nutrio-sensible, pouvait réguler la formation de 
nouveaux vaisseaux. Nos résultats suggèrent que la restriction d’acides aminés soufrés 
(méthionine et cystéine) favorise l'expression du factor de croissance vasculaire VEGF et la 
croissance capillaire in-vivo, indépendamment de l'hypoxie ou de l'HIF1α mais nécessitant la 
kinase GCN2 et le facteur de transcription ATF4. 
 L'activation de GCN2/ATF4 augmente l'expression de cystathionine-y-lyase et la 
production de sulfure d'hydrogène (H2S), connu pour ses propriétés pro-angiogéniques. Dans 
les EC humaines, le H2S favorise l’angiogenèse en inhibant le transport d'électrons 
mitochondrials, stimulant la production d'ATP glycolytique. 
 H2S est un gaz produit de manière endogène avec des effets protecteurs sur le 
système vasculaire, et peut être mesuré dans le sérum. Dans une cohorte de patients 
hospitalisés pour une maladie vasculaire occlusive avancée et de patients sains nous avons 
constaté que les taux sériques d’H2S étaient plus élevés chez les patients sains. De plus, 
parmi les patients qui ont subi une intervention chirurgicale pour les maladies vasculaires, la 
survie à 6 et 24 mois était plus élevée chez les patients avec un taux préopératoire élevé 
d’H2S. En conclusion, nos résultats démontre qu’une RA, via H2S participent à la fonction du 
système vasculaire et pourrait jouer un rôle majeur dans la survie/ récupération des patients 
ayant subi un intervention vasculaire. 
AASR   Amino acid starvation response 
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ABBREVIATIONS 
AMPK   AMP-activated kinase 
ATF4   Activating transcription factor 4 
CBS   Cystathionine β- synthase  
CGL (CSE, CTH) Cystathionine-gamma-lyase 
CPT1   Carnitine palmitoyltransferase 1 
Cyst   Cysteine 
DR   Dietary restriction 
EC   Endothelial cell 
eIF2α   Eukaryotic translation initiation factor α 
ERAS   Enhanced recovery after surgery 
FAO   Fatty acid oxidation 
FGF21   Fibrobalst growth factor 21 
GCN2   General control nonderepressible 2 
H2S   Hydrogen Sulfide 
HUVECs   Human Umbilical Vein Endothelial Cells  
IGF-1   Insulin growth factor-1 
IRI   Ischemia Reperfusion Injury 
Met   Methionine 
MR   Methionine Restriction 
mTORC  Mechanistic target of rapamycin 
NO   Nitric Oxide 
PAD   Peripheral artery disease 
RA   Restriction alimentaire 
VEGF   Vascular endothelial growth factor 
VEGR2  Vascular endothelial growth factor receptor 2 
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INTRODUCTION  
Dietary restriction 
When the food intake of an organism is reduced to below what they would eat if given unlimited 
access to food, but not so much that they are malnourished, they age at a slower rate and live 
longer (1). This phenomenon of dietary restriction (DR), defined as reduced nutrient/energy 
intake without malnutrition, is the most potent intervention to increase lifespan and decrease the 
incidence and severity of age-related diseases from single-celled yeast to fruit flies to non-
human primates (2).  
While long term DR prolong life, more recent data indicate that short-term DR (in the 
range of days to weeks) can increases resistance to multiple forms of stress, that range from 
chemotherapy to surgical ischemia reperfusion injury (IRI) (8–11). For example, 2-4 days of 
water-only fasting is sufficient for protection in models of IRI to the liver or the kidney, a model 
that is relevant to organ transplantation (3). Similarly, 6-7 days of reduced total food or isolated 
protein intake protects against warm ischemia reperfusion injury to brain, liver or kidney (4-6). 
Importantly, short-term protein restriction or fasting also protect from chronic re-occlusive 
vascular wall adaptations, such as intimal hyperplasia, which can result in recurrent end-organ 
ischemia, loss of limb, reduced brain function, or even death (7).  
 Despite strong evidence of the evolutionary conservation of DR benefits in humans (8), 
voluntary food restriction is impractical for most people. Thus, uncovering common nutritional 
and molecular mechanisms that require either minimal dietary alterations, or can be targeted by 
pharmacological interventions, is of great significance (9, 10). 
 
Nutritional requisite 
Although protein is equal in caloric content to carbohydrate, restriction of protein (but not 
sugar or fat) contribute to dietary preconditioning beyond its caloric value (Figure 1) (4, 11). 
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Importantly, preconditioning against surgical stress in rodents can be achieved without enforced 
food restriction (caloric restriction) by using diets reduced in or lacking protein (amino acid 
restriction, protein free regimen, Figure 1). This is an important difference when considering 
clinical translational potential due to the difficulties inherent in enforced restriction of food intake 
even for short periods of time.  
It is also important to note that different organs can have different requirements for 
protection even against the same injury. For example, while in the renal IRI model both protein 
and calorie restriction contribute additively to organ protection (12), protein restriction alone 
contributes disproportionately to organ protection against hepatic IRI (11). Much future work is 
required in order to determine the optimal balance of calories from protein vs. sugar and fat, as 
well as the total calorie intake, for optimal stress resistance, which itself will likely depend on the 
specific surgery as well as patient-specific risk factors. 
 
Methionine	  restriction	  
Restriction of sulfur amino acids methionine (Met) and cysteine (Cys) is common to 
numerous DR regimens across evolutionary boundaries and is thus a potential shared 
nutritional trigger of DR benefits. Orentreich's initial studies demonstrated that the inception of 
methionine restriction (MR) early in life increased median and maximum lifespan by 30 and 
Figure 1:  Schematic of 
diets in which 18% of 
calories are contributed by 
protein (complete), 
sucrose (PF), NEAAs 
(NEAA only), or EEAs 
(EAA only, top). Mice 
preconditioned with these 
diets were protected 
against various form of 
surgical stress (bottom), 
including ischemia 
reperfusion injury to the 
heart, brain, liver, kidney 
or limbs.  
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40%, respectively (13). In mammals, MR benefits actually require combined methionine and 
cysteine restrictions (14), and thus could be more accurately referred to as sulfur amino acid 
(SAA) restriction. MR also extends lifespan and stress resistance in yeast (15) flies (16), worms 
(17) and rodents (13, 18). In humans, MR has been used to complement cancer treatment (19) 
and to improve metabolic fitness (20, 21). Evidence in favor of a mechanistic overlap stems 
from fly studies, in which DR-mediated lifespan extension can be abrogated by giving essential 
amino acids (EAA) including Met, but not EAA lacking Met (22). We also recently showed SAA 
abrogated benefits of stress resistance in mice (23, 24). 	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Amino acid sensing and molecular basis for DR benefits  
 
The ability to sense and respond to fluctuations in environmental nutrient levels is 
requisite for life (25). During food excess, nutrient-sensing pathways engage anabolism and 
storage, whereas scarcity triggers nutrient mobilization via internal storage degradation. In the 
context of DR, it is therefore coherent that the same pathways sensing nutrients are involved in 
DR benefits.  
 	    
Figure 2: Effects of dietary restriction on surgical stress. A, model of the metabolic response to 
surgical stress. Surgery perturbs metabolic and immune homeostasis through effects on afferent 
(autonomic and sympathetic) nerve input from the area of trauma leading to local and systemic 
catecholamine release, increased levels of proinflammatory acute phase reactants, metabolic 
adaptations including glycogen mobilization, and vascular changes including vasoconstriction and 
increased heart rate. Parallel activation of the hypothalamic-anterior pituitary-adrenomedullary axis 
promotes release of cortisol from the adrenal cortex, resulting in a partially counterbalancing response 
characterized by protein and fat mobilization, immunosuppression, and dampening of the action of 
anabolic hormones such as IGF1/insulin and testosterone. B, Conserved molecular signaling that 
regulate longevity and and stress resistance in vertebrates. Dietary restriction controls the activity of 
various signal transduction pathways either directly or indirectly through the reduced levels of 
circulating growth factors such as IGF-1 and the thyroid hormone thyroxine (T4) and triiodothyronine 
(T3). In this model propose that the mechanism of surgical stress resistance caused by modulation of 
these nutrient signaling pathways include a transient increase in free radical superoxide (ROS) and 
hydrogen sulfide (H2S) production. Sirt 1 indicates Sirtuin 1; AMPK, AMP-activated protein kinase; 
FOXO, forkhead box O transcription factors; IGF-1, insulin-like growth factor 1; mTOR, mammalian 
target of rapamycin; S6K, S6 kinase; GCN2, general control nonderepressible 2; ATF4, Activating 
Transcription Factor 4 ROS, reactive oxygen species; H2S, hydrogen sulfide. 
 12 
General control nonderepressible 2:  
Proteins are synthetized in the ribosome, which incorporates amino acids into a nascent 
polypeptide by the sequential binding of a specific transfer RNA (tRNA) covalently linked to its 
cognate amino acid. Amino-acid-specific aminoacyl tRNA synthetases (aaRSs) execute the 
loading of amino acids to their cognate tRNAs, and uncharged tRNAs accumulate when levels 
of free amino acids are minimal. The general control nonderepressible 2 (Gcn2) protein is a 
serine/threonine protein kinase that contains two central regulatory regions, a histidyl-tRNA 
synthetase-like domain (HisRS) and a C-terminal domain (CTD), which function together to 
sense nutrient depletion(26-30). Typically upon DR, low levels of one or more amino acids 
promote accumulation of uncharged cognate tRNAs. Uncharged tRNAs directly activate the 
kinase domain of GCN2, facilitating phosphorylation of the eukaryotic translation initiation factor 
α (eIF2α). Phosphorylated eIF2α reduces general translation initiation efficiency, it promotes 
translational up-regulation mRNAs with specific regulatory sequences upstream of the initiating 
Met codon, including the activating transcription factor 4 (ATF4) (31). ATF4 in turns stimulates 
expression of target genes involved in non-essential amino acid biosynthesis, amino acid 
transport, collectively known as the amino acid starvation response (30) (Figure 2). 
Interestingly, deprivation of a single amino acid can result in deacylation of non-cognate tRNAs 
as well. For example, leucine starvation of auxotrophic yeast results in accumulation of 
uncharged serine and threonine tRNAs in addition to leucine tRNAs (30, 32).   
 Because GCN2 regulates adaptive changes to perceived amino acid deficiency, mice 
lacking this protein appear normal in the absence of such a challenge. This is not the case for 
one of its downstream effectors, ATF4. ATF4-knockout mice display multiple developmental 
abnormalities and are smaller than control littermates (33). Cells lacking ATF4 require excess 
non-EAAs including cysteine (or antioxidants such as glutathione or N-acetylcysteine) (34). In 
addition, cells lacking ATF4 have reduced levels of CSE, the enzyme responsible for the 
 13 
conversion of cystathionine to cysteine (35). Moreover, elevated ATF4 levels have been 
described in liver and isolated fibroblasts of long-lived, stress-resistant rodent models including 
hypopituitary Snell dwarf mice (36), and are associated with extended longevity upon nutrient 
deprivation, altered ribosomal function, or rapamycin treatment in yeast (37). 
In the context of dietary preconditioning against IRI, GCN2 is required for protection from 
renal and hepatic ischemia reperfusion injury induced by dietary tryptophan deficiency (4). 
However, GCN2 does not appear to be required for preconditioning by total protein deprivation 
(11, 12), likely due to redundancy in protein-sensing mechanisms including mTORC1 as 
described below. GCN2 can also be activated pharmacologically by the proline tRNA synthase 
inhibitor halofuginione (38). In mice, pretreatment with halofuginone protects against renal IRI in 
a GCN2-dependent manner (4).  
 
Mechanistic target of rapamycin complex 1:  
In all eukaryotes, the mechanistic target of rapamycin (mTOR) is a conserved Ser/Thr 
kinase comprised of three essential and evolutionarily conserved core subunits (mTOR, Raptor 
and mLST8) forming mTOR complex 1 (mTORC1). This kinase integrates information on 
energy, amino acid and growth factor availability to cell fate decisions regarding anabolism or 
catabolism, including cell growth and autophagy (39-42). Under nutrient/energy restriction, 
mTORC1 is activated to stimulate anabolic processes that convert nutrients and energy into 
macromolecules, including protein, lipid and nucleic acids (Figure 2). Interestingly, while GCN2 
can detect the absence of any amino acid, the presence of specific amino acids such as leucine 
(43, 44) or argininie (45) is sensed specifically by the protein complex mTORC1.  
At the lysosome level, entry of amino acids, promotes Ragulator activity. In this manner, 
amino acids stimulate the formation of RagA/BGTP–RagC/DGDP heterodimers, which bind directly 
to mTORC1 and recruit the inactive kinase complex to the lysosomal surface for its activation. 
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Activated mTORC1 promotes protein synthesis via mRNA translation through two sets of direct 
downstream targets: the eukaryotic initiation factor 4E (eIF4E)-binding proteins (4E–BP1 and 2) 
and the ribosomal S6 kinases (S6K1 and 2)(25, 39, 40, 46-48).  
In the context of DR inhibition of mTORC1 (49, 50) or its direct target, S6K (51) 
promotes lifespan and healthspan. Importantly, we recently showed that in mice, one week on 
protein free diet reduced hepatic mTORC1, coinciding with protection against hepatic IRI (11). 
Whether this is a direct result of reduced amino acid (leucine) levels, or more likely a reduction 
of growth factor levels also required for mTORC1 activation, remains to be determined. 
However consistent with the importance of reduced mTORC1 in dietary preconditioning, liver-
specific deletion of the upstream mTORC1 repressor gene TSC1 (The LTsc1KO mice), results 
in constitutive hepatic mTORC1 activation independent of diet, and prevents protein restriction 
from preconditioning against hepatic IRI (11, 24). Rapamycin (Sirolimus) is a partial mTORC1 
inhibitor used in humans to prevent T and B cell-mediated organ transplant rejection, and also 
as a vascular stent coating to prevent intimal hyperplasia (52). In mice, long-term rapamycin 
treatment extends longevity (49, 50), but does not protect mice from hepatic IRI despite 
reducing hepatic mTORC1 signaling (11).  
 
AMP-activated kinase:  
AMP-activated kinase (AMPK) is a conserved energy-sensing protein kinase present in 
all eukaryotes as heterotrimers comprising catalytic α subunit and regulatory β and γ subunits. 
AMPK is allosterically activated when cellular energy is low via AMP and/or ADP as well as by 
several upstream kinases, e.g. serine/threonine kinase 11 (LKB1), Ca2+/calmodulin-dependent 
protein kinase kinase β (CaMKKβ) and transforming growth factor-β-activated kinase 1 
(TAK1)(53). It also reduces anabolic mTORC1 signaling by phosphorylating the mTORC1 
inhibitor, TSC2.  
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Activation of AMPK promotes energy production by increasing glucose uptake in the 
short term and facilitating a switch to oxidative metabolism in the long term. 
AMPK is activated upon fasting or DR regimens involving enforced food restriction 
(Figure 2); somewhat surprisingly it is also activated upon protein restriction independent of 
calorie intake (12). Due to essential nature of AMPK function and redundancy in catalytic AMPK 
subunit genes, genetic experiments to test the requirement in dietary preconditioning have not 
yet been performed. However, AMPK activation by the allosteric activator 5-aminoimidazole-4-
carboxamide ribonucleotide (AICAR) protects against ischemic injury in rats when given at high 
doses before injury (54). AMPK activation by the endogenous lipokine adiponectin, which is 
increased upon DR, is also essential for the cardioprotective effects of DR against myocardial 
infarction (55) 
 
Hydrogen Sulfide 
Hydrogen sulfide (H2S) is a gas easily identified by its distinctive odor of rotten eggs. 
While toxic at high levels, H2S produced endogenously by CGL or CBS (Figure 4) acts on the 
vasculature and the brain as a signaling molecule to reduce blood pressure (56) and prevent 
neurodegeneration (57). Low levels of exogenous H2S also extends lifespan of worms (18, 24) 
and induce suspended animation in mammals (58). H2S has numerous other cardiovascular 
benefits, including pro-angiogenesis in vitro and in vivo (59, 60), reduced vascular restenosis 
Figure 3: Model of the transmethylation and transsulfuration pathway (TSP). Arrows trace sulfur from 
Met to Cys through various metabolites and downstream cellular processes via the enzymes 
Cystathionine Beta- Synthase (CBS) and Cystathionine Gamma-Lyase (CGL). Metabolites in green 
(taurine, GSH and H2S) have demonstrated potential to protect against IRI. MAT: methionine adenosyl 
transferase, SAM: S- Adenosylmethionine, SAH: S-Adenosylhomocysteine, SAHH: S-
adenosylhomocysteine hydrolase, MS: Methionine synthase, BHMT: Betaine homocysteine 
methyltransferase.  Picture and Legend from Hine et al, Cell 2015. 
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(intimal hyperplasia)(61, 62), anti‐atherosclerotic activity (63), and reduced binding of 
neutrophils to the wall of blood vessel (64). On the other hand, in humans, serum H2S 
concentration declines with age (65) and the levels of the H2S producing enzymes are reduced 
in patients suffering vascular diseases (66, 67). We have recently demonstrated that mice 
lacking the H2S-producing enzyme CGL fail to gain the protective effects of DR, while adenoviral 
overexpression of CGL in the liver, or delivery of H2S itself, recapitulate DR-like benefits without 
the need for any dietary intervention (24). Thus, a model has emerged in which the well-known 
benefits of multiple DR regimens are linked to a common effector molecule: endogenous H2S 
gas produced as part of an adaptive response to nutrient/energy deficiency. 
Whether free H2S is a circulating gasotransmitter that acts as a paracrine, or autocrine 
molecule is still being debated and difficult to address (68, 69). However, the enzyme CGL 
secreted by endothelial cells (EC)s and hepatocytes circulates in the plasma/serum, and 
actively produces H2S in human blood (70), which may be critical for the systemic vascular 
benefits of H2S (71). H2S has many potential mechanisms of action, including sulfhydration, or 
formation of –SSH moieties on surface-exposed Cys residues, of an ever-growing list of protein 
targets (57, 68, 72-75). In ECs, for example, such targets include the Kir6.2 regulatory subunit 
of the KATP channel and the VEGF receptor leading to vessel relaxation and angiogenesis, 
respectively (73, 75). H2S also has direct antioxidant properties, and can participate in 
mitochondrial energy production by donating electrons to the mitochondrial electron transport 
chain protein SQR, with a potential role in protection from organ ischemia (76, 77).  
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Angiogenesis 
Structure of the vasculature 
 The vascular system of the human body is comprised of an extensive network of 
arteries, capillaries, and veins that deliver oxygen and nutrients to every part of the body, 
remove waste and provide gateways for patrolling immune cells (78) (Figure 4). Small blood 
vessels (capillaries), consist only of endothelial cells (ECs), whereas larger vessels are 
organized in three distinct histological layers (Figure 4, right): the intima, the media and the 
adventitia. The intima, consists of a single layer of ECs surrounded by circularly arranged elastic 
bands or internal elastic laminae. The media mainly consists of SMCs and, which controls the 
caliber of the vessel. The external layer is entirely made of connective tissue. It also contains 
nerves and capillaries supplying vessel, especially in the larger vessels. 
 
Endothelial cells 
The endothelium, line the inner surface of all vessel. It is not only a barrier, between the 
circulating blood and organs but has a central role in maintain vascular homeostasis. It secretes 
numerous para-, endo- and auto-crine molecules such as nitric oxide (NO) (79) and H2S (68). 
ECs are plastic cells, that can switch between growth states (80), and undergo multiple 
Figure 4: Left: The vascular tree. Graphical representation of the major arteries, from the aorta to small 
sized arteries to the capillaries, formed of one single layer of endothelial cells. Picture adapted from: 
https://www.flickr.com/photos/43635707@N00/131520207/in/photostream/.  
Right: Schematic of an artery: The inner layer (intima) is formed by the endothelium, separated to the 
media by the internal elastic laminae. The media containing smooth muscle cells (SMCs) is lining on the 
external elastic laminae. The outer layer, the adventitia consists of connective tissue including 
fibroblasts. 	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developmental and functional transitions during fetal, neonatal and adult life. This plasticity is 
crucial to maintain a healthy microvascular network, providing adequate blood supply to organs 
throughout life and during metabolic stresses (81). Inadequate vessel maintenance or growth 
causes ischemia in diseases such as myocardial infarction, stroke, and neurodegenerative or 
obesity-associated disorders, whereas excessive vascular growth or abnormal remodeling 
promotes many ailments including cancer, inflammatory disorders, and eye disease (82).  
 
Mechanism 
Angiogenesis is the formation or sprouting of new blood vessels from existing ones. 
Perhaps most well characterized mechanism is oxygen deprivation (hypoxia) that stabilizes the 
transcription factor hypoxia inducible factor 1 (HIF1α, (83), stimulating proangiogenic signals 
such as vascular endothelial growth factor (VEGF). Upon stimulation, ECs become motile, 
invasive and protrude filopodia (Figure 5). These tip cells at the forefront of the vascular branch 
extend long filopodia and navigate but rarely proliferate, probing the environment for guidance 
Figure 5: A: Steps of vessel sprouting: (1) tip/stalk cell selection; (2) tip cell navigation and stalk cell 
proliferation; (3) branching coordination; (4) stalk elongation, tip cell fusion, and lumen formation; and 
(5) perfusion and vessel maturation. Picture and legend from Potente M et al., Cell 2011. B: 
Schematic overview of a growing vessel sprout. In tip cells at the leading front of a newly formed 
vessel sprout, binding of VEGF to VEGFR2 induces upregulation of Dll4. In the adjacent EC, Dll4-
dependent activation of Notch decreases the expression of VEGFR2, thereby preventing this EC to 
adopt a tip cell phenotype and inducing stalk cell differentiation. Stalk cells proliferate and elongate the 
sprout. Quiescent “phalanx” cells line established vessels (bottom). VEGFR2 signaling in the tip cells 
also increases the expression of the glycolytic enzyme PFKFB3 and enhances glycolytic energy 
production. Glycolytic enzymes are concentrated in the lamellipodia and filopodia, colocalizing with 
actin filaments (F-actin). This compartmentalization of glycolysis with F-actin provides local, rapid ATP 
production needed for actin-cytoskeletal remodeling required for migration. Tip cell is indicated in 
yellow, stalk cells in green, and phalanx cells in orange. Picture and legend from Vandekeere S et al., 
Microcirulation 2016 	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cues (82, 84). Following tip cells, stalk cells proliferate, elongate some filopodia and establish a 
lumen. Finally, blood flow, the establishment of a basement membrane, and the recruitment of 
mural cells (pericyte) stabilize new connections (Figure 5) (82). The sprouting process iterates 
until the hypoxia is relieved by subsequent improved tissue perfusion, abrogating proangiogenic 
signals and re-establishing quiescence.  
VEGF 
Given the complexity of a process such as angiogenesis, it is remarkable that a single 
growth factor, VEGF, regulates angiogenesis so predominantly. VEGF (also known as VEGF-A) 
is the main component of the VEGF family. The major proangiogenic signal is generated from 
the ligand-activated VEGF receptor-2 (VEGFR-2, also known as FLK1) (85). Neuropilins such 
as NRP1 and NRP2 are VEGF co-receptors, which enhance the activity of VEGFR-2. Similar to 
VEGFR-2 deficiency, the loss of VEGF aborts vascular development (84). VEGF is also 
reduced in diabetic patients, which correlates with poor angiogenesis following soft tissue injury 
and impaired wound healing (86, 87). Activating VEGFR-2 mutations cause vascular tumours 
(88). VEGFRs are tyrosine kinase receptors carrying an extracellular domain for ligand binding, 
a transmembrane domain, and a cytoplasmic domain, including a tyrosine kinase domain. The 
cytoplasmic domain harbors binding site for the SH2 domain of the p85 subunit in the PI3-
kinase complex and to activate the PI3K pathway, crucial for ECs growth (89). In addition, the 
SH2 domain of PLCγ binds to the 1175-PY site of VEGFR-2. The PLCγ-PKC-MAPK pathway is 
highly activated upon VEGF bounding and is a crucial signal for ECs proliferation (90, 91). 
Interestingly, VEGF stimulates H2S production from EC. In turn, H2S sulfhydrates the VEGFR2, 
that increases its dimerization, trans-autophosphorylation and activation (73).  
Metabolic requirements 
Blood vessels transport nutrients to energy-utilizing tissues, and hence, vessels as well 
as proangiogenic signals can affect metabolism (92). The opposite is also true, where metabolic 
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node affects vessel growth. For example, in condition of nutrient deprivation, the PGC-1a/ERR-
a pathway mediates exercise-induced angiogenesis (93). Similarly, energy deprivation, 
increases cellular levels of AMP, activating AMPK, which induces VEGF-driven angiogenesis 
(82). Moreover, FOXO1 transcription factor, unregulated during fasting, promotes endothelial 
quiescence by antagonizing MYC, which leads to a coordinated reduction in the proliferative 
and metabolic activity of ECs (94). Interestingly, FOXO is controlled by SIRT1, a member of the 
sirtuin family of NAD+-dependent deacylases that mediate the health benefits of dietary 
restriction and, in the case of SIRT1 can extend lifespan when overexpressed (95, 96). 
Recent data indicate that ECs generate up to 85% of their ATP via glycolysis and are 
thus “addicted” to glucose (Figure 6) (80). Importantly, VEGF stimulates glycolysis. On the 
other hand, the loss of the glycolytic 
activator PFKFB3 in ECs impaired 
filopodia/lamellipodia, migration and 
ultimately vessel formation (Figure 
5B). Despite the significantly lower 
energy yield per molecule of glucose 
via glycolysis (2 ATP) vs. oxidative 
metabolism (34 ATP), glycolysis 
offers other advantages to ECs. For 
instance, anaerobic glucose 
metabolism enables ECs to 
vascularize avascular anoxic tissues, 
an activity that would not be possible 
if they would rely primarily on 
oxidative glucose metabolism. 
Figure 6: Overview of general metabolism.  
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Furthermore, glycolysis can generate more molecules of ATP in a shorter time span as 
compared to oxidative metabolism, thus rapidly providing ECs with the necessary energy to 
sprout and form new vessels, and thereby quickly restore oxygen supply to the surrounding 
tissue.  
 
In normal conditions, fatty acid β-oxidation (FAO) contributes to less than 5% of the total 
amount of ATP in ECs (97). Surprisingly, new data demonstrated that FAO is also essential for 
de novo nucleotide synthesis and angiogenesis (98). Carnitine palmitoyltransferase 1 (CPT1) 
controls the transfer of long-chain fatty acids into the mitochondria, where they are oxidized, and 
is the rate-controlling step of FAO. In ECs, CPT1A silencing reduced FAO and impaired de novo 
synthesis of deoxyribonucleotides for DNA replication. Subsequently, vessel sprouting was 
reduced due to decreased EC proliferation. By contrast, CPT1A knock down did not affect EC 
migration or motility. Finally, in mice, pharmacological CPT1 blockade inhibited pathological 
ocular angiogenesis (97, 98). 
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AIM OF THE STUDY  
Dietary restriction (DR), defined as reduced food intake without malnutrition is best 
known for extending lifespan in experimental model organisms, but also increases resistance to 
a variety of clinically relevant stressors, including those associated with surgery. Recently we 
discovered that hydrogen sulfide (H2S) is increased upon DR in the liver and plays an essential 
role in mediating DR benefits the context of surgical stress (Chapter 1). 
Angiogenesis, the formation of new blood vessels by endothelial cells (ECs), is an 
adaptive response to nutrient/oxygen deprivation orchestrated by vascular endothelial growth 
factor (VEGF) during ischemia (e.g. vessel occlusion or tumorigenesis) or exercise. Hypoxia is 
the best-understood trigger of VEGF expression via the transcription factor HIF1a. Nutrient 
deprivation is inseparable from hypoxia upon ischemia, yet its role in angiogenesis is poorly 
characterized. Interestingly, H2S was shown by others to promote angiogenesis. In the second 
part of this work, we found that restricting the intake of dietary sulfur-containing amino acids 
methionine and cysteine promote angiogenesis. We then tested the functional consequences of 
increased capillary density in rodent preclinical models. We have made progress towards 
understanding the underlying molecular mechanisms, including the role of upstream amino acid-
sensing pathways and downstream effector molecules such as hydrogen sulfide. We also 
worked to elucidate practical methods for increasing angiogenesis through dietary methionine 
restriction in the shortest time period and with the minimal restriction of nutrients, with the long-
term goal of translating such benefits to clinically relevant applications (Chapter 2).  
Finally, H2S that is endogenously produced gas, with broader protective effects on the 
vascular system. H2S can also be measured in blood serum, but the biological significance or 
predictive value with regard to vascular health is unknown. Using lead acetate methods and 
mass spectrometry we quantified H2S in patients undergoing vascular surgery including carotid 
endarterectomy (n=49), open lower extremity arterial revascularization (n=44) or major leg 
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amputation (n=22) as well as in 20 control patients. We found that control patients that did not 
require cardiovascular surgery had the highest serum H2S production capacity and free Sulfur.  
Moreover, we pre-operative serum H2S levels predicted post-operative survival (Chapter 3). 
These date built up on the importance of H2S in vascular homeostasis. The will serve as basis 
to develop guidelines for brief DR or pharmacological DR mimetics such as increasing 
endogenous H2S production to precondition against the stress and potential complications of 
surgery. 
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RESULTS 
 
Chapter 1: Is Overnight Fasting before Surgery Too Much or Not Enough? How Basic 
Aging Research Can Guide Preoperative Nutritional Recommendations to Improve 
Surgical Outcomes: A Mini-Review  
 
This work has been published in 2016 in Gerontology  
 
Summary 
Dietary restriction (DR) is best known for extending lifespan in experimental model organisms, 
but also increases resistance to a variety of clinically relevant stressors, including those 
associated with surgery. Extended periods of DR, lasting months to years, are required for 
optimal longevity benefits in rodents, but short-term dietary preconditioning (less than 1 week) 
remarkably protects from acute injury. Here, we discuss recent advances in our understanding 
of the mechanistic basis of short-term DR and fasting in the context of surgical stress 
resistance, including upstream amino acid sensing by the GCN2 and mTORC1 pathways, and 
down- stream effector mechanisms including increased insulin-dependent prosurvival signaling 
and elevated endogenous hydrogen sulfide production. We also review the current trend in 
preoperative nutrition away from preoperative fasting and towards carbohydrate loading. Finally, 
we discuss the rationale for the nonmutually exclusive use of brief DR or pharmacological DR 
mimetics to precondition against the stress and potential complications of surgery.  
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Chapter 2: Amino acid restriction triggers angiogenesis via GCN2/ATF4 regulation of 
VEGF and H2S production. 
 
This work is pending revision in Cell 
 
Summary 
Angiogenesis, the formation of new blood vessels by endothelial cells (ECs), is an adaptive 
response to nutrient/oxygen deprivation orchestrated by vascular endothelial growth factor 
(VEGF) during ischemia (e.g. vessel occlusion or tumorigenesis) or exercise. Hypoxia is the 
best-understood trigger of VEGF expression via the transcription factor HIF1α. Nutrient 
deprivation is inseparable from hypoxia upon ischemia, yet its role in angiogenesis is poorly 
characterized. Here, dietary sulfur amino acid restriction in mice promoted VEGF expression 
and capillary growth in skeletal muscle independent of hypoxia or HIF1α, instead requiring the 
amino acid-sensing eIF2α kinase GCN2 and the transcription factor ATF4. GCN2/ATF4 
activation also increased cystathionine-γ-lyase expression and pro-angiogenic hydrogen sulfide 
(H2S) production. H2S boosted glycolytic ATP production by inhibiting mitochondrial electron 
transport in ECs, and was required for angiogenesis triggered by amino acid deprivation, 
exercise or local VEGF overexpression. Amino acid deprivation is thus a powerful pro-
angiogenic trigger independent of hypoxia. 
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Highlights 
*Sulfur amino acid restriction triggers angiogenesis independent of hypoxia or HIF1α 
*GCN2/ATF4 pathway regulates VEGF and CGL expression upon amino acid restriction 
*CGL-dependent H2S production in ECs is required for skeletal muscle angiogenesis 
*H2S triggers EC glycolysis and migration via mitochondrial respiration inhibition
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Summary 
Angiogenesis, the formation of new blood vessels by endothelial cells (ECs), is an adaptive 
response to nutrient/oxygen deprivation orchestrated by vascular endothelial growth factor 
(VEGF) during ischemia (e.g. vessel occlusion or tumorigenesis) or exercise. Hypoxia is the 
best-understood trigger of VEGF expression via the transcription factor HIF1α. Nutrient 
deprivation is inseparable from hypoxia upon ischemia, yet its role in angiogenesis is poorly 
characterized. Here, dietary sulfur amino acid restriction in mice promoted VEGF expression 
and capillary growth in skeletal muscle independent of hypoxia or HIF1α, instead requiring the 
amino acid-sensing eIF2α kinase GCN2 and the transcription factor ATF4. GCN2/ATF4 
activation also increased cystathionine-γ-lyase expression and pro-angiogenic hydrogen sulfide 
(H2S) production. H2S boosted glycolytic ATP production by inhibiting mitochondrial electron 
transport in ECs, and was required for angiogenesis triggered by amino acid deprivation, 
exercise or local VEGF overexpression. Amino acid deprivation is thus a powerful pro-
angiogenic trigger independent of hypoxia.   
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Introduction  
Angiogenesis is the formation of new blood vessels from existing ones through 
sprouting, proliferation and migration of endothelial cells (ECs). In adult mammals, angiogenesis 
is a critical adaptive response to a wide variety of normal and pathophysiological conditions 
characterized by inadequate supply of oxygen and nutrients, ranging from tissue ischemia upon 
vessel occlusion or tumorigenesis to endurance exercise.  
 Hypoxia is the best-understood trigger of angiogenesis, stabilizing the oxygen-sensitive 
transcription factor hypoxia inducible factor (HIF)-1α in multiple cell types and promoting 
expression of the master regulator of angiogenesis, vascular endothelial growth factor (VEGF). 
VEGF expression can also be induced by the transcriptional co-activator PGC1α upon 
oxygen/nutrient deprivation through an ERR-α-dependent, HIF-1α independent pathway (Arany 
et al., 2008). 
 VEGF acts via binding to EC-specific cell-surface tyrosine kinase receptors (VEGFR2), 
triggering an orchestrated cascade of signal transduction via the PI3K and MAPK pathways 
involving critical second messengers nitric oxide (NO) and cyclic GMP (cGMP) and changes in 
gene expression facilitating EC migration, proliferation and vessel formation (Olsson et al., 
2006). VEGF-mediated angiogenesis is potentiated by the NAD+-dependent deacetylase 
SIRT1, which deacetylates and inactivates FOXO transcription factors (Potente et al., 2007) 
involved in negative regulation of EC migration and tube formation (Potente et al., 2005). VEGF 
signalling also triggers changes in cellular energy metabolism, namely increased glucose 
uptake and glycolysis, necessary to provide rapid energy for EC migration (De Bock et al., 
2013). 
 Hydrogen sulfide (H2S) is a pro-angiogenic gas produced in ECs upon VEGF stimulation 
(Papapetropoulos et al., 2009) primarily by the transsulfuration enzyme cystathionine-gamma-
lyase (CGL) (Wang, 2012). Like NO, which in addition to activating cGMP synthesis functions 
through post-translational modification (S-nitrosylation) of target proteins (Fukumura et al., 
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2006), H2S promotes angiogenesis through post-translational modification (sulfhydration) and 
activation of at least two proximal signal transduction components, VEGFR2 (Tao et al., 2013) 
and eNOS (Altaany et al., 2014; Coletta et al., 2012). VEGF-induced angiogenesis is 
compromised upon genetic CGL deficiency in aorta explant assays ex vivo (Papapetropoulos et 
al., 2009), as is neovascularization following arterial occlusion in vivo (Kolluru et al., 2015). 
However, the mechanism by which VEGF stimulates endogenous H2S production, as well as 
the relative contribution of H2S vs. NO to angiogenesis, remains unclear (Katsouda et al., 2016). 
 In addition to hypoxia, nutrient depletion is a hallmark of tissue ischemia that ECs must 
contend with in order to perform angiogenesis and restore tissue homeostasis. While PGC1α 
responds to nutrient deprivation independent of hypoxia, and can drive VEGF production by 
muscle cells, it is not activated in ECs themselves (Arany et al., 2008). Furthermore, 
pharmacological approaches to promote angiogenesis under conditions of chronic ischemia by 
targeting PGC1α or HIF1α have to date been unsuccessful (Chu and Wang, 2012). Thus a 
deeper understanding of the mechanisms underlying angiogenesis is needed in order to restore 
vascular health in the context of tissue ischemia without promoting tumor growth, both of which 
increase upon aging.  
Dietary restriction (DR), defined as reduced nutrient/energy intake without malnutrition, 
is best known for its ability to extend lifespan, improve metabolic fitness and increase stress 
resistance (Colman et al., 2009; Fontana et al., 2010; Hine et al., 2015). Dietary restriction 
specifically of sulfur amino acids (methionine and cysteine), also known simply as methionine 
restriction (MR), leads to many of these same benefits but without enforced restriction of total 
calorie intake (Miller et al., 2005; Orentreich et al., 1993; Perrone et al., 2013).  
We recently reported that both DR and MR increase CGL expression and endogenous 
H2S production in liver in vivo and in hepatocytes in vitro, and that increased H2S is necessary 
and sufficient for short-term DR-mediated stress resistance upon ischemic injury (Hine et al., 
2015). However, the mechanisms underlying nutrient regulation of CGL expression and H2S 
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production, and the potential of DR to modulate angiogenesis via H2S, remain unknown. DR 
promotes revascularization and recovery in a model of femoral artery ligation in rodents (Kondo 
et al., 2009), and maintains vascular health in rodents and non-human primates  in part by 
preserving capillary density in skeletal muscle (Omodei and Fontana, 2011). Although the 
mechanism remains unknown, this could occur in part via SIRT1, which is activated in some 
tissues upon DR (Cantó and Auwerx, 2009; Wang, 2014) and required for VEGF-dependent 
angiogenesis (Potente et al., 2007). On the other hand, protection afforded by DR against 
cancer in rodent models is thought to occur in part through inhibition of angiogenesis, thus 
preventing tumor neovascularization (Hursting et al., 2013). 
Here, we identified dietary restriction of sulfur amino acids as a novel pro-angiogenic 
trigger promoting rapid growth of new capillaries in skeletal muscle. This occurred through 
coordinate regulation of VEGF and CGL expression and H2S production in multiple cell types, 
including ECs, via an amino acid sensing mechanism independent of hypoxia, HIF1α or PGC1α, 
but dependent on SIRT1. We also identified the requirement for CGL-derived H2S in VEGF-
dependent angiogenesis, and a novel mechanism of pro-angiogenic H2S action in ECs involving 
a switch from oxidative to glycolytic metabolism. 
  
Results 
Dietary sulfur amino acid restriction induces functional angiogenesis via increased VEGF 
in vivo 
We tested the potential of isolated nutrient restriction independent of ischemia or 
hypoxia to impact angiogenesis in vitro using a model of sulfur amino acid restriction (Hine et 
al., 2015). Human umbilical vein endothelial cell (HUVEC) cultured in media lacking methionine 
(Met, M) and cysteine (Cys, C) for 16 hrs displayed increased VEGF mRNA expression and 
protein secretion into the media (Fig. 1A). This correlated with increased pro-angiogenic 
potential, including migration (Fig. 1B) and formation of capillary-like structures (tube formation, 
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Fig. 1C). M&C deprivation also increased sprout length in HUVEC spheroid cultures, an effect 
that was abrogated by the VEGF receptor inhibitor SU5416 (Fig. 1D).  
We next tested the requirement for SIRT1 in angiogenesis induced by M&C deprivation. 
SIRT1 is activated upon DR in some tissues (Cantó and Auwerx, 2009; Wang, 2014) and 
required for VEGF-mediated angiogenesis in ECs under conditions of oxidative stress in vitro 
and maintenance of vascular density upon aging in vivo (Das et al., see accompanying 
manuscript). Blocking SIRT1 activity with the inhibitor EX527 significantly reduced HUVEC tube 
formation upon M&C deprivation, with the main effects occurring at the branch points (Fig. 1E, 
FigS1A). Thus, the pro-angiogenic pathway triggered by amino acid (M&C) deprivation of ECs is 
dependent on both VEGF and SIRT1 activity. 
 To test the potential of dietary sulfur amino acid restriction to increase angiogenesis in 
vivo, mice were given ad libitum access to a Met restricted (MR) diet that is reduced in Met and 
lacking Cys (Miller et al., 2005; Orentreich et al., 1993; Perrone et al., 2013). Young adult 
wildtype (WT) mice on MR for 2 mo maintained a lower body weight despite normal food intake 
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relative to mice fed a control diet containing normal Met and Cys levels (Fig. S1B). Co-
immunostaining for VEGF and the EC marker isolectin B4 (IB4) revealed increased VEGF 
protein in both muscle fibers and ECs upon MR (Fig. 1F). Expression of VEGF mRNA was also 
significantly increased upon MR in different muscle beds (gastrocnemius, thigh) and to a lesser 
extent in the liver, but not in the brain or heart (Fig. 1G). Interestingly, increased VEGF 
transcription was observed upon different DR regimens that shared a reduction in sulfur amino 
acids, including protein calorie restriction (PCR, consisting of a Protein-free diet fed at 40% 
Calorie Restriction) or 3 d of water-only fasting (Fast) (Fig. S1C). 
Strikingly, MR resulted in increased vascular density in skeletal muscle as determined by 
immunostaining (Fig. 1H) and flow cytometric analysis (Fig. S1D, E) for the EC marker CD31. 
Consistent with VEGF dependence, this effect was blocked by the VEGF receptor inhibitor 
axitinib at a dose previously shown to inhibit neovascularization in vivo (Ma and Waxman, 2008) 
(Fig. 1H, Fig. S1E). 
Figure 1: Dietary sulfur amino acid restriction induces functional angiogenesis via 
increased VEGF in vivo 
(A) VEGF mRNA levels (left) and secreted protein concentration in the media (right) of HUVEC 
cultured in control (Ctrl) or sulfur amino acid deficient (-M&C) media for 16 hrs. (B) 
Representative wound closure (left, 10X magnification at time = 20 hr; dotted lines indicate 
boundary of the scratch wound at time = 0 hr) and area under the curve (A.U.C., right) from 
HUVEC in the indicated media. (C) Representative capillary-like structures (left, tube formation 
at 40X magnification) and mean tube length quantification (right) in HUVEC cultured in the 
indicated media for 24 hrs. (D) Representative images (left, 40X magnification) and quantification 
(right) of sprouting EC spheroids in the indicated media +/- VEGFR2 inhibitor SU5416 for 24 hrs. 
(E) Quantification of tube branch points per field of view in HUVECs seeded onto growth factor-
replete Matrigel and incubated with in the indicated media +/- SIRT1 inhibitor Ex-527 for 18 hrs. 
All cell-based assays were repeated at least 3 times. (F) Representative transverse sections of 
gastrocnemius muscle stained for VEGF (left, 40X magnification), IsolectinB4 (IB4, middle, 40X 
magnification) and merged (VEGF red, IB4 green, DAPI blue; right, insert 160X magnification) in 
mice preconditioned for 2 mo on control (Ctrl) or methionine restricted (MR) diets. (G) 
Expression of VEGF mRNA in the indicated organ (GM, gastrocnemius muscle) of mice on Ctrl 
or MR diets as indicated for 2 mo; n = 3-7/group. (H) Representative transverse sections (left, 
40X magnification) and quantification (right) of gastrocnemius muscle stained for endothelial 
marker CD31 in mice fed for 2 wks on Ctrl or MR diets with or without VEGFR2 inhibition 
(Axitinib); n=4-5/group. (I) Longitudinal Doppler imaging of blood flow in WT mice preconditioned 
on Ctrl or MR diets as indicated for 1 mo prior to femoral artery occlusion (I, ischemic; NI, non-
ischemic). Left: representative infrared images on the indicated day after occlusion. Right: 
quantification of blood-flow recovery; n=7-8 per group. Error bars indicate SEM; *P < 0.05, 
**P < 0.005, ***P < 0.001 compared to Ctrl by Student’s t test.  	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The functional significance of MR-induced neovascularization was tested in a model of 
ischemic injury induced by femoral artery occlusion. Mice were preconditioned on MR or control 
diets for 1 mo prior to surgical artery occlusion and returned to a complete diet after surgery 
(Fig. S1E). The return of blood flow indicative of neovascularization was then followed over 10 d 
using laser Doppler imaging (Fig. S1F). Although blood flow was similarly interrupted in both 
groups immediately after occlusion (d0), return of blood flow was markedly accelerated in MR 
preconditioned mice relative to the control group, with significant improvement as early as 3 d 
after ischemia (Fig. 1I). These data are consistent with neovascularization induced by dietary 
amino acid restriction as a critical factor in the improved physiological response to acute blood 
flow cessation. 
 
GCN2-dependent, hypoxia independent regulation of VEGF and angiogenesis upon 
amino acid restriction 
We next sought to determine the mechanism of increased VEGF expression upon M&C 
deprivation. Stabilization of the transcription factor HIF1α upon hypoxia is the best characterized 
trigger of VEGF expression in multiple cell types including ECs and myocytes  (Liu et al., 1995). 
However, consistent with normoxic conditions, VEGF expression upon M&C deprivation in 
cultured HUVECs was unaffected by HIF1α RNAi knock-down (KD) (Fig. S2A, B) and coincided 
with a reduction of HIF1α protein levels (Fig. 2A). The transcriptional co-activator PGC1α can 
also induce VEGF independently of HIF1α upon total nutrient/growth factor deprivation in 
specific cell types including myocytes although not in ECs (Arany et al., 2008). Consistent with 
this, endogenous PGC1α mRNA expression in HUVECs was very low and unaffected by M&C 
deprivation (Fig. S2C), while exogenous PGC1α overexpression in HUVECs failed to modulate 
VEGF expression (Fig. S2D). Therefore, VEGF induction upon M&C deprivation in ECs 
occurred independently of hypoxia or the canonical HIF1α and PGC1α pathways. 
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The amino acid starvation response (AASR) is triggered by direct binding of uncharged 
cognate tRNAs to the general control nonderepressible 2 (GCN2) kinase, resulting in 
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Figure 2: GCN2-dependent, hypoxia independent regulation of VEGF and 
angiogenesis upon amino acid restriction 
(A) Western blot of HIF1α , eIF2α  (p-Ser51, total) and ATF4 in HUVEC cultured in control 
(Ctrl) or sulfur amino acid deficient (-M&C) media for 16 hrs. (B) Relative VEGF mRNA 
expression in HUVEC 2 d after transfection with ATF4 or control scrambled siRNA and 
cultured in the indicated media for 16 hrs. (C) Secreted VEGF protein concentration in the 
media of HUVEC 2 d after transfection with an ATF4 overexpressing (ATF4OE) or control 
construct (Empty). (D) VEGF mRNA expression in GCN2+/+ and GCN2-/- primary mouse EC 
cultured in the indicated media for 16 hrs. (E) Representative images (top, 40X 
magnification) and quantification (bottom) of GCN2+/+ and GCN2-/- sprouting EC spheroids 
cultured in the indicated media for 24 hrs. All cell-based assays were repeated at least 3 
times. (F) VEGF mRNA in C2C12, WT myotubes, MDF and MEF cultured in M&C deficient 
media relative to control (Ctrl) media for 16 hrs. (G) Western blot of HIF1α, PGC1α ,  eIF2α  
(p-Ser51, total) in C2C12 cultured in control (Ctrl) or sulfur amino acid deficient (-M&C) 
media for 16 hrs. (H) VEGF mRNA expression in GCN2+/+ and GCN2-/- primary mouse EC 
cultured in control (Ctrl) or sulfur amino acid deficient (-M&C) media for 16 hrs. (I-K) VEGF 
mRNA expression in skeletal muscle (I), plasma VEGF (J) and representative transverse 
sections (left, 40X magnification) and quantification (right) of gastrocnemius muscle stained 
for CD31 (K) in GCN2+/+ or GCN2-/- mice fed for 2-4 wks on Ctrl or MR diets; n=5-6/group. 
Error bars indicate SEM; *P < 0.05, **P < 0.005, ***P < 0.001 compared to Ctrl by Student’s t 
test.  	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phosphorylation of its direct target, eukaryotic translation initiation factor 2 α (eIF2α)  and 
translational derepression of select mRNAs, including that encoding the transcription factor 
ATF4 (Wek et al., 1995). The AASR has been implicated in DR-mediated resistance to ischemia 
reperfusion injury (Peng et al., 2012), but has not been assessed in ECs. Consistent with GCN2 
activation upon M&C deprivation in ECs, Western blot analysis revealed increased eIF2α 
phosphorylation and ATF4 expression (Fig. 2A) and increased expression of the ATF4 target 
ASNS (Fig. S2E). ATF4 was required for VEGF transcriptional upregulation upon M&C 
deprivation (Fig. 2B; Fig. S2E), while ATF4 overexpression alone increased VEGF secretion 
independent of nutrient deprivation (Fig. 2C; Fig. S2F). The requirement for GCN2 upstream of 
eIF2α/ATF4 was tested in primary ECs isolated from WT and GCN2-/- mice (Fig S2G). Similar to 
HUVECs, M&C deprivation significantly increased VEGF and ASNS expression (Fig. 2D; Fig. 
S2H), and sprout length (Fig. 2E) in WT ECs, each of which was abrogated in the absence of 
GCN2.  
Because VEGF can be secreted by many cell/tissue types, including muscle fibers, we 
next asked if GCN2/ATF4 regulated VEGF expression upon M&C deprivation in other cell types. 
In all cell lines tested, including mouse primary skeletal myotubes, C2C12 myotubes, primary 
dermal fibroblasts (MDF) and spontaneously immortalized mouse embryonic fibroblasts (MEF), 
M&C deprivation significantly increased VEGF expression (Fig. 2F). In C2C12 myotubes, this 
induction of VEGF coincided with increased eIF2α phosphorylation (Fig. 2G) and ATF4 activity 
(Fig. S2I) and reduced HIF1α protein levels (Fig. 2G). Notably, it was unaffected by HIF1α RNAi 
knock-down (KD) under normoxic (20%) or hypoxic (<1%) oxygen tensions (Fig. S2J-L), 
consistent with independent regulation of VEGF upon oxygen and nutrient deprivation in 
myotubes as observed in ECs.  
Finally, the genetic requirement for GCN2 was tested in vitro and in vivo. VEGF 
induction in primary skeletal myotubes upon M&C restriction in vitro required GCN2 (Fig. 2H). 
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Similarly, increased VEGF mRNA expression in muscle (Fig. 2I), circulating VEGF protein in 
plasma (Fig. 2J) and increased vascular density (Fig. 2K) upon 2-4 wks of MR were lost in 
GCN2KO mice. Taken together, these data reveal amino acid restriction and the GCN2/ATF4-
dependent AASR as a novel trigger of increased VEGF expression and angiogenesis 
independent of hypoxia, HIF1α or PGC1α. 
 
VEGF signalling and AASR converge on endothelial H2S production by CGL 
VEGF promotes angiogenesis in part by stimulating CGL-dependent production of the 
pro-angiogenic gas H2S in ECs (Lin et al., 2013; Papapetropoulos et al., 2009), however 
mechanisms of CGL regulation in ECs and the importance H2S in angiogenesis remain poorly 
understood. Recently we found that dietary sulfur amino acid restriction increases CGL 
expression and H2S production in multiple cell and tissue types (Hine et al., 2015), prompting us 
to test the potential contribution of CGL-dependent H2S to angiogenesis in the context of amino 
acid restriction.   
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 Two complementary assays were used to test the ability of M&C deprivation to stimulate 
H2S production specifically in ECs. In the first, the ability of cells to produce H2S in the presence 
of excess added substrate (cysteine) is visualized by the highly selective interaction between 
H2S and lead acetate to form the black precipitate, lead sulfide. In the second, endogenous H2S 
production is visualized with a sensitive and selective fluorescent probe added to live cells or 
fresh-frozen tissue sections without the need for exogenous substrate (Singha et al., 2015). 
Both assays revealed a significant increase in H2S production upon M&C deprivation similar in 
magnitude to exogenous VEGF addition and sensitive to the CGL inhibitor PAG (Fig. 3A, B). 
Nutrient deprivation also boosted endogenous H2S production in primary hepatocytes, while 
VEGF did not because hepatocytes lack VEGFR2 (Fig. S3A). 
We next tested the potential contribution of the GCN2-dependent AASR to CGL mRNA 
regulation. Like VEGF mRNA, CGL mRNA was strongly induced in ECs upon M&C deprivation, 
and this was lost in ECs lacking GCN2 (Fig. 3C) or upon ATF4 knockdown (Fig. 3D; Fig. S2E). 
Importantly, VEGF mRNA was not affected by the absence of CGL (Fig. S3B), consistent with 
CGL and VEGF as independent downstream targets of the AASR. Interestingly, exogenous 
VEGF increased CGL (but not CBS or 3-MST) mRNA and protein expression in ECs 
independent of nutrient deprivation (Fig. S3C, D), suggestive of a positive feedback loop 
between VEGF and CGL expression.  
Figure 3: VEGF signalling and AASR converge on endothelial H2S production by CGL 
(A) Representative H2S production capacity as indicated by black lead sulfide formation from 
EC deprived of M&C for 16 hr or treated with VEGF (50 ng/ml) in the presence or absence of 
the CGL inhibitor propargylglycine (PAG, 100 µM) as indicated. (B) Representative (left) 
endogenous H2S production and quantification of the intensity (right) using an H2S-specific 
fluorescent probe in HUVEC upon treatment with VEGF (50 ng/ml) or cultured in media lacking 
sulfur amino acids (-M&C). (C) CGL mRNA expression in GCN2+/+ and GCN2-/- primary mouse 
EC cultured in control (Ctrl) or sulfur amino acid deficient (-M&C) media for 16 hrs. (D) CGL 
mRNA expression in HUVEC 2 d after transfection with ATF4 or control scrambled siRNA and 
cultured in the indicated media for 16 hrs. (E) Representative images (left, 40X magnification) 
and quantification (right) of HUVEC spheroids cultured in control media (Ctrl) or media lacking 
M&C (-M&C) for 24 hrs in the presence of vehicle (Veh) or CGL inhibitor PAG (100 µM). (F) 
Representative images (left, 40X magnification) and quantification (right) of CGL-/- primary EC 
sprouts in control media (Ctrl) or media lacking M&C (-M&C) for 24 hrs. All cell-based assays 
were repeated at least 3 times. Error bars indicate SEM; ***P < 0.001 compared to Ctrl within 
genotype by Student’s t test.  	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The functional relevance of endothelial CGL-derived H2S in angiogenic potential in vitro 
was assessed in the EC spheroid assay. Increased sprout length of EC spheroids upon M&C 
deprivation was prevented by CGL inhibition with PAG in HUVECs (Fig. 3E) and by genetic 
CGL ablation (CGL-/-) in mouse ECs (Fig. 3F). Thus, CGL is required for angiogenesis induced 
by M&C deprivation in vitro. 
 
CGL is necessary and sufficient for angiogenesis in vivo 
We next tested the requirement for CGL-derived H2S in angiogenesis triggered by 
nutrient deprivation in vivo. CGL is thought to be the major H2S producer in ECs in vivo (Wang, 
2012), which we confirmed using the H2S-specific P3 probe in fresh-frozen sections of 
gastrocnemius muscle from CGL WT and KO mice (Fig. 4A). P3 fluorescence indicative of 
endogenous H2S production co-localized with CD31+ cells in WT but not CGLKO mice, further 
suggesting ECs as the major producer of endogenous H2S in this tissue (Fig. 4A). Quantification 
of P3 intensity in WT and CGLKO mice fed Ctrl vs. MR diets for 2wks confirmed a CGL-
dependent increase in EC H2S production upon MR in vivo (Fig. 4B). Coincident with failure to 
increase H2S, CGLKO mice demonstrated no increase in capillary density upon MR in vivo as in 
the WT group (Fig. 4C). Taken together, CGL-derived H2S is required for angiogenesis triggered 
by nutrient deprivation. 
 We next asked if CGL-derived H2S is sufficient to promote angiogenesis independent of 
amino acid restriction. Overexpression of CGL in gastrocnemius muscle of WT mice via intra-
muscular injection of CGL-overexpressing adenovirus increased muscle H2S production 
capacity (Fig. S4A) and vascular density (Fig. 4D) independent of any other pro-angiogenic 
stimulus, suggesting that CGL-derived H2S is sufficient to trigger angiogenesis.  
To test this apparent general requirement for CGL-derived H2S in angiogenesis 
independent of the upstream stimulus, we induced angiogenesis by either treadmill exercise 
training, a potent stimulus for angiogenesis in adult skeletal muscle (Rowe et al., 2014), or by 
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VEGF overexpression via intra-muscular injection of VEGF-overexpressing (ad-VEGF165) 
adenovirus. Exercise training increased endogenous VEGF mRNA expression in WT mice (Fig. 
S4B), while both exercise training (Fig. 4E) and local VEGF overexpression via adenoviral gene 
delivery (Fig. 4F) increased capillary density in WT but not CGLKO mice. Taken together, these 
data indicate that CGL-mediated H2S production is necessary for VEGF-mediated 
neovascularization in vivo independent of the upstream pro-angiogenic stimulus. 
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Figure 4: CGL is necessary and sufficient for angiogenesis in vivo 
 (A) Representative transverse sections (20X magnification) of gastrocnemius muscle from 
CGL+/+ and CGL-/- mice stained for CD31 and endogenous H2S. (B) Quantification of 
endogenous H2S production in CD31+ EC in the gastrocnemius muscle of CGL+/+ and CGL-/- 
mice fed for 2 wks on Ctrl or MR diets as indicated; n=4-5/group. (C) Representative 
transverse section (left, 40X magnification) and quantification (right) of gastrocnemius muscle 
stained for CD31 from CGL+/+ and CGL-/- mice fed for 2 wks on Ctrl or MR diets as indicated; 
n=4-5/group. (D) Representative transverse sections of gastrocnemius muscle stained for 
CD31 (left, 40X magnification) and quantification (right) 2 wks after Ad-Null or Ad-CGL 
injections; n=4/group. (E) Representative transverse section (left, 40X magnification) and 
quantification (right) of gastrocnemius muscle stained for CD31 from CGL+/+ and CGL-/- mice 
subjected to low intensity running (exercised) vs. control (sedentary) for 1mo; n=5-6/group. (F) 
Representative transverse sections of gastrocnemius muscle stained for CD31 (left, 40X 
magnification) and quantification (right) from CGL+/+ and CGL-/- mice 6 d after intramuscular 
injection of control (Ad-Null) or VEGF165 -expressing (Ad-VEGF) adenovirus; n=4/group. Error 
bars indicate SEM; **P < 0.005, ***P < 0.001 compared to Ctrl by Student’s t test. 	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H2S promotes glucose uptake and ATP generation by glycolysis for EC migration 
CGL is a promiscuous enzyme that can convert cystathionine to cysteine as part of the 
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Figure 5: H2S promotes glucose uptake and ATP generation by glycolysis for EC 
migration 
 (A) Time-dependent wound closure (left) and quantification (right, A.U.C., area under the 
curve) in HUVEC +/- 100µM NaHS in the presence of vehicle or mitomycin C (MitoC) to 
inhibit proliferation. (B, C) Representative images (B) and quantification (C) of migration 
speed (left) and distance (right) from time-lapse video imaging of GFP+ HUVEC infected 
with control (Ad-Null) or CGL adenovirus (Ad-CGL) as indicated. (D) Extracellular 
acidification rate (ECAR) indicative of glycolysis in CGL+/+ and CGL-/- primary mouse EC 
pretreated for 1 hr with VEGF (50 ng/ml) or NaHS (100 µM). (E) Relative glucose uptake 
in HUVEC pretreated with NaHS for 1 hr. (F) C13-labeled metabolite levels measured by 
mass spectrometry-scaled intensity in C13 glucose pulsed HUVEC pretreated for 1 hr +/- 
NaHS (100 µM). (G) Extracellular acidification rate (ECAR) indicative of glycolysis in 
HUVEC pretreated for 1 hr with NaHS (100µM). (H) Time dependent ATP production in 
HUVEC treated with 100 µM NaHS at time=0. (I, J) Representative wound closure (left) 
and quantification (right, A.U.C) from HUVEC treated with 100 µM NaHS in the presence 
of vehicle or 1 mM 2-DG (I) or infected with a control (Ad-Null) or CGL adenovirus (Ad-
CGL) at multiplicity of infection 50 (J) in the presence of vehicle or the glycolysis inhibitor 
2-deoxyglucose (2-DG, 1mM). All cell-based assays were repeated at least three times. 
Error bars indicate SEM; *P < 0.05, **P < 0.005, ***P < 0.001 compared within genotype 
to Ctrl by Student’s t test. 	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transsulfuration pathway, but that can also use cysteine to produce H2S and serine. We thus 
sought to directly test H2S as the CGL metabolite relevant to angiogenesis. H2S delivery in the 
form of NaHS promoted EC proliferation/migration indicative of increased angiogenic potential in 
the wound closure assay (Fig. 5A). Blocking proliferation with mitomycinC (MitoC) only partially 
reduced H2S-induced wound closure (Fig. 5A), consistent with migration as a critical factor in 
H2S-induced angiogenic potential. To confirm the effects of CGL on migration, time-lapse video 
imaging of GFP+ HUVECs revealed that cells overexpressing CGL (Ad-CGL) formed 
lamellipodial projections over larger areas (Fig. 5B) coincident with increased migration speed 
and greater cell body displacement (Fig. 5C).  
To determine where in the VEGF signal transduction pathway H2S acts to promote EC 
migration, we first considered signalling events proximal to VEGF in which H2S has been 
previously implicated, including sulfhydration and activation of VEGFR2 (Tao et al., 2013) and 
eNOS (Altaany et al., 2014; Coletta et al., 2012). However, eNOS inactivation using RNAi KD 
(sieNOS) or L-NG-nitroarginine methyl ester (L-NAME) had no effect on the pro-angiogenic 
activity of CGL/H2S on migration in the wound closure assay in vitro (Fig. S5A-E). Similarly, L-
NAME failed to block angiogenesis in vivo (Fig. S5F), consistent with a critical role for H2S in 
angiogenesis downstream of (or redundant with) eNOS activation, and prompting us to consider 
pro-angiogenic mechanisms of H2S action further downstream of proximal VEGF signaling.  
Cell migration requires rapid ATP generation to facilitate actin cytoskeleton 
rearrangement, which in ECs is met by increasing glycolytic metabolism (De Bock et al., 2013; 
Schoors et al., 2014). We thus examined glucose uptake and oxidative vs. glycolytic energy 
metabolism as a function of genetic and pharmacological H2S modulation in ECs. Consistent 
with the pro-angiogenic effect of increased glycolysis, treatment of WT mouse ECs with either 
VEGF or NaHS stimulated glycolytic metabolism as evidenced by an increase in extracellular 
acidification rate (ECAR, Fig. 5D). In CGLKO ECs, glycolysis under basal conditions was 
significantly reduced relative to WT controls, and this was rescued to WT levels by exogenous 
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H2S (NaHS) administration, while VEGF failed to boost glycolysis (Fig. 5D). In HUVECs, NaHS 
similarly boosted glucose uptake (Fig. 5E) and glycolysis as shown by increased accumulation 
of glycolytic metabolites in 13C-glucose-labeled cells (Fig. 5F) and increased ECAR (Fig. 5G; 
Fig. S5G). This induction of glycolysis upon NaHS administration was unaffected by axitinib or 
L-NAME (Fig. S5H), and thus most likely mediated downstream of proximal VEGFR2 signalling. 
Importantly, exogenous VEGF and H2S boosted intracellular ATP levels over a similar rapid time 
course (Fig. 5H). Consistent with the importance of glycolysis and ATP generation in EC 
migration, the pro-migratory effects of exogenous H2S addition or CGL overexpression were 
blocked by the glycolysis inhibitor 2-deoxy-D-glucose (2-DG; Fig. 5I, J). 
 
H2S shifts oxidative/glycolytic balance by transient inhibition of mitochondrial electron 
transport 
By what mechanism does H2S promote glucose uptake and glycolysis in ECs? H2S has 
been reported to sulfhydrate and activate GAPDH (Mustafa et al., 2009), a rate-limiting step in 
glycolysis (Shestov et al., 2014). However, preventing sulfhydration by addition of the reducing 
agent dithiothreitol (Mustafa et al., 2009) had no effect on induction of glucose uptake by NaHS 
(Fig. S6A).  
 Inhibition of oxidative phosphorylation can also precipitate a rapid shift to glycolysis 
subsequent to transient ATP depletion and initiation of adaptive responses including AMPK 
activation, which boosts glucose uptake and glycolytic metabolism (Wheaton et al., 2014). 
Consistent with such a role for H2S in regulation of oxidative/glycolytic balance, CGLKO ECs 
displayed increased oxygen consumption under basal conditions relative to WT cells (Fig. 6A) 
and decreased acetyl-CoA entry into the TCA cycle (Fig. S6B). AMPK was activated within 5 
min of NaHS treatment (Fig. 6B) and returned to baseline after 30min, while treatment with an 
AMPK inhibitor (Compound C) prevented the increase in glycolysis, glucose uptake and 
migration (Fig. 6C; Supplemental Fig. 6C, D). Because of the rapid and transient nature of 
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AMPK activation, we hypothesized that brief treatment with H2S would be sufficient to trigger EC 
migration. Indeed, 10min NaHS treatment was sufficient to promote EC migration during the 
subsequent 12hr period, and that this was blocked by pharmacological AMPK inhibition (Fig. 
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Figure 6: H2S shifts oxidative/glycolytic balance by transient inhibition of 
mitochondrial electron transport 
 (A) Basal oxygen consumption rate (OCR) indicative of mitochondrial respiration in CGL+/+ 
and CGL-/- primary mouse EC. (B) Western blot of ACC (pSer79, total) and AMPK (Thr172, 
total) in HUVEC treated with NaHS at the indicated time. (C) Extracellular acidification rate 
(ECAR) indicative of glycolysis in HUVEC pretreated for 1 hr with NaHS (100µM) +/- the AMPK 
inhibitor Compound C (Comp. C) as indicated. (D) Schematic of the experiment (left) and time-
dependent wound closure quantification (migration A.U.C., right) in HUVEC treated with 
NaHS for 10 min in the presence of vehicle or Comp. C (10µM). (E) OCR (left) and ECAR 
(right) over time in HUVEC pretreated for 2 hrs with 100µM NaHS followed by oligomycin (oligo, 
2.5µM) injection at the indicated time. (F) ECAR in HUVEC pretreated for 2 hrs with cyanide 
(KCN, 10µM), oligomycin (2µM) or phenformin (Phen, 500µM) expressed as a percent of control 
over time after addition of 10mM glucose. (G) Relative wound closure (migration A.U.C.) 
expressed as fold change relative to control in HUVEC treated with oligomycin (2µM), 
phenformin (500µM) or cyanide (10µM) +/-  2DG (1mM) as indicated. (H) C13-labeled 
metabolite levels measured by mass spectrometry-scaled intensity in C13 glucose pulsed 
HUVEC in the presence or absence of KCN. (I) Western blot of ACC (pSer79, total) and 
AMPK (Thr172, total) in HUVEC treated with KCN (10µM) at the indicated time. (J) ATP 
production in HUVEC treated with KCN at the indicated time. All cell-based assays were 
repeated at least three times. Error bars indicate SEM; *P < 0.05, **P < 0.005, ***P < 0.001 
compared within genotype to Ctrl by Student’s t test. 
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6D). Finally, treatment of ECs with NaHS resulted in a concomitant shift from oxidative 
phosphorylation to glycolysis that was not further affected upon addition of the Complex V 
inhibitor oligomycin (Fig. 6E).  
 A previously established mechanism of H2S action responsible for its toxicity at high 
concentrations is non-competitive inhibition of Complex IV of the mitochondrial electron 
transport chain (ETC) (Wang, 2012). In order to assess the specific contribution of ETC 
inhibition to the pro-angiogenic activity of H2S, we compared H2S to another Complex IV 
inhibitor, cyanide, as well as oligomycin and the Complex I inhibitor, phenformin. Each ETC 
inhibitor increased EC glycolysis (Fig. 6F; Fig. S6E) and stimulated 2-DG-sensitive EC migration 
(Fig. 6G; Fig. S6F) without increasing H2S (Fig. S6G). Metabolic tracing studies using 13C-
glucose (D-Glucose-1,2-13C2) confirmed similar effects of cyanide (KCN) on glycolysis (Fig. 6H), 
glucose uptake (Fig. S6H), AMPK activation (Fig. 6I) and intracellular ATP (Fig. 6J) as 
previously observed for H2S. Importantly, ETC inhibition did not induce EC apoptosis under the 
same conditions (Fig. S6I).  Together, these data are consistent with a mechanism of H2S action 
in angiogenesis involving transient inhibition of mitochondrial respiration by direct inhibition of 
ETC, resulting in a shift from oxidative phosphorylation to glycolysis.  
 
Discussion 
 A model for a previously unrecognized pro-angiogenic pathway activated by dietary 
amino acid restriction and controlled by the GCN2/ATF4-dependent AASR is presented in Fig. 
7. While VEGF production was the major output of this pathway in muscle fibers, CGL and H2S 
production appeared to dominate in ECs. The genetic requirement for CGL in angiogenesis 
triggered by nutrient deprivation, exercise or VEGF injection strongly suggests an essential role 
for H2S in VEGF-mediated angiogenesis independent of the upstream trigger. Finally, we 
uncovered a mechanistic role for H2S in boosting rapid anaerobic ATP production via inhibition 
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of mitochondrial oxidative phosphorylation in ECs, the first time that this otherwise toxic mode of 
H2S action has associated with a beneficial outcome. 
 
Translational implications for pro-angiogenic effects of dietary amino acid restriction and 
SIRT1 activation  
 While hypoxia is the best-
characterized trigger of VEGF 
expression and angiogenesis upon 
vessel occlusion, solid tumor growth or 
exercise training, oxygen and nutrient 
restriction are inextricably linked under 
these circumstances. Yet, little is 
known about how ECs respond to 
nutrient restriction independently of 
hypoxia.  
 Here, we found that the 
GCN2/ATF4-dependent AASR was not 
only activated in ECs upon amino acid 
restriction independent of hypoxia, but 
was itself a powerful pro-angiogenic 
trigger. Activation of this pathway 
increased VEGF expression in multiple 
cell types in vitro and tissues in vivo, 
and additionally controlled CGL 
expression and H2S production in ECs. 
Figure 7: Model for the role of amino acid 
deprivation in the regulation of angiogenesis 
through the GCN2/ATF4 amino acid starvation 
pathway independent of hypoxia, and the role of 
CGL-mediated H2S production in the regulation of 
glycolysis and EC migration downstream of VEGF 
signaling.	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 These findings reveal the AASR as a new target for modulation of angiogenesis by 
pharmacological or even dietary manipulations. This has therapeutic value for example in the 
context of limb ischemia, a major complication of cardiovascular disease and diabetes that is 
not amenable to treatment by exercise. In the context of cancer chemotherapy, where inhibition 
of angiogenesis is desired, it is also important to recognize the AASR as an independent 
pathway with the ability to contribute to tumor vascularization.  
 Additionally, in an accompanying manuscript, Das et al. report an important interaction 
between H2S and SIRT1 in the regulation of angiogenesis in the context of oxidative stress and 
aging. In ECs subject to oxidative stress in vitro, exogenous H2S potentiated the pro-angiogenic 
effects of NAD+ supplementation (via NMN addition). As with M&C-induced angiogenesis under 
normal conditions (Fig. 1E), this effect was dependent on SIRT1 (Das et al.). Strikingly, 
H2S/NMN supplementation in old mice reversed age-associated loss of muscle vascular density 
and improved exercise performance (Das et al.). Although the mechanism by which H2S 
augments SIRT1 function remains to be worked out, these data suggest that H2S and SIRT1 
function in a critical axis regulating angiogenesis with the potential to mitigate or reverse 
oxidative stress-induced and aging-related changes in vascular health.  
 Loss of vascular function is associated with many of the age-related diseases that 
restrict human healthspan, including hypertension, atherosclerosis, heart failure, stroke, 
neurodegeneration and complications of type II diabetes (Askew et al., 2005; Duscha et al., 
1999; Rivard et al., 1999; Stern et al., 2003). While many of these phenotypes are ameliorated 
or reversed by DR in experimental models (Ahmet et al., 2011; Winnik et al., 2015), future 
experiments are required to determine to what degree increased angiogenic potential 
contributes to these benefits, and the role of SIRT1 activation (Haigis and Sinclair, 2010; 
Naiman et al., 2012; Satoh et al., 2013) and increased H2S production (Hine et al., 2015) in this 
process. Nonetheless, the potential to modulate these pathways with pharmacological agents 
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holds promise for leveraging the benefits of DR on vascular health without the need for reduced 
food intake. 
  
Transcriptional, post-translational and substrate-level regulation of CGL and H2S 
production by diet 
Previously we found that CGL mRNA and protein levels, as well as hepatic H2S 
production capacity, are increased upon DR and repressed by dietary sulfur amino acids, but 
the molecular requirements for dietary control of H2S production were not elucidated (Hine et al., 
2015). Here, we revealed a requirement for the AASR in the coordinate regulation of CGL as 
well as VEGF upon nutrient restriction. In all cells tested, sulfur amino acid deprivation 
increased CGL and VEGF gene expression via the integrated stress response through GCN2 
activation and ATF4 stabilization (Lee et al., 2008). Interestingly, additional regulation of H2S 
production appeared to occur in ECs on a post-translational level, as evidenced by rapidly 
increased H2S production upon VEGF addition, possibly via calcium-calmodulin stimulation of 
CGL (Yang et al., 2008). Future studies will be required in order to determine the relative 
contributions of GCN2/ATF4-dependent transcriptional regulation of CGL and VEGF-dependent 
post-translational activation of H2S production. Moreover, despite the crucial importance of CGL 
in ECs (here) and hepatocytes (Hine et al., 2015), the potential role of other H2S-generating 
enzymes, CBS or 3-MST, present in other tissues in vivo must also be considered.  
The use of a fluorescent probe to visualize H2S production in frozen sections in vivo also 
allowed us to confirm that endogenous H2S was increased upon amino acid restriction. This was 
not possible in our previous study (Hine et al., 2015) in which the lead sulfide method was 
employed because of the requirement for addition of exogenous cysteine as substrate in this 
assay. Nonetheless, the increase in endogenous H2S production by CGL in ECs upon removal 
of its substrate, Cys, from the diet presents an apparent paradox. It should be pointed out, 
however, that the source of free Cys for H2S generation by CGL is not currently known, but 
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could come from pools distinct from diet-derived or de novo-produced Cys. For example, 
cytoplasmic glutathione levels which are in the millimolar concentration range could be utilized 
to produce Cys, as could lysosomal Cys produced upon autophagy, which is also increased in 
the context of nutrient deficiency. In support of this latter notion, the benefits of MR on longevity 
in yeast require autophagy (Ruckenstuhl et al., 2014).  
 
Mechanisms of H2S action in ECs 
While the major mechanism by which H2S is thought exert its biological activities is 
through post-translational modification of target proteins via sulfhydration of surface-exposed 
cysteine residues, thus altering protein activity (Mishanina et al., 2015), H2S can also alter the 
function of metal-containing proteins via direct interaction with metallocenters. A classic 
example of this is sulfide coordination of the copper-heme iron complex in Complex IV of the 
mitochondrial ETC that reversibly inhibits terminal electron transfer to oxygen (Nicholls and Kim, 
1982). 
Our data regarding inhibition of mitochondrial respiration in the pro-angiogenic effects of 
H2S in ECs is consistent with the importance of this latter mechanism of H2S action in biology, 
not only for its toxicity at high H2S concentrations, but also for its ability to alter cellular 
oxidative/glycolytic energy balance at physiological levels. EC generate 85% of their ATP via 
glycolysis, and are thus “addicted” to glucose (De Bock et al., 2013). Despite the significantly 
lower energy yield per molecule of glucose via glycolysis (2 ATP) vs. oxidative metabolism (34 
ATP), glycolysis offers other advantages to ECs. For instance, anaerobic glucose metabolism 
enables ECs to vascularize avascular anoxic tissues, an activity that would not be possible if 
they would rely primarily on oxidative glucose metabolism. Furthermore, glycolysis can generate 
more molecules of ATP in a shorter time span as compared to oxidative metabolism, thus 
rapidly providing ECs with the necessary energy to sprout and form new vessels, and thereby 
quickly restore oxygen supply to the surrounding tissue.  
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The effects of H2S on cellular energy metabolism may also have important implications 
for cancer, both in terms of therapeutic inhibition of angiogenesis (Schoors et al., 2014) as well 
as in energy metabolism of the tumor itself. Interestingly, a number of tumors and cancer cells 
lines upregulate GCN2 (Lehman et al., 2015; Wang et al., 2013) or H2S production 
(Bhattacharyya et al., 2013; Sen et al., 2015; Sonke et al., 2015; Szabo et al., 2013), and thus 
possibly contributing to the Warburg effect through inhibition of mitochondrial respiration. 
In the context of ageing, genetic alteration of the worm electron transport chain that 
reduced mitochondrial function results in a longer lifespan (Dillin et al., 2002; Lee et al., 2003). 
This is potentially counterintuitive, as normal ageing in humans as well as premature aging in 
mouse models is also associated with reduced mitochondrial function (Short et al., 2005; 
Trifunovic et al., 2004). Although further experiments are required, the notion that H2S is a 
reversible inhibitor of Complex IV could explain the difference between it and cyanide, a lethal 
compound that irreversibly inhibits the same ETC component. In support of this idea, mice with 
transient or partial deletion of various mitochondrial electron transport components prolong life, 
(Liu et al., 2005) while severe mitochondrial impairment shortens lifespan of worms (Rea et al., 
2007).   
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Experimental Procedures 
Mice  
All experiments were performed with the approval of the Harvard Medical Area or Boston 
University Institutional Animal Care and Use Committee (IACUC). 8-14 wk old male or female 
C57BL/6 mice (The Jackson Laboratory, Bar Harbor, ME) were used for all experiments unless 
otherwise indicated. Male and female CGL+/+ and CGL-/- mice on a mixed 129/C57BL/6 
background (Yang et al., 2008) and GCN2 KO and control mice on a C57BL/6 background 
(Peng et al., 2012) were bred at our facility. 
Dietary regimens: Mice were given ad libitum (AL) access to food and water unless 
otherwise indicated. Experimental diets were based on Research Diets D12450B with 
approximately 18% of calories from protein (hydrolysed casein or individual crystalline amino 
acids (Ajinomoto) in the proportions present in casein), 10% from fat and 72% from 
carbohydrate. MR diets containing 1.5g Met/kg food and lacking Cys (Miller et al., 2005) in the 
context of a 14% protein/ 76% carbohydrate calorie diet were provided AL. In experiments with 
CGL+/+ and CGL-/- mice, the control diet was supplemented with 4.3g Cys/kg food to 
compensate for the inability of CGL-/- mice to make Cys. AL food intake per gram of body weight 
was monitored daily for several days and used to calculate calorie restriction (CR) based on 
initial animal weights. Protein free diets were kept isocaloric by replacing casein/amino acids 
with an equal weight of sucrose and provided either AL or 40-50% CR as indicated. Animals 
were fed daily with fresh food between 6pm and 7pm. Water-only fasting was accomplished by 
transferring mice to a fresh cage with free access to water but without food for 3 d.  
Pharmacological interventions: Axitinib and L-NAME were supplemented at a daily dose 
of ~30mg/kg/d and 80mg/kg/d respectively in the food as previously described (Alonso et al., 
2010; Ma and Waxman, 2008).  
Adenoviral-mediated gene delivery: Local overexpression of CGL or VEGF in 
gastrocnemius was accomplished by intramuscular injection of 40 µl of 109 PFUs of an 
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adenovirus-type 5 (dE1/E3) containing the CMV promoter driving expression of the mouse CGL 
gene (Ad-mCTH/CGL, Genbank RefSeq BC019483, ADV-256305 Vector Biolabs) or the human 
VEGF gene (Ad-hVEGFA165 Genbank RefSeq NM_001171626, Vector Biolabs) or the 
negative control virus Ad-CMV-Null (1300 Vector Biolabs) once weekly for 2 wks.  
Hindlimb ischemia model 
12 wk old C57BL/6 (wild-type) WT mice were anaesthetized with isoflurane and body 
temperature maintained on a circulating heated water pad. Following a 1 cm groin incision, the 
neurovascular pedicle was visualized under a microscope (LW Scientific, Z2 Zoom 
Stereoscope) and the femoral nerve carefully dissected out. The femoral vein (located medially) 
was separated from the femoral artery (located laterally) allowing electrocoagulation of the left 
common femoral artery, proximal to the bifurcation of superficial and deep femoral artery while 
sparing the vein and nerve. Once the artery was occluded, the surgical site was inspected for 
any residual bleeding (Hoefer et al., 2004; Mirabella et al., 2011).  
Laser Doppler perfusion imaging (LDPI) was performed as described previously (Hoefer 
et al., 2004; Mirabella et al., 2011). Briefly, mice were kept under isoflurane anaesthesia, and 
body temperature maintained on a circulating heated water pad. Blood flow recovery was 
monitored at d 0 (immediately post-surgery), d1, d3, and d10 using an LDPI analyzer (Moor 
Instruments, Inc. DE). The LDPI intensity of the ischemic foot was normalized to the 
contralateral foot and represented as relative blood flow of the ischemic limb (Ischemic/Non-
ischemic ratio).  
Mouse Exercise Training 
 12 wk old male 129/C57BL/6 WT and CGL KO mice were randomized into sedentary or 
exercise group. Mice were exercised on a Columbus Instruments 6 lane treadmill. Mice were 
acclimatized to the treadmill at 8 m/min for 5 min for 3d prior to exercise training. Mice ran 
30min/d at 5° incline at 12 m/min for the first wk of training. Mice continued running 30min/d at 
5° incline at 14 m/min for an additional 3 wk to reach 1 mo total of exercise training. Sedentary 
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controls and exercised animals were co-housed. Mice were euthanized 1 hr after the final 
exercise bout (Narkar et al., 2008; Narkar et al., 2011).  
Gene expression analysis by qPCR  
Total RNA was isolated from tissues and cells using RNeasy Mini Kit (Qiagen) and 
cDNA synthesized by random hexamer priming with the Verso cDNA kit (Thermo). qRT-PCR 
was performed with SYBR green dye (Lonza) and TaqPro DNA polymerase (Denville). Fold 
changes were calculated by the ΔΔCt method using Hprt, 18S and/or b-Actin genes as 
standards, and normalized to the experimental control. Primer sequences are as follows:  
mouse CGL F: TTGGATCGAAACACCCACAAA R: AGCCGACTATTGAGGTCATCA 
mouse HPRT F: TTTCCCTGGTTAAGCAGTACAGCCC R: 
TGGCCTGTATCCAACACTTCGAGA 
mouse Actin F:AGCTTCTTTGCAGCTCCTTCGTTG R:TTCTGACCCATTCCCACCATCACA 
mouse 18S F: CATGCAGAACCCACGACAGTA R: CCTCACGCAGCTTGTTGTCTA 
mouse VEGF F: CTGTAACGATGAAGCCCTGGAG R: TGGTGAGGTTTGATCCGCAT  
mouse ATF4 F: GAA ATG GCC GGC TAT GG R: TCC CGG AAA AGG CAT CCT 
mouse ASNS F: GTCAAGAACTCCTGGTTCAAG R: GATCTGACGGTAGAAGTAGC  
human VEGF F: AGCTGCGCTGATAGACATCC R: CTACCTCCACCATGCCAAGT 
human HIF1a  F: GAAGTGGCAACTGATGAGCA R: GCGCGAACGACAAGAAA  
human PGC1a F: CTGCTAGCAAGTTTGCCTCA R: AGTGGTGCAGTGACCAATCA 
human CGL F: CAACATCACTGTGGCCATTC R: AGAGGCAGCAATTACACCAGA 
human ATF4 F: CTATACCCAACAGGGCATCC R: GTCCCTCCAACAACAGCAAG 
human ASNS F: GCGGAGTGCTTCAATGTAAC R: CCAATAAGAAAGTGTTCCTGGG 
human ACTIN F: GTTGTCGACGACGAGCG R: GCACAGAGCCTCGCCTT 
human HPRT F: ACCCTTTCCAAATCCTCAGC R: GTTATGGCGACCCGCAG  
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Immunoblotting   
 Cells were homogenized with passive lysis buffer (Promega), normalized for protein 
content, boiled with SDS loading buffer and separated by SDS-PAGE. Proteins were transferred 
to PVDF membrane (Whatman) and blotted for CGL (ab151769 Abcam), HIF1a (10006421 
Cayman Chemical), p-eIF2a Ser51 (9712S Cell Signaling), total eIF2a (9722S Cell Signaling), 
ATF4 (11815 Cell Signaling), Actin (13E5 Cell Signaling) and Tubulin (2146S Cell Signaling) 
and secondarily with HPR conjugated anti-rabbit antibody (Dako).  
VEGF ELISA  
 Mouse VEGF ELISA kit was purchased from Peprotech and the assay was performed as 
per manufacturer’s instructions. 100 µl of plasma or cell culture media was used for each 
analysis. 
Immunostaining  
 CD31 immunostaining was performed on 50 µm frozen sections of unfixed 
gastrocnemius muscle using the primary anti-mouse CD31 (17-0311-82, ebioscience), anti-
mouse VEGF (Novus Biologicals) and Isolectin B4 (Life Technologies) at a dilution of 1:100. 
Sections were fixed for 5 min with PFA 4% and rinsed in PBS, the immunostaining was then 
performed as previously described (Longchamp et al., 2014). CD31 area was quantified from 
randomly photographed 10 µM stack sections (6 images per section, 4 sections per muscle per 
mouse) using Fiji software (http://fiji.sc/Fiji). All quantifications were performed blindly. 
H2S measurements 
 
Lead sulfide method on live cells: For detection of H2S production in live cells, growth 
media was supplemented with 10mM Cys and 10 µM Pyridoxal 5’-phosphate hydrate (PLP, 
Sigma), and a lead 6x4 inch pieces of lead acetate paper, made by soaking 703 size blotting 
paper (VWR) in 20 mM lead acetate (Sigma) and then vacuum drying, was placed over the 
plate for 2-24 hrs of further incubation in a CO2 incubator at 37OC until lead sulfide was detected 
but not saturated. 
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H2S detection with fluorescent probe on live cells: For detection of endogenous H2S 
production in live cells, growth media was supplemented with 10 µM P3 probe (Singha et al., 
2015) for 30 min prior to fixation. Quantitative measurements were performed with a microplate 
reader (Biotek Synegy2) using a 360 nm excitation and 528 nm emission wavelength. 
Qualitative assessment was performed using a 2 photon microscope (Zeiss LSM780 w/ Mai Tai 
HP 2-photon laser (Spectra Physics) at 880 nm excitation and 520-550 emission (Singha et al., 
2015).  
H2S detection with fluorescent probe on tissue sections: 50 µm frozen sections of 
unfixed gastrocnemius muscle were incubated with 20 µM P3 probe (Singha et al., 2015) for 5 
min and washed with PBS 2 times. Sections were then fixed for 5 min in 4% PFA prior to 
immunostaining as described above. 
Cell culture conditions 
 Simulated in vitro MR: Pooled human umbilical vein endothelial cells (HUVECs) were 
obtained from Lonza (C2519A, Lonza) and used between passage 1 and 5. HUVECs were 
cultured in endothelial basal medium (EBM-2) supplemented with 2% FBS and endothelial 
growth medium SingleQuots (Clonetics, Lonza) at 37OC in 5% O2. Complete media are denoted 
as “control” (Ctrl) throughout the manuscript.  
Primary hepatocytes were isolated by collagenase treatment (Liberase, Roche), Percoll 
(GE Healthcare) gradient centrifugation and initially cultured in William’s E media (Sigma) with 
5% FBS for several hours.  
Primary mouse endothelial cells were isolated from the lung by collagenase digestion 
(Liberase, Roche) followed by sequential affinity selection method using Dynabeads™ goat anti-
rat conjugated to rat-anti mouse CD31 (BD Biosciences, San Jose, CA), and cultured in 
endothelial basal medium (EBM-2) supplemented with 2% FBS and endothelial growth medium 
SingleQuots (Clonetics, Lonza). At least three independent primary mouse EC cultures per 
genotype was tested per experiment.  
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When cultures reached confluence, the media was removed and replaced either with 
complete DMEM or DMEM lacking Met&Cys (Sigma) both supplemented with the same amount 
of dialysed FBS plus endothelial growth medium SingleQuots (Clonetics, Lonza) from 1 to 24 
hrs.  
Pharmacological interventions and hypoxia: L-NAME (100 µM), NaHS (100 µM), PAG 
(100 µM), SU5416 (20 µM), Axitinib (10 µM) and Ex527 (10 µM) were supplemented as 
previously described (Alonso et al., 2010; Hine et al., 2015; Price et al., 2012).	  Hypoxia was 
induced via oxygen displacement with nitrogen gas. 
Transient transfection and siRNA knockdown in vitro: siRNA knockdown of human 
activating transcription factor 4 (ATF4), human endothelial nitric oxide synthase (eNOS), human 
hypoxia-inducible factor 1-alpha (HIF1a) and scrambled control was performed in HUVEC using 
lipofectamine RNAiMAX (Life Technologies) and 30nM siRNA purchased from Ambion (Ambion, 
Life Technologies) as described previously (Hine et al., 2015). All experiments were performed 
2 d after transfection. Knockdown was confirmed by immunoblot and/or qPCR. 
 Adenoviral-mediated gene delivery in vitro: HUVEC were infected overnight in complete 
medium and collected 2 d later using Ad-m-CTH or the negative control virus Ad-CMV-Null 
adenovirus amplified and purified by Vector Biolabs (Philadelphia, PA, U.S.A.).  
Spheroid capillary sprouting assay 
 Hanging drops of HUVEC or primary mouse ECs in EGM2 (De Bock et al., 2013) were 
embedded in Matrigel® (Corning) and cultured in the indicated media for 24 hrs to induce 
sprouting. Compounds were added at the indicated concentrations during the gel culture step, 
using corresponding vehicle concentrations as control. Images were captured with a Zeiss LSM 
510 Meta NLO confocal microscope (oil objectives: x 40 with NA 1.3, x 63 with NA1.4, x 100 
with NA 1.3; Carl Zeiss, Munich, Germany) or a Leica laser-scanning SP5 confocal microscope 
(Leica, Manheim, Germany). Analysis of the sprout length was performed using ImageJ 
software. 
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Wound healing assay 
A single scratch wound was created using a sterile p200 pipette tip on a confluent field 
of ECs, 24 hrs after seeding (100,000 cells per well in 24-well plate) and after cells were 
mitotically arrested (1 µg/ml MitoC overnight). Repopulation across the scratch wound was 
recorded by phase-contrast microscopy every 4 hrs for up to 20 hrs using a digital camera. 
Wound closure (gap area at time = x hr relative to time = 0 hr) was determined at each time 
point from digital images using ImageJ software.  
Glucose uptake 
HUVEC were pretreated for 1 hr with VEGF (peprotech) 50ng/ml, NaHS 100µM or KCN 
10µM. Cells were then depleted in Krebs-Ringer Bicarbonate Buffer (KRB; NaH2PO4/Na2HPO4 
10mM, NaCl 136mM, KCl 4.7mM, MgSO4 1.25mM, CaCl2 1.25mM, pH7.4), without glucose 
and serum for 30 min and then incubated for 6 min in a solution containing 0.5µCi 2-DG. On ice, 
cells were then washed in cold PBS 3 times, lysed, and sample counted in a liquid scintillation 
counter. Samples were normalized to protein content as measured from the same cells by BCA. 
Seahorse 
Cellular oxygen consumption and extracellular acidification rate was measured using the 
Seahorse Cell Metabolism Analyzer XF96 (Seahorse Biosciences). Cells were plated at a 
density of 12,000 cells and untreated or pretreated with 100 µM NaHS, Cyanide 10 µM or 
Phenformin 500µM for 2 hrs. After 24 hrs, media was changed to unbuffered XF assay media 
with 0 or 11mM glucose, 0 or 2mM glutamine and pyruvate at pH7.4 and basal OCR and ECAR 
measured for 5 blocks of 2 min mixing and 5 min measuring. Glucose (10 mM final), 2-DG (50 
mM final) and Oligomycin (2.5 µM final) were injected at indicated times. All plates were 
normalized to protein content as measured from the same cells after Seahorse by BCA.  
Metabolite profiling for glucose flux analyses 
To determine the relative levels of intracellular metabolites, extracts were prepared and 
analyzed by LC/MS/MS. Triplicate 15-cm confluent plates were incubated in EGM-2 media in 
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presence or absence of 100 µM NaHS 105 min prior to extraction. For D-[1,2-13C
 
]- glucose flux 
studies, cells were washed once with serum- and glucose free DMEM and then incubated in 
DMEM containing a 10 mM 1:1 mixture of D-[1,2-13C
 
]-glucose and unlabeled D-glucose for 15 
min. Metabolites were extracted on dry ice with 4-mL 80% methanol (-80°C), as described 
previously (Ben-Sahra et al., 2013). Insoluble material was pelleted by centrifugation at 3000g 
for 5 min, followed by two subsequent extractions of the insoluble pellet with 0.5-ml 80% 
methanol, with centrifugation at 16000g for 5 min. The 5 ml metabolite extract from the pooled 
supernatants was dried down under nitrogen gas using an N-EVAP (Organomation Associates, 
Inc).  
Dried pellets were resuspended using 20 µL HPLC grade water for mass spectrometry. 10 µL 
were injected and analyzed using a 5500 QTRAP triple quadrupole mass spectrometer 
(AB/SCIEX) coupled to a Prominence UFLC HPLC system (Shimadzu) via selected reaction 
monitoring (SRM). Some metabolites were targeted in both positive and negative ion mode for a 
total of 287 SRM transitions using pos/neg polarity switching. ESI voltage was +4900V in 
positive ion mode and –4500V in negative ion mode. The dwell time was 3 ms per SRM 
transition and the total cycle time was 1.55 seconds. Approximately 10-14 data points were 
acquired per detected metabolite. Samples were delivered to the MS via normal phase 
chromatography using a 4.6 mm i.d x 10 cm Amide Xbridge HILIC column (Waters Corp.) at 350 
µL/min. Gradients were run starting from 85% buffer B (HPLC grade acetonitrile) to 42% B from 
0-5 minutes; 42% B to 0% B from 5-16 minutes; 0% B was held from 16-24 minutes; 0% B to 
85% B from 24-25 min; 85% B was held for 7 min to re-equilibrate the column. Buffer A was 
comprised of 20 mM ammonium hydroxide/20 mM ammonium acetate (pH=9.0) in 95:5 
water:acetonitrile. Peak areas from the total ion current for each metabolite SRM transition were 
integrated using MultiQuant v2.0 software (AB/SCIEX). For stable isotope labeling experiments, 
custom SRMs were created for expected 13C incorporation in various forms for targeted 
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LC/MS/MS. Peak areas of metabolites detected by mass spectrometry were normalized to 
median and then normalized to protein concentrations.  
Statistical analyses 
 Data are displayed as means +/- standard error of the mean (SEM) and statistical 
significance assessed in GraphPad Prism using Student’s t tests unless otherwise specified. A 
P-value of 0.05 or less was deemed statistically significant.  
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Figure S1.  
(A) Representative capillary-like structures (left) and total tube length quantification (right) in 
HUVEC cultured in the indicated media in presence or absence of the SIRT1 inhibitor Ex-527 
for 16 hrs. (B) Daily body weight (left) and food intake expressed as grams of food eaten per 
gram of mouse body weight (right) of mice given ad libitum access to methionine restricted (MR) 
vs. control (Ctrl) diet for 2 mo; n=10-15/group. (B) Expression of VEGF mRNA in gastrocnemius 
muscle of mice subject to 1 wk of 40% protein calorie restriction (PCR) or 3 d water-only fasting 
(Fast) expressed relative to Ctrl diet group; n=3-7/group. (C) Flow cytometric analysis of CD31 
positive cells from the indicated organs of mice fed a Ctrl or MR diet for 2 mo and expressed as 
a ratio relative to Ctrl; n=3-4/group. (D) Flow cytometric analysis of CD31 positive cells from 
gastrocnemius muscle of mice fed for 2 wks on Ctrl or MR diets with or without VEGFR2 
inhibition (Axitinib, +A); n=4-5/group. (E) Schematic representation of the hindlimb ischemia 
procedure. Error bars indicate SEM; *P < 0.05, **P < 0.005 compared to Ctrl by Student’s t test.  
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Figure S2. 
(A) HIF1α mRNA expression (left) and protein level (right) in HUVEC 2 d after transfection with 
HIF1α siRNA or control scrambled (Sble) siRNA. (B) VEGF mRNA expression in HUVEC 2 d 
after transfection with HIF1α or control scrambled (Sble) siRNA and cultured in the indicated 
media for 16 hrs. (C) PGC1α mRNA levels of HUVEC cultured in the indicated media for 16 hrs. 
(D) PGC1α and VEGF mRNA levels in HUVEC, 2 d after transfection with a PGC1α 
overexpressing construct, and expressed relative to cells transfected with a control empty 
vector. (E) Relative ATF4 (left) and Asns (right) mRNA expression in HUVEC 2 d after 
transfection with ATF4 siRNA or control scrambled siRNA and cultured in the indicated media 
for 16 hrs. (F) Western blot of ATF4 (left) or ATF4 and Asns mRNA (right) expression in HUVEC 
2 d after transfection with a CMV-driven ATF4 over-expressing construct (ATF4OE) or empty 
vector (Empty). (G) Representative images of primary mouse ECs stained for CD31 (red), Actin 
(green) and DAPI (blue) at a 40X magnification. (H) Asns mRNA in GCN2+/+ and GCN2-/- 
primary mouse EC cultured in M&C deficient media relative to control (Ctrl) media for 16 hrs. (I) 
Asns mRNA levels of C2C12 cultured in the indicated media for 16 hrs. (J) HIF1α mRNA 
expression in C2C12 cells 2 d after transfection with HIF1α or control scrambled (Sble) siRNA. 
(K, L) HIF1α protein level (K) and VEGF mRNA (L) in C2C12 2 d after transfection with HIF1α 
siRNA or control scrambled (Sble) siRNA under 20 or <1% oxygen in presence or absence of 
M&C. All cell-based assays were repeated at least three times. Error bars indicate SEM; 
*P < 0.05, **P < 0.005 ***P < 0.001 compared to Ctrl by Student’s t test. 
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Figure S3. 
(A) Representative images (10X magnification) of H2S-specific probe fluorescence in primary 
mouse hepatocytes treated with VEGF (50 ng/ml) or deprived of all amino acids as well as 
serum (-Nutrients) for 16 hrs. (B) VEGF mRNA in CGL+/+ and CGL-/- primary mouse EC cultured 
in M&C deficient media relative to control (Ctrl) media for 16 hrs. (C, D) CBS, CGL and 3-MST 
mRNA expression (left) and protein level (right) in HUVEC 16hrs after treatment with VEGF. All 
cell-based assays were repeated at least three times. Error bars indicate SEM; **P < 0.005 
***P < 0.001 compared to Ctrl by Student’s t test. 
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Figure S4. 
(A) H2S production capacity of gastrocnemius muscle extracts of Ad-Null or Ad-CGL infected 
mice 1 wk after i.m. injection; n=3/group. (B) Expression of VEGF mRNA in the gastrocnemius 
muscle of mice subjected to low intensity running (exercised) vs. control (sedentary) for 1mo; 
n=5-6/group. 
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Figure S5. 
(A) Western blotting of eNOS in HUVEC 2 d after transfection with eNOS or control scramble 
(Sble) siRNA. (B) Quantification of time-dependent wound closure (area under the curve, 
A.U.C.) in HUVEC scratch wound assays 2 d after transfection with eNOS siRNA or control 
scramble (Sble) siRNA +/- NaHS (100 µM) as indicated. (C) Quantification of wound closure 
(A.U.C.) in HUVEC scratch wound assays +/- NaHS (100 µM) or eNOS inhibitor L-NAME (100 
µM). (D) Western blot of CGL in HUVEC 2 d after infection with a control (Ad-Null) or CGL-
expressing adenovirus (Ad-CGL) at the indicated multiplicity of infection (MOI). (E) 
Quantification of wound closure (AUC) in HUVEC scratch wound assays 2 d after infection with 
control (Ad-Null) or CGL-expressing adenovirus (Ad-CGL) at multiplicity of infection 50 +/- L-
NAME (100 µM) as indicated. (F) Representative transverse sections of gastrocnemius muscle 
stained for CD31 (left, 40X magnification) and quantification (right) from mice fed Ctrl or MR 
diets +/- L-NAME for 2 wks as indicated; n=4/group. (G) Extracellular acidification rate (ECAR) 
over time in HUVEC pretreated for 2 hrs with VEGF (50ng/ml) or NaHS (100 µM) and then treated 
with 10 mM Glucose, 2.5 µM Oligomycin and 50 mM 2-DG injection as indicated by the arrows. (H) 
Extracellular acidification rate (ECAR) over time in HUVEC pre-treated for 2 hrs with axitinib (10 
µM) or L-NAME (100 µM) and then treated with NaHS or 2-DG as indicated by the arrows. All cell-
based assays were repeated at least three times. Error bars indicate SEM; *P < 0.05, 
**P < 0.005, ***P < 0.001 compared to Ctrl by Student’s t test. 
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Figure S6. 
(A) Relative 2-DG uptake in HUVEC treated with NaHS for 1 hr in presence or absence of 
dithiothreitol (DTT) to prevent sulfhydration. (B) C13-labeled metabolite levels measured by 
mass spectrometry-scaled intensity in C13 glucose pulsed HUVEC +/- NaHS. (C) Relative 2-DG 
uptake in HUVEC treated with NaHS for 1 hr in presence or absence of Compound C (Comp. 
C). (D) Wound closure quantification (A.U.C., area under the curve) in HUVEC treated with 
NaHS in presence or absence of Compound C (Comp. C). (E) Extracellular acidification rate 
(ECAR) over time in HUVEC pretreated for 2 hrs with cyanide 10µM, oligomycin 2µM (Oligo) or 
phenformin 500µM (Phen) and then treated with 10 mM glucose, 2.5 µM oligomycin and 50 mM 2-
DG as indicated by the arrows. (F) Representative image of wound closure in MitoC-treated 
HUVEC scratch wound assays in the presence of 10 µM Cyanide (KCN, left), 500 µM 
Phenformin (Phen, middle) or 2 µM oligomycin (oligo, right) +/- 1 mM 2-DG. (G) Quantification of 
endogenous H2S production by H2S-specific fluorescent probe intensity in HUVEC treated for 2 
hrs with cyanide (10µM), oligomycin (2µM, Oligo), phenformin (500µM, Phen) or NaHS (100 µM) as 
indicated. (H) Relative 2-DG uptake in HUVEC treated with KCN for 1 hr.  (I) Quantification of 
HUVEC that fail to exclude PI dye after 2 hrs treatment with NaHS (100 µM), cyanide (10µM) or 
oligomycin (2µM) as indicated. All cell-based assays were repeated at least three times. Error 
bars indicate SEM; **P < 0.05, ***P < 0.005, compared within genotype to Ctrl by Student’s t 
test. 
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Chapter 3: Association of Serum Hydrogen Sulfide Production with Post-operative 
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Abstract 
 
Background – Hydrogen Sulfide (H2S) is an endogenously produced gas with broad protective 
effects on the vascular system. Circulating H2S levels correlate positively with vascular health, 
but are difficult to measure quantitatively. Activities of enzymes that produce H2S can also be 
measured in blood serum, however the biological significance or predictive value with regard to 
vascular health is unknown. 
 
Methods – Clinical history and blood were prospectively collected from patients undergoing  
vascular surgery (mean age 69 years, male 67%), including carotid endarterectomy (n=49), 
open lower extremity arterial revascularization (n=44) or major leg amputation (n=22) as well as 
in 20 control patients (mean age 68.4 years, male 65%). H2S production, was measured using 
the lead acetate method. Free sulfur, CBS and CGL activity was quantified using mass 
spectrometry and compared in patient with vascular disease versus control. Given the Gaussian 
distribution of serum H2S, we divided high (n=57) versus low (n=58) H2S producing patients to 
examine if serum H2S was associated with 1 and 2-year mortality following surgery. For 
comparison of continuous clinical, demographic variables, and H2S, either Pearson or 
Spearman correlation testing was used depending upon the normality of distribution. 
 
Results – Control patients that did not require cardiovascular surgery had the highest serum 
H2S production capacity [mean±SD (81±13)]. Among patients that underwent surgery for 
vascular disease, preoperative serum H2S production capacity was significantly lower in patients 
with mortality [mean±SD (53±7); n= 20 all-cause mortality events during a 2 year follow up] than 
those alive [mean±SD (57± 8)]. Furthermore, the percentage of survival in the low H2S (defined 
as <median) was lower [6 months, 2 years (78 and 74)] compared to high H2S (defined as 
>median), [6 months, 2 years (93, 91)].  
 
Conclusions – Serum H2S production capacity was linearly correlated with mortality following 
surgical revascularization and may serve as an easily quantified measure with biological 
significance with regards to vascular health. 
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Introduction 
Hydrogen sulfide (H2S) is a colorless gas with a characteristic rotten-egg odor found in various 
natural and industrial sources (1). Although toxic at high levels, H2S produced at low 
concentrations by degradation of Cys or homocysteine by CGL or CBS acts on the vasculature 
and the brain as a signaling molecule to prevent neurodegeneration (2), reduce blood pressure 
(3), protect from hear failure (4, 5), promote angiogenesis (6, 7) and protect from limb ischemia 
(8) Exogenous H2S can also extend lifespan of worms (9) and induce suspended animation in 
mammals (10). 
 
Results 
Circulating H2S has previously been inversely correlated with reduced cardiovascular health (8, 
11), however the absolute values of these measurements and the source of H2S remain 
controversial (12). We thus chose to use the lead sulfide method to test H2S production capacity 
in serum (rather than actual free or bound H2S) of rodents on the most effective pro-
longevity intervention (13-16), 
calorie restriction (CR). One week 
of CR significantly increased serum 
H2S production (p<0,05; Fig. 1), 
providing proof of principle that 
serum H2S production capacity is 
plastic.  
 
In human ischemic heart disease and stroke, underlying atherosclerosis, are the world’s 
leading cause of death, accounting for a combined 30% (15 million) of the mortality 
worldwide. Therefore, we measured H2S production capacity in patients suffering chronic 
Figure 1: Circulating H2S is increased by Caloric 
restriction. 
Representative plasma H2S production capacity (left) 
and quantification (right) in mice fed for 1 week on 
control (Ctrl) or 50% caloric restricted (CR) diets. 
Error bars indicate SEM; p<0.05 by Student t test. 	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ischemia, underlying advanced atherosclerosis 
(vascular cohort) compared a control cohort (ctrl, table 
1). The vascular and control population consisted of 
115 and 20 patients, respectively. Both group were 
similar in terms of age, sex and BMI. Although the 
prevalence of hypertension (HTN) was similar in both 
group (3), other cardiovascular risk factors and 
disease (diabetes, hyperlipidemia, renal insufficiency, 
stroke, PAD, MI) as well as antiplatelet therapy, 
statin use and anti-hypertensive medication were 
more prevalent in the vascular cohort (Table 1).  
Comparison of control versus vascular patients 
revealed 1.4 fold higher serum H2S (p<0.0001; 
Fig. 2 and S1). Given the Gaussian distribution of 
serum H2S among patients that underwent 
surgery (vascular cohort, Fig 3A), we divided high 
(n=57) versus low (n=58) H2S producing patients to examine if serum H2S was associated 
with clinical 1 and 2-year mortality following surgery. Among patients that underwent surgery 
for vascular disease, preoperative serum H2S production capacity was significantly lower in 
patients with mortality [mean±SD (53±7); n= 20 all-cause mortality events during a 2 year 
follow up] than those alive [mean±SD (57± 8)]. Furthermore, the percentage of survival in the 
low H2S (defined as <median) was lower [6 months, 2 years (78 and 74)] compared to high 
H2S (defined as >median), [6 months, 2 years (93, 91)].  
Figure 2: Circulating H2S 
production is reduced in patients 
with vascular disease and 
correlates with survival.  
Representative plasma H2S 
production capacity (left) and 
quantification (right) from human 
patients suffering vascular occlusive 
disease (Disease, n=115), versus 
healthy age-matched individuals 
(Healthy, n=20) as detected by the 
lead sulfide method. Error bars 
indicate SD; p<0.0001 by Mann-
Whitney (Wilcoxon rank sum).  	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Interestingly, using LC-MS, we found that in the CBS activity was reduced but that free Sulfur 
was increase in plasma level in patients undergoing vascular surgery procedure, consistnat with 
the observation that H2S protects from cardiovascular disease (Fig. 4) 
 
 
  
  
Figure 3: Pre-operative serum H2S correlates with survival.  
(A) Distribution of H2S plasma level in patients undergoing vascular surgery procedure. 
(B) Kaplan-Meier survival curve for patients with low (n=58) and high (n=57) plasma H2S 
before undergoing vascular surgery procedure. P value is derived from log-rank 
calculation.  	  
Figure 4: CBS activity and sulfide levels. 
CBS activity (A) and free Sulfur (B) in plasma 
level in patients undergoing vascular surgery 
procedure 	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Discussion 
Here we find that serum H2S increased H2S production capacity is detectable in serum 
upon nutrient restriction in rodents, and correlates with survival in patients suffering vascular 
disease.  
Caloric restriction represents the best-studied anti-aging model in rodents. To date, 
molecular mechanism underlying pleiotropic benefits on health and lifespan are not completely 
understood. Previously we found that in mouse liver, endogenous H2S increased upon CR. H2S 
production was necessary and sufficient for surgical stress resistance, using model of hepatic 
ischemia reperfusion injury in mice. Furthermore, H2S was associated with extended longevity in 
fly, worm and yeast models (17). Here we found increased serum H2S production in mice fed 
with a CR for 1 week compared to ad-libitum fed animals (Ctrl).  
Circulating proteins that change in abundance across the lifespan have the potential to 
serve as instructive biomarkers and, potentially, targetable modifiers of aging conditions (18-20). 
In a small study including 57 patients, total plasma sulfide is negatively related to severity 
of congestive heart failure and predict mortality. (21). In mice with heart failure, H2S levels are 
decreased in the heart and blood. Additionally, systemic H2S supplementation in mice lacking 
the H2S producing enzyme CGL (CGL KO) restored H2S blood levels and prevented heart 
failure (4). In our study, we found H2S to be an important predictive marker of survival in patient 
following vascular surgery. Interestingly, H2S levels affected 8-mo mortality but benefit was lost 
after. Taken together, these data are consistent with increased serum H2S as a marker of 
health, and pro-longevity factor. These findings also further support a role for the clinical utility of 
measuring H2S in the context of vascular surgery. 
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Material and Methods 
Mice  
All experiments were performed with the approval of the Harvard Medical Area or Boston 
University Institutional Animal Care and Use Committee (IACUC). 8-12 weeks old male and 
female C56/BL6 (The Jackson Laboratory, Bar Harbor, ME) were used for all experiments 
unless otherwise indicated.  
Dietary regimens: Mice were given ad libitum (AL) access to food and water unless 
otherwise indicated. Experimental diets were based on Research Diets D12450B with 
approximately 18% of calories from protein (hydrolyzed casein or individual crystalline amino 
acids (Ajinomoto) in the proportions present in casein), 10% from fat and 72% from 
carbohydrate. AL food intake per gram of body weight was monitored daily for several days and 
used to calculate 50% dietary restriction (CR) based on initial animal weights. Animals were fed 
daily with fresh food between 6pm and 7pm. Fasting was applied by transferring mice to a fresh 
cage without food for 3 days.  
 
Human Study Participants and Serum Collection 
 Patients undergoing carotid endarterectomy for symptomatic or asymptomatic stenosis 
and patients undergoing lower limb amputation or bypass following critical limb ischemia at a 
single institution in 2013 provided written informed consent for prospective collection of 
demographic, clinical, and duplex ultrasonography data under a Partners Human Research 
Committee institutional review board–approved protocol. Fifteen milliliters of peripheral blood 
were obtained at the time of the surgery from peripheral intravenous line placement. Serum was 
isolated by centrifugation for 15 min at 2000g at room temperature. All samples were 
immediately snap frozen in liquid nitrogen then stored at -80°C until the time of analysis.  
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H2S measurements 
Lead sulphide method: 20 µl of serum was diluted 150 µl of PBS containing 100 mM Cys 
and 3 mM PLP. 6x4 inch pieces of lead acetate paper, made by soaking 703 size blotting paper 
(VWR) in 20 mM lead acetate (Sigma) and then vacuum drying, were placed over the 96-well 
dish and incubated for 2-24 hrs at 37OC until lead sulphide was detected but not saturated. 
Quantification of lead sulfide H2S production capacity assays was done using the IntDen 
measurement in ImageJ software as previously published(13, 17).  
 
Statistical Analyses 
Data are displayed as means +/- Standard error of the mean (SEM) if not specified and 
statistical significance assessed in GraphPad Prism using Student’s t tests to compare values 
and one-sample t test to compare means to a hypothetical value of 1 or 100 when data was 
normalized to the average value of the control group. Non-Gaussian distributed data were 
compared using the Mann Whitney t-test. Continuous clinical and demographic variables 
Pearson or Spearman correlation testing was utilized depending upon the normality of 
distribution.   A P-value of 0.05 or less was deemed statistically significant.  
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Supplemental Materials 
Supplemental Figure 1: 
Plasma H2S production capacity from human patients suffering vascular occlusive disease 
(Disease, n=115), versus healthy age-matched individuals (Healthy, n=20) as detected by the 
lead sulfide method.  
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Supplemental table 1: Baseline Study Population Characteristics. 
Variable Vascular Cohort  (n=115) 
Control Cohort 
(n=20) 
Mean age, years (SD) 69 (9) 68 (2.3) 
Sex 
 
 
   Male (%) 73 (63) 13 (65) 
   Female (%) 42 (37) 7 (35) 
Race 
 
 
   White (%) 97 (84) 18 (90) 
   Hispanic (%) 10 (9) 0 
   Black (%) 4 (3.5) 0 
   Other (%) 4 (3.5) 2 (10) 
Mean BMI (SD) 28.3 (5.3) 28.7 (7.2) 
Comorbidities 
 
 
   Prior stroke (%) 24 (21) 0  
   Peripheral arterial disease (%) 75 (65) 0  
   Prior MI (%) 30 (26) 0  
   Prior coronary intervention (%) 44 (38) 0 
   Heart failure (%) 19 (17) 0  
   HTN (%) 106 (92) 19 (95) 
   Hyperlipidaemia (%) 98 (85) 6 (30) 
   Diabetes mellitus (%) 45 (39) 2 (10) 
   COPD (%) 7 (6) 0  
   Renal insufficiency (%) 16 (14) 5 (1) 
   Malignancy 23 (20) 4 (20) 
   Smoking status 
 
 
            Never 25 (22) 9 (45) 
            Former 60 (52) 11 (55) 
            Current 30 (26) 0 
Preoperative medications 
 
 
   Aspirin (%) 102 (89) 6 (30) 
   Clopidogrel (%) 28 (24) 0 
   Warfarin (%) 11 (10) 2 (10) 
   Low molecular weight heparin (%) 6 (5) 0 
   Unfractionated heparin (%) 14 (12) 0 
   Statin (%) 99 (86) 7 (35) 
   Beta blocker (%) 89 (77) 10 (50) 
   Calcium channel blocker (%) 37 (32) 3 (15) 
   ACE-inhibitor (%) 49 (43) 8 (40) 
   ARB (%) 13 (11) 0 
Procedure 
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   Carotid endarterectomy (%) 49 (43) 0 
   Infrainguinal revascularization (%) 44 (38) 0 
   Lower extremity amputation (%) 22 (19) 0 
SD, standard deviation; N.A., not available; BMI, body mass index; MI, 
myocardial infarction; HTN, hypertension; COPD, chronic obstructive 
pulmonary disease; ACE, angiotensin converting enzyme; ARB, angiotensin 
receptor blocker; HDL, high density lipoprotein; LDL, low density lipoprotein; 
CRP, C-reactive protein; Cr, creatinine 
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CONCLUSION AND PERSPECTIVES  
The aim of this work was to investigate the role of nutrients in vascular homeostasis, 
especially following surgery.  
The first chapter, provides an update on the nutritional basis, nutrient sensing 
mechanisms, and downstream effectors of protection by short-term DR in preclinical models of 
surgical stress. While DR clearly protects from oxidative stress, ionizing irradiation and 
chemotherapy (1), we have used mouse models of surgical stress, in particular ischemia-
reperfusion injury to the liver and kidney (2-5), as well as stroke (6) not only understand the 
underlying mechanisms of DR but to demonstrate that in the context of surgery, DR works 
rapidly (2 days in rodents) (7) and that protein restriction alone, especially restriction of the 
sulfur amino acids methionine and cysteine are sufficient for the benefits of DR (2, 3). These 
and other observations (8), have strengthened the translational potential of “pre-surgical short-
term DR”. Although the implementation of these dietary measures in human is appealing, the 
immediate challenge is to define the timing and examine if DR would be applicable to everyone 
(9) or identify the patients or procedure(s) that might benefits the most and those at risk of 
adverse effects.  
In the second aim we tested the potential of isolated nutrient restriction independent of 
hypoxia to impact the formation of new vessels (angiogenesis). Previously we found that CGL 
as well as hepatic H2S production capacity are increased upon DR, and repressed by dietary 
sulfur amino acids, but the molecular requirements for dietary control of H2S production were 
not elucidated (2). Here, we revealed a requirement for the AASR in the coordinate regulation of 
CGL as well as VEGF upon nutrient restriction. In all cells tested, sulfur amino acid deprivation 
increased CGL and VEGF gene expression via the integrated stress response through GCN2 
activation and ATF4 stabilization (10). Interestingly, additional regulation of H2S production 
appeared to occur in ECs on a post-translational level, as evidenced by rapidly increased H2S 
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production upon VEGF addition, possibly via calcium-calmodulin stimulation of CGL (11). Future 
studies will determine the relative importance of each pathway. 
More importantly, we identified an unrecognized pro-angiogenic pathway activated by 
dietary amino acid restriction and controlled by the GCN2/ATF4-dependent AASR. These 
findings reveal the AASR as a new target for modulation of angiogenesis by pharmacological or 
even dietary manipulations. This has therapeutic value for example in the context of limb 
ischemia, a major complication of cardiovascular disease and diabetes that is not amenable to 
treatment by exercise. In the context of cancer chemotherapy, where inhibition of angiogenesis 
is desired, it is also important to recognize the AASR as an independent pathway with the ability 
to contribute to tumor vascularization. 
The discovery that H2S boosts glycolytic ATP production by inhibiting mitochondrial 
electron transport in ECs, especially complex I and IV provides a novel mechanism of H2S 
action in biology, not only for its toxicity at high H2S concentrations. It further demonstrates the 
H2S ability to alter cellular oxidative/glycolytic energy balance at physiological levels. EC 
generate 85% of their ATP via glycolysis (12). Despite the significantly lower energy yield per 
molecule of glucose via glycolysis anaerobic glucose metabolism enables ECs to vascularize 
avascular anoxic tissues, an activity that would not be possible if they would rely primarily on 
oxidative glucose metabolism. The effects of H2S on cellular energy metabolism may also have 
important implications for cancer, both in terms of therapeutic inhibition of angiogenesis (13) as 
well as in energy metabolism of the tumor itself. Interestingly, a number of tumors and cancer 
cells lines upregulate GCN2 (14, 15) or H2S production (16-19), and thus possibly contributing 
to the Warburg effect through inhibition of mitochondrial respiration. 
In human, ischemic heart disease and stroke, are the world’s leading cause of death, 
accounting for a combined 30% (15 million) of the mortality worldwide. In the last chapter, we 
hypothesized that circulating H2S production was a relevant marker of vascular health. Clinical 
history and blood were prospectively collected from patients undergoing vascular surgery as 
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well as 20 controls, healthy patients. Consistent with our hypothesis, serum H2S was 
significantly higher in healthy individuals. Furthermore, among patients that underwent surgery 
for vascular disease, preoperative serum H2S production was linearly correlated with survival. 
Consistently, in another study, including 57 patients, total plasma sulfides are negatively related 
to severity of congestive heart failure and predict mortality (21). In mice with heart failure, H2S 
levels are decreased in the heart and blood. Taken together, these data are consistent with 
increased serum H2S as a marker of health. These findings also further support a role for the 
clinical utility of measuring H2S in the context of vascular surgery. 
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FUTURE DIRECTIONS 
Basic research  
ECs are plastic cells, located at the interface between blood and organs, that can switch 
between growth states(12), and undergo multiple developmental and functional transitions 
during fetal, neonatal and adult life. This plasticity is crucial to maintain a healthy microvascular 
network, providing adequate blood supply to organs throughout life and during metabolic 
stresses(20). In the latest stages of life, impaired EC regenerative potential leads to progressive 
organ failure throughout the body, suggesting that improved understanding of the fundamental 
mechanisms underlying EC plasticity and aging would have tremendous impact on lifespan and 
quality of life. Aging itself is associated with reduced capillary density; reduced new vessel 
formation; reduced number and function of endothelial precursor cells; and increased EC 
senescence. Extensive published and preliminary data indicate that H2S has a key role in 
regulating well as vascular remodeling/angiogenesis. However the role of CGL/H2S in vascular 
homeostasis with advancing age, its role in the vascular benefits of DR or the relevant cellular 
source of H2S in this context are unknown. In addition, the H2S generating enzymes circulate at 
high level in healthy individuals, but declines dramatically with vascular diseases in concert with 
the emergence of multiple age-associated pathologies in muscle and other tissues. Based on 
these data, we propose that H2S represent a new endothelial-derived circulating anti-aging 
molecule, which holds therapeutic promise to restore more youthful function to aging 
tissues (appendix 1). In this project, we will use DR as well as transgenic models to stimulate 
endogenous H2S production from endothelial cells. We will define H2S therapeutic relevance in 
the prevention and treatment of age-related disease, especially skeletal muscle dysfunction and 
hypertension, central elements of the vascular aging process.  
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Clinical translation 
1. Circulating H2S levels correlate positively with vascular health (e.g. blood pressure, 
muscle function(21-23) and dietary restriction (24) in mice. In human, single nucleotide 
polymorphism (SNP) in CGL is linked to variation in serum homocysteine(25). Our 
preliminary data indicates that in PAD patients, serum H2S is significantly reduced 
compared to healthy control and inversely correlates with metabolic health (Chapter 3). 
Importantly, in PAD patients undergoing open surgical revascularization, pre-operative 
serum H2S linearly correlates with 2-years survival following surgery (Chapter 3). Thus, 
we propose to expand our analysis in humans, and determine the relationship 
between serum H2S production and cardiovascular health in human, using the 
Cohort study of Lausanne (CoLaus, Appendix 1, 26-29). 
 
2. In rodent, removing protein from thee diet for about a week dramatically protects from 
injury such as ischemia reperfusion and other surgical related injury. In human, there is 
currently no pre-operative dietary consensus nor guidelines that aim to reduce surgical 
mortality or complications. To prevent bronchoaspiration, general anesthesia and 
sedation require stomach emptying via fasting 2 hrs after clear fluids, 4 hrs after 
ingestion of breast milk or 6 hrs in the case of non human milk and 8 hrs after a meal 
containing fat or meat. Enhanced recovery after surgery (ERAS) protocols are 
increasingly used multimodal perioperative care pathways designed to achieve early 
recovery after surgical procedures. The key components of ERAS protocols include 
preoperative counseling, optimization of nutrition, standardized analgesic and anesthetic 
regimens and early mobilization. Interestingly, pre-operative 12.6% oral carbohydrate 
loading is one cornerstone of ERAS. 100g of carbohydrate administered the day before, 
and 50g the day of the surgery are thought to alleviate surgical induced insulin 
resistance, “reduce catabolism”, and thirst. Several studies report shorter length of stay 
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and a reduction in patient discomfort. While non-mutually exclusive, we aim to 
determine the safety and feasibility of implementing a defined protein-calorie 
restriction regimen as a nutriceutical intervention to improve recovery after 
surgery. Ongoing Clinical trial, in collaboration with with Prof. C.-K. Ozaki at Brigham 
Women’s Hospital in Boston (USA) is currently evaluating the safety of a 3-day diet 
reduced in both total calories (1000 kcal/daily) and total protein before carotid 
endarterectomy. Future work will help us to define what is the most effective diet and for 
how long. Will the diet need to be individualized to clinical parameters such as age, body 
mass index, diabetes, etc.? The challenge of voluntary reduced food intake scales with 
the severity and duration of food restriction. We aim for maximal efficacy within the 
shortest time frame and with the least restrictive diet. In these early phase clinical trials, 
safety will be measured using clinical observation and blood glucose measurement. 
Weight loss will be recorded, with a drop over 7% of body mass during the pre-
conditioning period considered as dangerous. Systemic adverse effects to evaluate will 
include fatigue, malaise and neuromuscular weakness. On the other hand, will primary 
endpoint for efficacy will be length of hospital stay and complication rate, surrogates 
efficacy can be assessed in the serum using H2S production capacity and available 
commercial ELISA kits for determine changes in insulin, IGF-1, leptin, adiponectin and 
FGF21 following diet.  
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SUMMARY 
Human aging and age-associated diseases represent one of the biggest health challenges faced by developed 
and developing countries. As the body ages, one of the most dramatic and threatening changes is a decline in the 
function of endothelial cells that line the vasculature, resulting in a failure in most physiological systems. The clinical 
manifestations are multiple, including hypertension, myocardial infarction, stroke, dementia, critical limb ischemia, muscle 
decline and exercise intolerance, vascular dementia, impaired wound healing, and erectile dysfunction. Importantly, 
vascular dysfunction in the elderly is one of the strongest predictors of imminent death. This suggests that a better 
mechanistic understanding underlying vascular aging, and novel strategies to intervene in this process could 
tremendously impact lifespan and the quality of life in this growing population of aged (>65 years old) individuals.  
Dietary Restriction (DR), defined as reduced food intake without malnutrition, was first described nearly a century 
ago by McCay and colleagues to extend lifespan in rats. Since then, DR has been extensively studied, in a multitude of 
organisms, and evidence supports that DR increases lifespan and confers protection against age-associated diseases 
such as hypertension and ischemia of the limbs, heart, or brain. However, despite DR’s health benefits, it would be 
extremely difficult to achieve adherence to such a stringent diet in humans. To this end, extensive efforts have been made 
towards the identification of the nutritional, cellular and molecular mechanisms that underlie DR benefits, and could prime 
pharmacological “DR-mimetics”. One step closer to this goal, we recently reported that DR increases endogenous 
hydrogen sulfide production (H2S) in the liver, via upregulation specifically of the enzyme cystathionine γ-lyase (CGL), but 
not other H2S producing enzymes. In this context, the increase in CGL/H2S was necessary and sufficient for DR-mediated 
protection from ischemic injury to the liver and for lifespan extension in worms. 
Extensive published and preliminary data indicate that H2S has a key role in regulating 
blood pressure as well as vascular remodeling/angiogenesis during muscle ischemia. However 
the role of CGL/H2S in vascular homeostasis with advancing age, its role in the vascular benefits 
of DR or the relevant cellular source of H2S in this context are unknown. In addition, the H2S 
generating enzymes circulate at high level in healthy individuals, but declines dramatically with 
vascular diseases in concert with the emergence of multiple age-associated pathologies in 
muscle and other tissues. Based on these data, we propose that H2S represent a new 
endothelial-derived circulating anti-aging molecule, which holds therapeutic promise to 
restore more youthful function to aging tissues. In this project, we will use DR as well as 
transgenic models to stimulate endogenous H2S production from endothelial cells. We will 
define H2S therapeutic relevance in the prevention and treatment of age-related disease, 
especially skeletal muscle dysfunction and hypertension, central elements of the vascular aging 
process, according to the following specific aims (Figure 1):  
 
Aim 1.  Evaluate the function of H2S in endothelial cells growth and plasticity, and clarify the basis for the age-
and ischemia-dependent effects on muscle function. 
Aim 2.  Determine the relationship between serum H2S production and cardiovascular health in mice and in 
human, using the Cohort study of Lausanne (CoLaus). 
 
Together these studies will lend important insights into the basic science of vascular aging, especially endothelial cells 
dysfunction, as well as open new avenues for the rapid development of therapeutics of age-related diseases, specifically 
skeletal muscle dysfunction and hypertension.   
Figure  1: Role of H2S 
in vascular aging 
	  2. RESEARCH PLAN 
2.1 Current state of research in the field 
2.1.1 Aging and dietary restriction 
The population aged 65 and over is projected to grow from 40 million in 2012 to 80 million in 2050 in the United 
State alone. According to the vascular theory of aging1, the progressive decline in endothelial function is one of the major 
causes of aging and age-related diseases, manifesting in diverse ways, from cardiac infarctions and strokes, to peripheral 
artery disease (PAD), exercise intolerance and sarcopenia to hypertension, erectile dysfunction, liver failure, osteoporosis, 
impaired wound healing, and frailty2-5. Despite the importance of endothelial function to human health and longevity, it is 
surprising how little we understand about its underlying causes 1.  
In 1935, Clive McCay discovered that dietary restriction (DR), or reduced food intake without malnutrition, extends 
lifespan in rats6,7, a finding later confirmed in in a multitude of organisms from yeast8 to worms9 to flies10,11, fish12, rodents 
13,14 and rhesus monkeys15,16. Notably, DR remains the only non-genetic method to increase longevity in every species 
studied. In humans, DR reduces risk factors for diabetes, cardiovascular disease, and cancer17,18. In the past years we 
and others demonstrated that short-term DR (2 days in rodents) improves the outcome of preclinical mouse models of 
acute and chronic vascular disease model such as ischemia-reperfusion injury to the liver and kidney19-23, stroke24 and 
vascular restenosis25. Importantly, our recent data implicate H2S produced by CGL (discussed below) in DR-mediated 
protection from ischemia reperfusion injury and lifespan extension19,26,27.  
 
2.1.2. Hydrogen sulfide 
Hydrogen sulfide (H2S) is a gas easily identified by its distinctive odor of rotten eggs. While toxic at high levels, 
H2S produced endogenously by CGL or CBS (Figure 2) acts on the vasculature and the brain as a signaling molecule to 
reduce blood pressure28 and prevent neurodegeneration29. Low levels of exogenous H2S also extends lifespan of 
worms19,27 and induce suspended 
animation in mammals30. H2S has 
numerous other cardiovascular benefits, 
including pro-angiogenesis in vitro and in 
vivo31,32, reduced vascular restenosis 
(intimal hyperplasia)33,34, anti‐
atherosclerotic activity35, and reduced 
binding of neutrophils to the wall of blood 
vessel36. On the other hand, in humans, serum H2S concentration declines with age37 and the levels of the H2S producing 
enzymes are reduced in patients suffering vascular diseases38,39. We have recently demonstrated that mice lacking the 
H2S-producing enzyme CGL fail to gain the protective effects of DR, while adenoviral overexpression of CGL in the liver, 
or delivery of H2S itself, recapitulate DR-like benefits without the need for any dietary intervention19. Whether free H2S is a 
circulating gasotransmitter that acts as a paracrine, or autocrine molecule is still being debated and difficult to address40,41. 
However, the enzyme CGL secreted by endothelial cells (EC)s and hepatocytes circulates in the plasma/serum, and 
actively produces H2S in human blood42, which may be critical for the systemic vascular benefits of H2S43. H2S has many 
potential mechanisms of action, including sulfhydration, or formation of –SSH moieties on surface-exposed Cys residues, 
of an ever-growing list of protein targets29,40,44-47. In ECs, for example, such targets include the Kir6.2 regulatory subunit of 
the KATP channel and the VEGF receptor leading to vessel relaxation and angiogenesis, respectively45,47. H2S also has 
Figure 2: Model of the Cysteine and Methionine metabolism, specifically the 
transsulfuration pathway. Arrows trace sulfur from Met to Cys and downstream 
cellular processes via cystathionine beta-synthase (CBS) and cystathionine 
gamma-lyase (CGL).	  
	  direct antioxidant properties, and can participate in mitochondrial energy production by donating electrons to the 
mitochondrial electron transport chain protein SQR, with a potential role in protection from organ ischemia48,49.  
 
2.1.3. Contribution of endothelial cells to organismal aging 
ECs are plastic cells, located at the interface between blood and organs, that can switch between growth states50, 
and undergo multiple developmental and functional transitions during fetal, neonatal and adult life. This plasticity is crucial 
to maintain a healthy microvascular network, providing adequate blood supply to organs throughout life and during 
metabolic stresses51. In the latest stages of life, impaired EC regenerative potential leads to progressive organ failure 
throughout the body, suggesting that improved understanding of the fundamental mechanisms underlying EC plasticity 
and aging would have tremendous impact on lifespan and quality of life. Aging itself is associated with reduced capillary 
density; reduced new vessel formation; reduced number and function of endothelial precursor cells; and increased EC 
senescence52. Systolic blood pressure continuously increases with age5,53 as well as the occurrence of vascular diseases, 
even in populations without other major risk factors54-56. Besides prevalence, mortality due to ischemia is higher in the 
elderly55,57. Mechanisms of age-associated decline in vascular function are complicated and poorly understood, but 
appear in many cases to be initiated by EC dysfunction58,59. While the mechanisms are currently unknown, in human and 
rodents, DR dramatically reduces endothelial dysfunction60, blood pressure61,62 and promotes angiogenesis as well as 
functional muscle recovery following femoral artery ligation63. Similarly, blood pressure is increased in CGL knockout 
mice28, and can be reduced by exogenous H2S64. 
 
2.1.4. H2S and vascular diseases 
The benefit of generating new blood vessels to the ischemic tissues is obvious40,65-67. In this regards, exogenous 
H2S promotes collateral vessel growth, capillary density, and blood flow in ischemic muscles following femoral artery 
ligation68, in the heart during heart failure32 and in wound healing69. Mice lacking endogenous CGL/H2S (CGL knockout / 
CGLKO mice), have decreased blood flow and vascular density, following limb and heart ischemia65,70, while cardiac- 
specific overexpression of CGL71 or exogenous H2S limits ischemia-reperfusion damage72,73. Similarly, H2S protects from 
ischemic in injury in the liver19, the brain74,75, and the kidney76. The growth of new blood vessels (angiogenesis) involves 
coordinate EC proliferation, migration and sprouting. In vitro, the absence of CGL reduces ECs sprouting77,78, while 
exogenous H2S increases EC proliferation, adhesion, migration, formation of tube-like structure and sprouting31,78.  
 
2.2 Current state of our research   
In the past 4 years spent between the Service of Vascular Surgery (CHUV, Lausanne) and the laboratories of 
Professors James R. Mitchell and C. Keith Ozaki at Harvard University (Boston, USA), including the funded period (SNSF, 
P1LAP3_158895, 01.12.2014 – 31.05.2016), I have contributed to a total of 11 peer-reviewed publications, including 10 
original research papers and 1 review. As a clinician-scientist, I will devote 50% of my time to this project (please see 
accompanying letter from Prof. J-M. Corpataux). 
The proposed 4-year project will be carried out in Lausanne, Switzerland, at the CHUV in the laboratory of 
vascular surgery (see “Resources” and letter of support Prof. J.-M. Corpataux). Beside our cutting edge laboratory of 
molecular and cellular biology, we benefit from a modern surgical suite in the animal facility. Importantly, we will continue 
our close local collaboration with Professors Jacques-Antoine Haefliger (with whom we share the laboratory space), as 
well as international collaboration with James R. Mitchell and C.- Keith Ozaki at the Harvard University (Boston, USA), 
both world experts in aging/DR and vascular biology, and Massimo Santoro at Leuven University (Leuven, Belgium), an 
	  expert on metabolism and angiogenesis (see letters of support). In addition, we are closely collaborating with Prof. Peter 
Vollenweider in the CHUV (Lausanne, Switzerland) for the handling and analysis of the CoLaus samples (Aim 2, see letter 
of support). 
Together with additional preliminary data presented below, this proposal builds on published expertise in vascular 
biology19,25,79-120, aging19,26,121-124, dietary interventions7,19-26,101,114,120-134 and hydrogen sulfide19,26,121. In Aim 1, we will test 
the functionality of H2S/CGL in preventing/reversing age-related vascular dysfunction using murine models in which 
improvement in endothelial function gives a measurable benefit. These models include i) longitudinal blood pressure 
measurement113,135-143 and ii) neovascularization and muscle function following femoral ligation, a validated pre-clinical 
model of peripheral artery disease (Figure 1, 6 and 113,135-143). In Aim 2, with Prof. Peter Vollenweider and the CoLaus 
team, we will examine the association between serum CGL/H2S and cardiovascular disease in human. 
Below I present the recent work that is directly related to this research proposal. 
 
2.2.1. Vascular density and skeletal muscle function decreases with age  	   As the body ages, there is senescence 
and apoptosis of muscle ECs, leading to blood 
vessel loss, decreased muscle perfusion, reduced 
muscle mass (sarcopenia) and a steady decline in 
strength, endurance and regenerative 
capacity51,56,144-146. However, the exact 
mechanism underlying the switch from young to 
old muscle is currently unknown. Our preliminary 
data indicates that aging reduces angiogenic 
potential, as shown by decreased ECs sprouting 
using the aortic-ring assay (Figure 3a). Similarly, 
vascular density as measured by CD31 
immunostaining of ECs was reduced in the 
skeletal muscle of aged (12 month-old), 
compared to young (10 week-old) mice (Figure 
3b). Reduced vascular density in aged mice was 
associated with reduction in muscle fiber size as 
well as decreased oxidative capacity (Figure 3c). 
At a functional level, these histological changes 
imparted running endurance as shown by 
significantly reduced running time and distance in 
aged mice (Figure 3d), using the treadmill assay as 
published147,148. Together, these findings demonstrate that muscle function is reduced by age, which could be facilitated 
by a decrease in vascular function.  
  
Figure 3. Decrease in endothelial function and exercise capacity 
with age.	  (a) Representative phase-contrast images of aortic rings 	  
from young (10 weeks) and old (12 months) WT mice (n=6 per age) 
(b) Representative transverse sections (40X magnification) of baseline 
TA muscle from young (10 weeks) and old (12 months) WT mice 
stained for CD31. (c) Representative transverse sections (40X 
magnification) of baseline TA muscle from young (10 weeks) and old 
(12 months) WT mice stained for H&E, mATPase (indicating type I and 
II fibers) and SDH activity (from left to right). (d) Time spent and 
distance run until exhaustion in treadmill exercise test in young (10 
weeks) and old (12 months) mice (n = 6 per age). Error bars indicate 
SD. *p<0.05, ***p<0.001 compared to young by Student’s t test .	  
	  2.2.2. Hydrogen sulfide produced via CGL decreases with age and vascular diseases 
The importance of CGL-derived H2S to maintain vascular health is unequivocal19,28,31,32,38,40,65,70,71,78,149,150. 
Recently, we found that H2S is crucial in the benefits of DR on lifespan and protection from ischemia19. Furthermore, 
H2S/CGL is decreased by vascular diseases38,39 and in the elderly37. Therefore, we hypothesized that H2S is critically 
linked to vascular aging. In our preliminary data, we took advantage of publically available data sets from aged versus 
young mice, and demonstrated down-regulation of CGL (but not CBS or 3-MST, data not shown) in multiple organs of 
aged mice, including the muscle (Figure 4a) and the heart (Figure 4b). Furthermore, “vasculo-protective interventions” 
such as exercise and DR, consistently increased 
CGL (Figure 4a and b, accession number 
GSE6323, 38063, 7640, 6718 and 68646). CGL is 
decreased in the muscle of patients suffering from 
limb ischemia38. Similarly, CGL is significantly 
reduced in human carotid atheroma of the plaque 
compared to distant macroscopically intact tissue 
(Figure 4c). Finally, serum H2S production is 
significantly lower in patients suffering arterial 
occlusive disease (defined as requiring surgical 
revascularization), compared to similar patients 
without arterial lesion (Figure 4d). Altogether, 
these preliminary data are consistent with a 
progressive decline in H2S production with age, 
and suggest an important interplay between H2S 
levels and vascular health (Figure 4).  
 
 
 
 
 
 
 
 
 
  
Figure 4: Beneficiary 
interventions such as 
running, DR and youth 
increase CGL in vascular 
tissues and in the serum. 
(a-c) Muscle (a), heart (b) and 
carotid (c) CGL expression 
using microarray data from 
the publicly available GEO 
data sets (accession number 
GSE6323, 38063, 7640, 
6718, 68646 and 43292) (d) 
Serum H2S production from 
human patients suffering 
vascular occlusive disease 
(Disease, n=115), versus 
healthy age-matched 
individuals (Healthy, n=20) as 
detected by the lead sulfide 
method. Error bars indicate 
SD; p<0.0001 by Mann-
Whitney (Wilcoxon rank sum). 
	  2.2.3. In endothelial cells, hydrogen sulfide is induced by DR and is required for vascular growth 
We previously demonstrated that DR induces H2S production via CGL (but not CBS and 3-MST), and protects 
from ischemic injury in vivo19. Exogenous H2S promotes EC migration, proliferation and formation of capillary-like 
structure31,40, while endogenous CGL promotes EC sprouting78. Here we propose that DR induction of endogenous H2S is 
fundamental to the growth of new blood vessels (see Longchamp et al., appendix 1). According to our preliminary data, in 
ECs, DR19, and the pro-angiogenic vascular endothelial growth factor (VEGF)151,152 stimulate H2S enzymatic production 
(measured using the lead acetate method, Figure 5a) and CGL, but not CBS and 3-MST, expression  (Figure 5b). H2S 
production in ECs is also abrogated by specific inhibition of CGL with DL-Propargylglycine (PAG, Figure 5a). Increased 
endothelial H2S production correlated with increased vascular growth in models such wound healing assay (Figure 5c), 
Figure 5: H2S produced via CGL promotes angiogenesis in-vitro and in the skeletal muscle in-vivo. (a) Representative H2S 
production capacity as indicated by black lead sulfide formation from EC in absence of methionine and cysteine (DR) for 16 hours or 
treated with VEGF (50 ng/ml) in the presence or absence of the CGL inhibitor propargylglycine (PAG, 100 µM) as indicated. (b) 
CBS, CGL and 3-MST mRNA expression in HUVEC 16 hours after treatment with VEGF. (c) Representative wound closure (left, 
10X magnification at time = 20 hours; dotted lines indicate boundary of the scratch wound at time = 0 hour) and area under the 
curve (A.U.C., right) from HUVEC in the indicated media. (d) Representative capillary-like structures (left, tube formation at 40X 
magnification) and mean tube length quantification (right) in HUVEC cultured in the indicated media for 24 hours. (e) Representative 
phase-contrast images of aortic rings from mice fed for 2 weeks on the indicated diet. (f) Representative images (left, 40X 
magnification) and quantification (right) of CGLKO primary EC sprouts in control media (Ctrl) or media lacking methionine and 
cysteine (DR) for 24 hours. (g) Time-dependent wound closure (left) and quantification (right, A.U.C., area under the curve) in 
HUVEC +/- 100µM NaHS in the presence of vehicle or mitomycin C (MitoC) to inhibit proliferation. (h) Quantification of migration 
speed (left) and distance (right) from time-lapse video imaging of GFP+ HUVEC infected with control (Ad-Null) or CGL adenovirus 
(Ad-CGL) as indicated. (i) Representative transverse sections (20X magnification) of gastrocnemius muscle from CGLWT and 
CGLKO mice stained for CD31 and endogenous H2S. (j, k) Representative transverse section (left, 40X magnification) and 
quantification (right) of gastrocnemius muscle stained for CD31 from CGLWT and CGLKO mice fed for 2 weeks on Ctrl or DR diets (i) 
or subjected to low intensity running (exercised) vs. control (sedentary) for 1 month (k); n=5-6/group. Error bars indicate SEM; 
*P < 0.05, **P < 0.005, ***P < 0.001 compared within genotype to Ctrl by Student’s t test.  
	  formation of capillary-like structures (tube formation, Figure 5d) and aortic ring sprouting (Figure 5e). Similarly, increased 
sprout length of EC spheroids upon DR was prevented by CGL inhibition with PAG in HUVECs (data not shown) and by 
genetic CGL ablation (CGLKO) in mouse ECs (Figure 5f). CGL is a promiscuous enzyme that can convert cystathionine to 
cysteine as part of the transsulfuration pathway, but that can also use cysteine to produce H2S, serine and glutathione 
(Figure 2). Importantly, DR reduces glutathione and cysteine levels (Figure 3D of 19), we thus directly tested H2S as the 
CGL metabolite relevant to angiogenesis. H2S delivery in the form of NaHS promoted EC proliferation/migration indicative 
of increased angiogenic potential in the wound closure assay (Figure 5g). Blocking proliferation with mitomycinC (MitoC) 
only partially reduced H2S-induced wound closure (Figure 5g), suggesting that migration is a critical factor in H2S-induced 
angiogenic potential. To confirm the effects of CGL on migration, time-lapse video imaging of GFP+ HUVECs revealed 
that cells overexpressing CGL (Ad-CGL) formed lamellipodial projections over larger areas (data not shown) coincident 
with increased migration speed and greater cell body displacement (Figure 5h). 
As illustrated above (Figure 3), skeletal muscle function relies on a abundant, fully functional vascular network 
upon physiological (e.g. exercise) or pathological condition (e.g. ischemia – vessel occlusion)153. Consistent with our 
findings using in-vitro models, in-vivo in skeletal muscle sections, P3 fluorescence, indicative of endogenous H2S 
production154, co-localized with CD31+ ECs in CGLWT but not CGLKO mice, further suggesting endothelial CGL (and not 
CBS or 3-MST) as the major producer of endogenous H2S in the skeletal muscle (Figure 5j). Coincident with a failure to 
increase H2S, CGLKO mice demonstrated no increase in vascular density upon 1 month of DR or following exercise as in 
the WT group (Figure 5j, k). CGLKO in a C57BL/6 background are a kind gift of Prof. James R. Mitchell, and are currently 
in the Lausanne vascular laboratory breeding colony. Taken together, CGL-derived H2S is required for angiogenesis 
triggered by nutrient deprivation or exercise (Figure 5, 4b and 19). 
 
2.2.4. Dietary or genetically induced CGL/H2S promotes vascular growth and muscle recovery following femoral ligation 
 To further study in vivo the role of 
CGL/H2S in vascular growth we used a 
mouse model of PAD via ligation of the 
femoral artery as published (Figure 6a and 
66,67). This results in limb muscle ischemia, 
followed by progressive 
neovascularization (quantified as the 
relative blood flow of the ischemic limb to 
the contralateral non ischemic limb, using 
laser doppler imaging, Figure 6b) and 
muscle regeneration (Figure 6c). In this 
context, aging results in impaired 
angiogenesis and more severe muscle 
injury51,55,56. Consistent with our	  
hypothesis that dietary induction of 
CGL/H2S promotes functional muscle 
recovery after ischemic injury, PAG 
treatment (a specific inhibitor of CGL), which blocks endothelial H2S production (Figure 5a) abrogated the 
Figure 6: Femoral artery ligation (FAL) to model limb ischemia. (a) Schematic 
representation of the FAL model. (b) Representative Laser Doppler Imaging of the 
ischemic and non ischemic limb at the indicated time. (c) Representative 
transverse sections of gastrocnemius muscle from WT mice stained for CD31, 
H&E, mATPase (indicating type I and II fibers) and SDH activity (from top to 
bottom).  
	  neovascularization induced by DR (Figure 7a). At a functional level, these changes in vascularization imparted running 
endurance as shown by significantly increased running time and distance in DR animals compared to ad libitum (AL)-fed 
control, which was abrogated by PAG (Figure 7b). To examine the importance of H2S produced via CGL, in absence of 
dietary intervention, we recently generated CGL overexpressing mice (CGLTg, Figure 7c-f) by inserting 157 kb fragment of 
genomic DNA containing the CGL-encoding gene, resulting in a duplication of the complete CGL gene (a kind gift of Prof. 
James R. Mitchell, and currently in the Lausanne vascular laboratory breeding colony). CGLTg mice are on a C57BL/6 
background. As predicted, Western blot analyses of multiple tissues confirmed that CGL was overexpressed in CGLTg 
mice compared to littermate controls (see CGL overexpression in liver extracts in Figure 7c). This correlated with 
increased H2S production (Figure 7d) and importantly, improved recovery following femoral ligation in vivo (Figure 7e). 
Finally, the functional benefits of CGL overexpression were demonstrated by significantly increased running time and 
distance in CGLTg mice compared to CGLWT controls, 4 and 14 days following femoral artery ligation (Figure 7f). 
  
 
 
 
 
Figure 7. Role of H2S following ischemic muscle injury (a) Longitudinal Doppler imaging of blood flow in WT mice 
preconditioned on Ctrl or DR diets as indicated for 2 weeks prior to femoral artery occlusion, in presence or absence of PAG 
(20mg/kg/day, a specific inhibitor of CGL) as indicated. I=ischemic; NI, non-ischemic. Left: representative infrared images on 
the indicated day after occlusion. Right: quantification of blood-flow recovery; n=6/group. (b) Time spent and distance run 
until exhaustion in treadmill exercise test 4 and 14 days after femoral artery occlusion, in mice preconditioned on Ctrl or DR 
diets for 2 wks, in presence or absence of PAG (n=6/group). (c-d) Immunoblot for the indicated protein (c) and H2S 
production (d) in liver extracts of CGLWT or CGLTg mice as indicated. (e) Longitudinal Doppler imaging of blood flow in in 
CGLWT or CGLTg as indicated. I=ischemic; NI, non-ischemic. Left: representative infrared images on the indicated day after 
occlusion. Right: quantification of blood-flow recovery; n=8/genotype. (f) Time spent and distance run until exhaustion in 
treadmill exercise test 4 and 14 days after femoral artery occlusion, in CGLWT or CGLTg; n=8/genotype. Error bars indicate 
SD. *p<0.05, **p<0.0 compared to Ctrl or WT by Student’s t test or two-way ANOVA. 	  
	  2.2.5. CGL/H2S regulates blood pressure 
In human, systolic blood pressure (SBP) continuously 
increases with age53,155. In addition mice lacking CGL display 
pronounced hypertension and diminished endothelium-
dependent vasorelaxation28. Preliminary results demonstrated 
that 1 week of DR significantly decreased blood pressure 
(Figure 8a), measured as published113. Importantly, mice 
treated with the CGL inhibitor PAG had higher blood pressure, 
which was not reduced by DR (Figure 8a). In accordance with 
the role of H2S as a physiologic vasodilator, preliminary data 
suggest that SBP is lower in mice overexpressing CGL (CGL 
Tg) than in their WT counterpart (Figure 8b).  
 
2.2.6. CGL is a circulating enzyme producing systemic H2S, which predicts survival in human patients undergoing surgical 
revascularization 
The enzyme CGL, secreted by EC and hepatocyte, circulates in 
the plasma/serum, and actively produces H2S in human blood42. 
Parabiosis experiments, in which two mice are surgically joined together 
and develop a single, shared circulatory system156, indicate that young 
blood containing humoral “rejuvenating” factors can ameliorate the 
function of aged tissues157-161. We hypothesized that CGL is a circulatory 
enzyme, important in the support of vascular health. Consitent with 
enzymatic H2S production in the serum, our prelimary data indicate that 
in human and mice, serum H2S production, using the lead acetate 
methods19, requires pyridoxal phosphate (PLP, Figure 9a) a coenzyme 
for CBS and CGL (but not 3-MST). Furthermore, we observed that 1 
week of DR (Figure 9b) and intravenous overexpression of CGL using 
adenovirus (ad-CGL), without any dietary intervention (Figure 9c) greatly 
increased serum H2S. This observation is consistent with our hypothesis 
that CGL is a circulating enzyme producing systemic H2S.  
  
Figure 9. Serum CGL/H2S is a circulating 
factor. (a) Human serum H2S production, in 
presence of absence of pyridoxal phosphate 
(PLP, as indicated) a coenzyme for CBS and 
CGL (but not 3-MST). (b,c) Mouse serum H2S 
production capacity in mice under 50% dietary 
restriction (DR, b) or one week after i.v. injection 
of an adenovirus overexpressing CGL (ad-CGL, 
c). Error bars indicate SEM. *p<0.05 compared 
to Ctrl-IP by two-way ANOVA. 
Figure 8 CGL/H2S regulates blood pressure in-vivo. (a) 
Systolic blood pressure in mice fed ad libitum (AL) or 50% 
restricted (DR) with or without specific inhibition of CGL 
with PAG (20mg/kg/day), as indicated. (b) Systolic blood 
pressure in CGLWT or CGLTg, at the indicated age. n=7-
8/group. Error bars indicate SEM. *p<0.05, #p<0.05 
compared to Ctrl, or vehicle respectively by two-way 
ANOVA. 	  
	   
Using the same assay described in Figure 5a, 9a-c and 19, our preliminary data in 115 vascular surgery patients 
with PAD reveal that the percentage of survival in the low H2S group (defined as <median) was lower [6 months, 2 years 
(78 and 74)] compared to the high H2S group (defined as >median), [6 months, 2 years (93, 91)], (Figure 10a). 
Interestingly, in the same patients, H2S production was inversely correlated with cholesterol and total triglyceride (Figure 
10b), well-described cardiovascular risk factors5,164,165. Thus, we propose that CGL is a circulating enzyme producing H2S, 
with biological impact in human vascular health.  
 
 
2.3 Detailed research plan 
Aim 1. Evaluate the function of H2S in endothelial cells growth and plasticity, and clarify the basis for the age-and 
ischemia-dependent effects on muscle function. 
Aim 1A. Evaluate the role of endothelial CGL/H2S on vascular homeostasis as a function of age and oxidative stress. 
Rationale: ECs are plastic cells that can switch between growth states50. In the latest stages of life, impaired ECs 
regenerative potential and senescence lead to progressive organ failure throughout the body166,167. Our preliminary data 
indicate that endogenous H2S induced by DR (Figure 5a, appendix 1 and 19,26), exogenous H2S (NaHS), and CGL 
overexpression increases angiogenesis (the formation of new blood vessel), as measured by increased ECs migration, 
migration speed, tube formation and sprouting both in-vitro and ex-vivo in young ECs (Figure 5). These data in normal 
“young” ECs will be first be confirmed, then angiogenesis will be further tested in-vitro, using the assays described above, 
in primary human and mouse ECs exposed to metabolic or oxidative stress, or in senescent EC166,167. Further ex-vivo 
experiment will be performed using aortic rings from young vs. old mice (see Figure 5 and appendix 1). These 
experiments will provide fundamental insight into the specific role of CGL/H2S to prevent and/or restore more youthful 
function to aging ECs. We predict that ablation of CGL/H2S production in ECs will accelerate senescence and reduce 
angiogenesis, while overexpression of CGL will delay ECs aging and/or restore ECs youth. 
  
Figure 10: Circulating H2S production correlates with survival in human 
(a) Kaplan-Meier survival curve for patients with low (n=58) and high (n=57) serum H2S before undergoing vascular surgery 
procedure. P value is derived from log-rank calculation. Error bars indicate SD; p<0.0001 by Mann-Whitney (Wilcoxon rank sum). 
(b) Total serum cholesterol (left) and triglyceride (right) as a function of circulating H2S. Bars indicate estimate and 95% confidence 
bands.  	  
	  Experimental Approach: 
To confirm and extend our preliminary results, ex-vivo aortic ring assays (as in Figure 3a and 5e) will be performed using 
the following mice models: 
1.  Young (10 weeks) and old (12 months) CGLWT and CGLTg aortas (n=7 per group, total 28). The number and total 
area of sprouts originating from aortic rings will be quantified at day 0, 3 and every day up to day 10. In addition, 
primary ECs will be isolated from the lung by collagenase digestion followed by sequential affinity selection method 
using positive selection of CD31 (as in Figure 5f and appendix 1), ECs sprouting will be assayed as described 
below. 
2. Young (10 weeks) and aging (6 months) CGLWT and CGLKO aortas (n=7 per group, total 28) and primary ECs 
isolated (as above in 1. and appendix 1). We note that for the age effect, 6 month-old mice (versus 12 month-old) 
will be used, allowing the detection of premature aging.  
 
To model the effect of age in-vitro, we will also compare the “angiogenic potential” (as in Figure 5 and appendix 1) in 
several models of stress/age-induced senescence in vitro. 
1. Young normal HUVECs (passages 1-5, Lonza) vs. old replicative senescent HUVECs (passages 21-16166). 
2. Young HUVECs exposed or not to chronic low-dose H2O2 to induce senescence-like phenotype. To mimic the 
age-related oxidative environment, HUVECs will be treated with H2O2 (40, 60 and 80µM for 1 hour and then 
cultured for another 24 hours as published168-170.  
3. Young HUVECs exposed or not to chronic high glucose and low dose palmitate. To model age-related metabolic 
stress HUVECs will be treated with high glucose (25 mM) and palmitate (1-200 µM) for 48 hours as published171,172. 
 
The “angiogenic potential” will be studied as follows: 
i. To assess migration, wound healing assay will be used in serum-starved (over night), mitotically arrested cells (1 
µg/ml Mitomycin C overnight). Migration will be quantified every 4 hours up to 16 hours, and expressed as the 
migrated area over the total area of the wound. 
ii. To assess proliferation, HUVECs will be seeded at a low density, serum starved overnight then incubated for 24
hours in media containing 2% serum and 100 µM BrdU in presence or absence of 100ng/ml of VEGF. Results will 
be expressed as a the ratio of BrdU positive cells per total (DAPI positive) cells, in multiples random fields, as 
published117.  
iii. To assess tube formation serum-starved (over night) HUVECs will be seeded in media with or without 100ng/ml of 
VEGF in a 24-well plate coated with 150 µL Matrigel® reduced growth factor basement membrane extract 
(Corning). Following an 18 hour-incubation, the number of branch points and total length of tubule networks will be 
quantified.  
iv. To assess senescence and DNA damage Senescence-associated beta-galactosidase (SA-β-Gal) and 
phosphorylated histone H2AX (γH2AX) will be quantified. Results will be expressed as ratio of SA-β-Gal or γH2AX 
positive cells to total number of cells171,172.  
v. To asses oxidative stress and apoptosis, Mitosox and Annexin V staining assays will be used, respectively. Single 
cell suspension will be stained with MitoSox (ThermoFischer) and with Annexin V kit (Pharmingen). H2O2 (500µM) 
will be used a positive control. Results will be expressed as fluorescence intensity (MitoSox) or as the ratio of 
Annexin V positive / total number cells alive171,172. 
	  The ability of CGL/H2S to restore angiogenic potential in "old/stressed" ECs (using the best model of aging defined above) 
will be tested in the following conditions: 
1. HUVECs will be infected with a control adenovirus (ad-Null, Ctrl) or an adenovirus overexpressing CGL (ad-CGL, 
Figure 5h). 48 hours post infection, cells will be assayed as described above. 
2. HUVECs will be treated 24 hours before and throughout the assay or not (Ctrl) with 200µM GYY413 (Sigma-Aldrich, 
long acting H2S releasing drug) or 10µM NaHS (Sigma-Aldrich, short acting H2S releasing drug). 
 
Aim 1B: Evaluate the impact of CGL/H2S on endothelial health and skeletal muscle function. 
Rationale: Skeletal muscle is an ideal tissue to study the effects of aging on the vascular system, with clearly documented 
reductions in capillary density and function, contributing to a loss of muscle mass (sarcopenia), exercise and regenerative 
capabilities (Figure 3 and 145,149,160,173,174 175-177). DR stimulates angiogenesis via endogenous H2S (Figure 4, 5), and 
muscle regeneration in young and old mice (Figure 7 and 63,178). ECs are the principal source of H2S in the muscle, and 
require CGL (Figure 5i). Here, we propose to examine if CGL/H2S can prevent and/or restore more youthful function to 
aging ECs in-vivo. We predict that overexpression of CGL in transgenic mice (CGLTg) will delay aging. In addition, we 
hypothesized that in old mice, 2-week DR will induce endothelial H2S production and restore the functions of ECs. 
 
Experimental Approach: 
1. To examine if CGL/H2S can prevent and/or delay the age-
dependant reduction in vascular density and muscle function, 
male, young (10 week-old) and old (12 month-old) CGLWT and 
CGLTg (n=10 per group) will undergo unilateral femoral artery 
ligation; a clinically relevant model of age-related vascular 
injury (Figure 6 and 149,160,179,180). Prior to femoral ligation, 
longitudinal non-invasive tail cuff blood pressure measures will 
be taken on all the mice over two weeks (Figure 11) in the awake, conscious animal using the BP-2000 Blood 
Pressure Analysis SystemTM in the Cardiovascular Assessment Facility (CAF) in the University of Lausanne 
(www.unil.ch/caf) as published113. 
In each of these experiments, the contralateral, uninjured limb will be used as the baseline (control). All 
the animals will return to a normal control chow diet after surgery. Longitudinal non-invasive limb and foot flow will 
be measured using Laser Doppler perfusion imaging (LDPI, Moor Instruments, Inc. DE) pre-and post-operatively at 
day (POD) 0, 1, 3, 5, 7 10, 14 in mice kept under isoflurane anaesthesia, and body temperature maintained on a 
circulating heated water pad (Figure 11). Blood flow will be expressed as Ischemic/Non-ischemic ratio by measuring 
the ratio of LDPI intensity of the ischemic foot to the contralateral foot. Muscle functionality will be examined using 
treadmill endurance test (Figure 3, 7 and appendix 1) pre-operatively and at POD 4 and 10. Endurance is measured 
as the function of time and distance ran. At POD14, animals will be euthanized and muscles (gastrocnemius, tibialis 
anterior (TA) and popliteal) from the control and ischemic limb harvested. The TA muscle and the upper half of the 
gastrocnemius will be OCT embedded, frozen and sectioned (7-10µm) for CD31, H2S (using the fluorescent 
probe154, H&E, myosin(m)ATPase assay, Succinate dehydrogenase histochemistry (as in Figure 3, 5, 6 and 
appendix 1). Vascular density will be expressed as the number and area of CD31+ cells per muscle fiber. Fibers 
size, number and type will be measured as described146,181,182. The distal/lower half of the gastrocnemius and the 
Figure 11: Aim 1B experimental design 
	  popliteal muscle will be snap frozen for molecular analyses, including gene (qPCR) and protein expression (western 
blot) of VEGF, CBS and CGL as published19,114,117,119.  
In addition, cardiac hypertrophy is a prominent pathological feature of age-related vascular dysfunction, 
that can be reversed by circulating factors161. Thus, we will weights the hearts at the time of sacrifice. Hearts will be 
fixed embedded, sectioned at midventricle and Masson Trichrome-stained to evaluate fibrosis and hypertrophy as 
published119,161. Heart weight will be normalized to tibia length, a standard method that corrects for differences in 
body frame size and that is more appropriate than normalization to body weight when using older mice161. 
 
2. To test if endogenous CGL/H2S can restore ECs youth, male, young (10 week-old) and old (12 month-old), C57BL/6 
WT will be randomly assigned into 2 preconditioning groups (n=10 per group) prior to surgery: 1) Control chow 2) 2-
week DR. The complete control diet purchased from Research Diets consists of semipurified ingredients with 72% 
calories in the form of carbohydrate (sucrose, maltodextrin); 10% calories as fat (lard, soybean oil); and 18% as 
protein from hydrolyzed casein). The DR regimens tested: 50% DR (50% of ad libitum fed control group, or ~0.11 g 
food/g mouse/day based on average consumption of ~0.22 g food/g mouse/day) as described previously183. All 
groups will then be subjected to the same Experimental Approach as in 1. from Aim 1B). 
 
Anticipated Results: Aim 1A. Ablation of CGL/H2S production should reduce sprouting in young but not in old, senescent 
ECs (Figure 5f). Acute overexpression of CGL (ad-CGL) and exogenous H2S should rescue age-dependent impairment in 
angiogenesis (Figure 5g, h) and prevent ECs senescence. Chronic overexpression of CGL (CGLTg) will prevent ECs aging.  
Aim 1B. Overexpression of CGL in transgenic mice (CGLTg Figure 7c-f) should delay EC aging and stimulate the 
formation of new blood vessels, muscle regeneration and muscle function in both young and old animals (Figure 5). Short-
term DR/endogenous H2S should promote angiogenesis and restore muscle function after injury in both young and old 
mice.  
 
Data Analysis and Statistical Considerations: Descriptive statistics (e.g. mean, median, standard deviation) will be 
calculated for each endpoint. Students t-test will be utilized for the primary endpoint when comparing between two groups, 
and 2-way-ANOVA for multiple comparisons. We will analyze each of the primary endpoints separately and adjust for 
multiple comparisons using False Discovery Rate (FDR)184. Based on prior reports and extensive experience with the 
femoral ligation model66,67 utilizing a detectable difference of 20% (LDI flow or running time/distance), a standard deviation 
of 12%, a desired power (1-beta) of 0.8, and p value of 0.05 (alpha =0.05), a total of 9 animals in each group are 
necessary to reach statistically meaningful conclusions185. Based on our preliminary and published results, in mice fed ad-
libitum, SBP is 15% higher than in littermates mice under DR. If we consider a standard deviation of 10% 28, a desired 
power (1-beta) of 0.8 and a p value of 0.05 (alpha =0.05), a total of 9 animals in each group are necessary to reach 
statistically meaningful conclusions185. For the aortic ring assay, our preliminary data suggest a detectable difference of 
50%. Using standard deviation of 30%, a desired power of 80% and an alpha of 5%, a total of 6 animals in each group are 
necessary to reach statistically meaningful conclusions185. Thus, for Aim 1 a total of 120 mice are needed. We also 
included an animal and specimen loss rate of 10 percent in determination of the resources necessary to complete this 
work, leading to a final total of 136 mice. 
Potential Problems, Limitations, Alternative Approaches: Aim 1A, Senescent ECs (defined here and elsewhere167 as cells 
that seized to proliferate for >2 wks and >50% are positive for SA-β-Gal and γH2AX). These characteristics are usually 
	  observed after passage 20. Depending on the HUVECs and murine ECs isolation this might vary. If so, we will consider 
defining the time course of senescence, using the molecular markers defined above. It is possible that in-vitro CBS is the 
predominant enzyme generating H2S, as it has been demonstrated that CBS expression is increased in-vitro under 
conditions of stress whereas in-vivo, our preliminary data consistently suggest that endothelial-H2S is mostly produced by 
CGL186. As an alternative strategy, we have experience using aminooxyacetic acid (AOAA, 100µM, Sigma-Aldrich), which 
inhibit both CBS and CGL as published187. In addition, CBS can be knocked-down using siRNAs in addition to CGL 
knock-down. Aim 1B. Aged mice may take longer for maximal effect than young healthy mice. If so, we will consider 
placing mice for longer periods of time on DR or using alternating regimens (such as methionine restriction, a diet that 
shares many of the benefits of DR but is given ad-libitum). In addition, the biological function of senescent ECs might 
differ in aged laboratory rodents than in humans, despite the many similarities in their vascular aging phenotypes188. If so, 
we will consider using a mouse model of premature aging (Cockayne syndrome (CS), lacking DNA repair genes Csa and 
Xpa (CX), as published (Brace et al, in press). These mice are currently in the Mitchell lab breeding colony.  
 
  
	  Aim 2. Determine the relationship between serum H2S production and cardiovascular health in mice and in 
human, using the Cohort study of Lausanne (CoLaus). 
Rationale: Circulating H2S levels correlate positively with vascular health (e.g. blood pressure, muscle function)32,38,70 and 
dietary restriction (Figure 4, 8, 9 and 62) in mice. In human, single nucleotide polymorphism (SNP) in CGL is linked to 
variation in serum homocysteine189. Published and preliminary data indicate that the enzyme CGL, secreted by ECs and 
hepatocytes, circulates in the serum, and actively produces H2S in human blood (Figure 4d, 10 and 42). Our preliminary 
data indicates that in PAD patients, serum H2S is significantly reduced compared to healthy control (Figure 4d) and 
inversely correlates with metabolic health (Figure 10b). Importantly, in PAD patients undergoing open surgical 
revascularization, pre-operative serum H2S linearly correlates with 2-years survival following surgery (Figure 10a). Here 
we propose 1) Characterize the association between H2S and the function of ECs in the mice from Aim 1B. , and 2). 
Expand our analysis (Figure 10) in humans, and define the association between serum CGL/H2S and cardiovascular 
diseases in the CoLaus cohort164,165,190,191. 
 
Experimental Approach:  
Aim 2A. Establish the importance of circulating/systemic H2S production in mice throughout life. 
1. First, to characterize serum H2S production, serum will be collected in male, young (10 week-old) and old (12 
month-old) CGLWT and CGLTg (n=10 per group) from Aim 1B. Small volume of tail blood (~150 microliter) will be 
collected 2d before surgery. Serum will be prepared from blood centrifugation as published114. Serum H2S 
production will be measured using the lead acetate assay. Briefly 20 microliter of serum will be incubated with 
10mM Cysteine and 1 mM Pyridoxal 5’-phosphate hydrate (PLP, Sigma) until lead sulfide darkening is visible, but 
not oversaturated (as in 19,26 and Figure 5a, 9). Mean intensity-1 of the darkening will be used to quantify the activity 
of H2S producing enzymes26,121. 
2.  Serum will be collected in male, young (10 week-old) and old (12 month-old), fed with 1) Control chow 2) 2-week 
DR (n=10 per group) from Aim 1B. Serum H2S production will be assessed as in 1. from Aim 2A 
3.  H2S production using lead acetate method is an indirect readout of the associated presence of CGL. In order to gain 
further insight into the exact level of circulating H2S-producing enzyme, large volume of serum will be collected in 
young (10 week-old) and old (12 month-old) C57BL/6 WT (n=10 per group). Blood will be collected by cardiac 
puncture (0.5 to 1 ml) under general anesthesia. Serum H2S production will be assessed as in 1. from Aim 2A. The 
exact level of circulating H2S-producing enzyme, CGL, CBS and 3-MST will be assessed by western blot, after 
clearing the samples of IgG and albumin (Albumin & IgG Depletion SpinTrap™, Sigma-Aldrich) and quantified as 
published117,119. 
 
Aim 2B: Determine the relationship between serum H2S and cardiovascular traits in CoLaus, a large human cohort. 
The CoLaus study, initiated in 2003, is a large population-based monocentric study in Lausanne, including 6738 
extensively phenotyped subjects at baseline and during a 5-years follow-up. All of the subjects were genotyped using 
Affymetrix 500K SNP chip. Designed to identify novel epidemiology and genetic determinants of cardiovascular health, the 
CoLaus cohort led to almost 100 original articles, and novel links between cardiovascular risk factor and disease with 
socioecomnomic status, mental disorders, dietary habits, biological mediators and single-nucleotide polymorphism 
(SNP)164,165,190-194. These experiments will be performed in collaboration with Prof. Peter Vollenweider and his team of 
bioinformaticians (please see accompanying letter of support). 
	  To examine the importance of serum H2S in human cardiovascular disease, serum H2S production will be assessed as in 
1. from Aim 2A. Serum H2S will be primarily correlated with major adverse cardiac events (MACE, defined as death, Q-
wave myocardial infarction and the need for repeat revascularization by redo-CABG or repeat percutaneous intervention). 
MACE was chosen as the primary endpoint as it provides greater statistical power than PAD for example, that occurs with 
a lower frequency. Secondary endpoints will include PAD and cardiovascular risk factors obtained at the somatic baseline 
assessment (http://www.colaus.ch/en/tableau_1.pdf). All statistically significant associations will be further tested for 
confounders using multivariate analysis195. 
 
Aim 2C: Determine the relationship between H2S producing enzymes and cardiovascular traits in the CoLaus study. 
We will further test for potential associations between 5 annotated SNPs for CBS (chr 21), 4 annotated SNPs for CGL (chr 
1) with MACE and H2S production (from Aim 2B). We note that there is no annotated SNP for 3-MST in the CoLaus cohort. 
In addition, we propose to confirm the SNP1364G>T (S403I) in exon 12 of CGL189 as a candidate causal mutation for high 
total serum homocysteine concentration. This work will be performed by Prof. Peter Vollenweider and his team of 
bioinformaticians (please see accompanying letter of support).	  
 
Aim 2D: Uncover novel genetic determinants of serum H2S production using the CoLaus study. 
From a discovery cohort in the CoLaus study, we will test all possible SNP – serum H2S pairs for association. After 
pruning according to SNP linkage and feature correlation, pairs indicating suggestively significant association (defined 
here as p-value below 5×10−8) in CoLaus will be considered for replication (two-stage GWAS design). This work will be 
performed by Prof. Peter Vollenweider and his team of Bioinformaticians (please see accompanying letter of support). 
 
Anticipated Results: Aim 2A. Serum CGL/H2S, will be boosted by CGL overexpression (CGLTg) and by DR in both young 
and old mice (Figure 9b, c). From a retrospective analysis of Aim1B, we predict that serum H2S will be correlated with 
reduction in blood pressure and muscle damage following femoral ligation. Aim 2B. We predict that serum H2S production 
will be reduced in patients with documented MACE and inversely correlate with systolic blood pressure, total triglyceride 
and cholesterol levels (Figure 9 and 10). Aim 2C, D We anticipate that annotated SNPs in CBS and/or CGL and/or 
regulating serum H2S will be associated with or predict the occurrence of MACE. 
 
Data Analysis and Statistical Considerations: For Aim 2A only, 20 mice are needed to reach statistically meaningful 
conclusions185, taking into account an animal and specimen loss rate of 10 percent (see Aim 1B for the analysis). The 
total number of mice needed to complete this work is 156 (Aim 1 and 2). For Aim 2B-D descriptive results will be 
expressed as number of participants and percentage or as mean ± standard deviation. Bivariate analysis will be 
conducted using Chi square test for categorical variables and using Student’s t test or one-way analysis of variance 
(ANOVA) for quantitative values. For continuous variables, post hoc pairwise comparisons using the method of Scheffe 
will be performed when the results of the ANOVA are statistically significant. Multivariable analysis will be conducted using 
logistic regression for binary dependent variables, and the results expressed as odds-ratio and (95 % confidence interval); 
for quantitative variables, multivariable ANOVA will be used and the results will be expressed as adjusted 
mean ± standard error. Logarithmic transformation will be applied to skewed traits. For Aim 2B, our preliminary data 
suggest a 1.4 fold decrease in serum H2S levels among patients suffering PAD compared to healthy control. Using a p 
value of 0.01 (alpha =0.01), desired power (1-beta) of 0.9 and common standard deviation of 25%, the sample size that 
	  will detect a statistically significant difference is 46. For biologically relevant linear variable (e.g. blood pressure, lipids, 
age), we anticipate a Pearson (R square) value of 0.1. Using a p value of 0.01 (alpha =0.01), the estimate sample size is 
272, which can be extracted from the cohort via simple randomization. Statistical analyses were conducted using SAS 
software (v9.3; SAS Institute, Inc, Cary, NC.). For Aim 2C, D. Upon completion of Aim 2 we plan to meet with Prof. Peter 
Vollenweider and the CoLaus team to determine the appropriate additional confirmatory cohorts based on preliminary 
data provided by the CoLaus study. 
 
Potential Problems, Limitations, Alternative Approaches: Aim 2A. Same as Aim 1B. Aim 2A. The effects of H2S produced 
by CGL in the serum on vascular health may be difficult to separate from the benefits of free H2S or sulfur species. Thus, 
we might measure H2S and sulfane sulfur levels using gas chromatography chemilumunescence (Agilent 7890 GC gas 
chromatography system and G660XA Series chemiluminescence detector)38. This can be easily accomplished in 
collaboration with Prof. James Mitchell in Boston. Aim 2B-D. Our primary endpoint (MACE) was chosen to increase 
statistical power. However, due to variation amongst humans with very different genetic backgrounds and diets, we may 
need to significantly increase the number of samples (see Data Analysis and Statistical Considerations) to detect a 
significant association between H2S and any MACE (primary endpoint).  
 
2.4 Schedule and milestones 
 
The experiments in Aim 1 and 2 can be accomplished 
within 4 years given that all of the mouse lines, models 
and human samples are available. General benchmarks 
for success beyond rigorous peer review and 
publication include access to cutting edge facilities and 
technical assistance available in Lausanne or Harvard 
University in Boston. 
 
 
2.5 Relevance and impact 
The progressive decline in vascular ECs function is one of the major causes of aging and age-related diseases 
including heart and cerebrovascular diseases, exercise intolerance, hypertension, impaired wound healing, and 
sarcopenia. The number of people of advanced age is going to double in the next 35 years, further compounding the 
problem. Yet the underlying cause of vascular decline with age is not known and there is little that can be done for frail 
patients. Although the implementation of health and social measures is necessary to improve the quality of life of older 
adults, the immediate challenge for medical gerontology is to identify pharmacological strategies to promote healthy aging 
“healthspan”. Next year, Metformin (an oral anti-diabetic molecule) will be the world first anti-aging molecule tested on 
humans in trials (https://clinicaltrials.gov/ct2/show/NCT02432287). This proposal will provide important mechanistic insight 
into the potential of endothelial H2S to improve vascular health in the context of aging and aging-related diseases such as 
hypertension and peripheral artery disease. Within this age group, cardiovascular disease is the leading cause of death, 
and the cost associated with treatment will continue to increase. The role of ECs, and the potential of endothelial-targeted 
therapies to promote vascular health in the context of aging remain mostly unexplored. The knowledge to be obtained 
	  through this research proposal will provide the basis for new translational research of DR and H2S-based therapies in 
humans. 
 
2.5.1. Future directions – Basic research  
1. Based on published42 and the data generated from Aim 1-2, we anticipate that ECs are the source of serum CGL. 
ECs as the source of H2S vascular benefits opens up a number questions, including whether autocrine, paracrine or 
endocrine signaling is mediating the benefits of H2S (e.g. protection from ischemia, neurodegeneration, etc). 
Furthermore, it questions whether some of the DR benefits (e.g. increase lifespan, stress resistance) require 
endothelial-derived circulating CGL/H2S. In the future, we may need to develop a model such as parabiosis in which 
two mice are surgically joined together and develop a single, shared circulatory system (Figure 9 and 156) using 
hetero-parabionts of mice lacking or not CGL specifically in ECs (CGLECKO).  
2. The data generated form Aim 2D, may provide a novel gene implicated in the regulation of H2S production, and 
relevant to the biology of aging, and beyond in the treatment and prevention of ischemia, metabolic syndrome, 
cancer or hypoxia. 
 
2.5.2. Future directions – Clinical translation 
1. The knowledge to be obtained from Aim 2 might validate the use of circulating H2S as a novel biomarker of vascular 
dysfunction or/and potential target for H2S based therapies in the treatment and prevention myocardial infarction, 
stroke, peripheral artery disease and aging. 
2. In addition, patients with artery disease undergoing surgery (e.g. vein graft) experience a number of surgical 
complications including poor wound healing, heart attack/stroke, and/or revascularization failure in the period of up to 
one year following surgery at a relatively high rate196. Although a number of risk factors for poor surgical outcome 
have been identified, no single risk factor or group of risk factors can accurately predict postoperative outcome, nor 
are there any interventional strategies to mitigate surgical risk 197. We propose that serum H2S could be a novel 
marker of surgical outcome, which could improve patient diagnosis, care and overall outcome. Importantly, we are 
currently evaluating the use of short-term DR preconditioning (with Prof. Ozaki at Brigham Women’s Hospital) in 
patients undergoing endovascular interventions. 
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a b s t r a c t
The saphenous vein is the conduit of choice in bypass graft procedures. Haemodynamic factors play a
major role in the development of intimal hyperplasia (IH), and subsequent bypass failure. To evaluate the
potential protective effect of external reinforcement on such a failure, we developed an ex vivomodel for
the perfusion of segments of human saphenous veins under arterial shear stress. In veins submitted to
pulsatile high pressure (mean pressure at 100 mmHg) for 3 or 7 days, the use of an external macroporous
polyester mesh 1) prevented the dilatation of the vessel, 2) decreased the development of IH, 3) reduced
the apoptosis of smooth muscle cells, and the subsequent ﬁbrosis of the media layer, 4) prevented the
remodelling of extracellular matrix through the up-regulation of matrix metalloproteinases (MMP-2,
MMP-9) and plasminogen activator type I. The data show that, in an experimental ex vivo setting, an
external scaffold decreases IH and maintains the integrity of veins exposed to arterial pressure, via in-
crease in shear stress and decrease wall tension, that likely contribute to trigger selective molecular and
cellular changes.
! 2013 Elsevier Ltd. All rights reserved.
1. Introduction
About one million vascular reconstructions are performed
annually worldwide, and the great saphenous vein remains the
most widely used conduit [1]. Still, 30e50% of the saphenous grafts
fail 1e18 months after the implantation [2]. The main reason for
this failure is intimal hyperplasia (IH), which reﬂects the adaptation
of a vein to the injuries caused by an arterial environment [3].
Insertion into the arterial circulation is associated with prolifera-
tion and migration of smooth muscle cells (SMCs) into the intima
layer [4,5], leading to wall thickening, vessel stenosis and, even-
tually, graft failure. Among the proteins involved in the develop-
ment of IH, selected matrix metalloproteinases (MMP-2 and MMP-
9) [6], tissue inhibitors of these enzymes (TIMP) [7], and possibly
the plasminogen activator inhibitor-1 (PAI-1) [8], play a major role,
due to their ability to selectively degrade components of the
extracellular matrix, to release SMCs and to promote SMCs migra-
tion [3]. Mechanical forces, and particularly low shear stress
and high wall tension, contribute to the development of these
changes [9]. Following implantation, the vein graft is immediately
subjected to arterial pressure as well as to circumferential, radial
and pulsatile deformations [10]. Further haemodynamic distur-
bances occur at the site of anastomoses, because of compliance
mismatches [11e13].
Mammalian studies suggest the utility of an external support to
prevent the over-distension of grafts, increasing shear stress and
reducing wall tension [14e19]. However, the molecular and
cellular events affected by such a reinforcement have not yet been
investigated under rigorous experimental conditions. We
hypothesised that a mesh reinforcement could preserve the ar-
chitecture of veins exposed to arterial haemodynamic conditions
and limit the development of IH through selective molecular
modulations. To compare the behaviour of human saphenous
veins in the absence and presence of an external macroporous
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polyester tubular mesh, we have developed an ex vivo vein
perfusion system (EVPS), which allows for the independent control
of the major haemodynamic forces affecting a venous graft, thus
permitting to differentiate their selective effect on speciﬁc mo-
lecular and cellular parameters [8,20].
2. Material and methods
2.1. Human saphenous veins
Twenty seven surplus segments of non varicose human saphenous veins,
hereafter referred to as veins, were obtained from of 27 randomly selected patients
(15 men and 12 women) with a median age of 72 years (interquartile range 51e82),
who underwent lower limb bypass surgery for critical ischaemia. A 9 cm long
segment of the greater saphenous vein, considered to be suitable for bypass surgery,
with an external diameter of 2.5e4mm, was harvested and stored at 4 "C in a RPMI-
1640 Glutamax medium, supplemented with 12.5% fetal calf serum (Gibco). All
sampled veins were used, whichever the native thickness of their intima layer.
Within 1 h after the surgery, the segment was divided in 3 equal parts. One part was
ﬁxed in either formalin for immunohistochemistry or rapidly frozen in liquid ni-
trogen for molecular analyses. A second part was reinforced with an external
macroporous polyester tubular mesh (ProVena, B.Braun Medical SA), hereafter
referred to as mesh, which covered the entire vein segment (Fig. 1), and whose
diameter (4 mm) was chosen to obtain a cross-sectional area quotient Qc > 0.45,
where Qc ¼ ah/ag (ah being the cross-sectional area of the host vessel, and ag that of
the interposition graft) (Fig. 1B and C). This part and the third segment of the very
same vein, which had not been reinforced by a mesh (control), were perfused in
parallel in the EVPS (Fig. 1A and B) for 3 or 7 days, at either low or high pressure. The
Ethical Committee of the University of Lausanne approved the experiments, which
are in accordance with the principles outlined in the Declaration of Helsinki of 1975,
as revised in 1983 for the use of human tissues.
2.2. Ex vivo perfusion system
The EVPS [8,20e22] was modiﬁed for the simultaneous perfusion of two vein
segments, one of which was reinforced with the mesh (Fig. 1). The 2 segments were
connected to the perfusion pump by a peroxide-treated silicone tubing (internal
diameter 3.2 mm; Ismatec", Switzerland), and maintained at 37 $ 0.1 "C in two
distinct perfusion chambers, which were placed inside a cell culture incubator
(Fig.1A). In all the experiments, themedium of both the chambers (250ml each) and
the perfusate (150 ml) was RPMI-1640, supplemented with Glutamax, 12.5% fetal
calf serum (Gibco), 8% 70 kDa dextran (Sigma), and 1% antibiotic-antimycotic so-
lution (10,000 U/ml penicillin G, 10 mg/ml streptomycin sulphate, 25 mg/ml
amphotericin B, and 0.5 mg/ml gentamycin). This mediumwas changed every 2 days.
The conditions of the perfusion were set to obtain a shear stress (SS) of 9e15 dyn/
cm2, as expected in the femoral artery [8], given by SS ¼ 4mQ/pr3, where m is the
viscosity of the perfusion medium set to 3.73$10%2 dyn s/cm2, as measured in a
Coulter viscometer (Coulter Electronics, HighWycombe, UK), Q the ﬂow rate (mL/s),
and r the radius (cm) of the vein segment.
Veins were exposed for 3 or 7 days to a pulsatile biphasic ﬂow of 60 pulses/min
under either low (MP¼ 7mmHg; systolic/diastolic pressure¼ 8$ 1/6$ 1mmHg) or
high perfusion pressure (MP ¼ 100 mmHg; systolic/diastolic pressure ¼ 120 $ 5/
90 $ 5 mmHg). Upon completion of the perfusion, the 5 mm proximal and distal
ends, which attached the vein to the equipment, were discarded. A central, 5 mm-
thick ring was cut from the remaining segment and ﬁxed in formalin for
morphometry. The remaining fragments were frozen and reduced into powder for
RT-PCR and Western blot analysis.
2.3. Morphometry
Morphometric analysis was performed on vein sections processed for Van
Gieson-elastin (VGEL) staining, using the Leica Qwin" software (Leica, Switzerland).
Twenty-four measurements of the thickness of the intima and media layers, as well
as of the perimeter of the internal (IEL) and external elastic laminae (EEL) weremade
in each sample at a magniﬁcation of &100 and &2, respectively.
2.4. Image processing and cleaved-caspase-3 staining quantiﬁcation
For the assessment of caspase-3 cleavage, images of human veins were con-
verted using the Fiji software (http://ﬁji.sc/Fiji), to provide a binary image with a
consistent threshold method. After application of the “open” binary operation,
particles with an area>50 pixels were summed, and related to the area of the region
of interest (one region per vein). At least 5 veins from different patients were ana-
lysed in the 5 experimental groups which we compared.
2.5. Quantitative real-time PCR
Quantitative real-time PCR analysis was, performed on vein RNA as previously
described [23,24], using the primers given in Table 1. All experiments included
negative controls (ampliﬁcation of distilled water or RNA samples that had not been
reversed transcribed). Levels of expression were determined relative to those of
GAPDH.
2.6. Western blots
Veins were reduced to powder and processed for Western blotting as previously
reported [23,24] using the following primary antibodies: rabbit polyclonal against
MMP2 (Abcam); rabbit polyclonal against MMP-9 (Abcam); mouse monoclonal
against TGFb2 (Abcam); rabbit polyclonal against PAI-1 (Novus Biologicals); mouse
monoclonal against eNOS (BD Biosciences); mouse monoclonal against HO-1
(Abcam); goat polyclonal against TIMP-1 (R&D systems), at dilutions 1:400e1000.
To evaluate total protein levels, membranes were probed with a mouse monoclonal
against a-Tubulin (Sigma), diluted 1:1000.
2.7. Immunostaining
Parafﬁn sections of veins were immunostained using the primary antibodies
mentioned above and an avidin-biotinylated horseradish peroxidase complex
(Vectastain Elite ABC Kit, USA), and counterstained with hemalun.
Frozen sections of unﬁxed veins were immunostained as previously described
[20,21], using the same antibodies at a dilution of 1:100e1:3000, a relevant sec-
ondary Alexa Fluor 488-labelled antibody (Dako), diluted 1:500 and counterstained
with 0.02% Evans Blue.
Fig. 1. The ex vivo perfusion system, A: A gearing pump (1) generates a pulsatile
signal controlled by a computer (2), which monitors the pressure (3) and ﬂow ve-
locity (4), and controls the minimal diastolic pressure (5). B: Two segments of a very
same saphenous vein were connected in parallel to the perfusion pump inside
separate perfusion chambers (6a and 6b in A), which were placed in a cell culture
incubator. C: View of the tubular mesh of 4 mm diameter, made of a polyester wire
deﬁning pores of 750 mm, and which was tested as external reinforcement. The insets
show enlargements of the boxed area, that highlight the honeycomb structure. Bar,
500 mm. D: Views of a same vein (stained with 2% Evan’s blue) inside the mesh
reinforcement, immediately before the perfusion (Ctrl) and after 3 and 7 days of
perfusion at a mean pressure of 100 mmHg. Bar, 500 mm. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of
this article.)
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2.8. Statistical analysis
Student’s t test and two-way analysis of variance with post hoc Bonferonni
correction (Statistical Package for the Social Sciences (SPSS 17.0, Chicago, Ill., USA))
were run to compare mean values between groups.
3. Results
3.1. Intimal hyperplasia and mesh reinforcement
We ﬁrst studied the morphometry of human saphenous veins
subjected or not (Ctrl) to a pulsatile ﬂow under arterial shear stress
at low (7mmHg) or high (100mmHg) pressure.Masson’s trichrome
staining, which differentiates smoothmuscle cells (SMCs) (red) and
connective tissues (blue), revealed that SMCs were equally
distributed in three layers, comprising an inner longitudinal, a
middle circular and an outer longitudinal layer in freshly isolated
veins (Ctrl). In absence of an external support, veins subjected to
100 mmHg perfusion for 7 days displayed thinning of the media
layer with persistence of only one of the three muscle layers. The
external reinforcement preserved the distribution of the SMCs and
media structure (Fig. 2, upper row). Immunostaining showed that
von Willebrand factor (vWf)-positive endothelial cells lined the
lumen of all veins (Fig. 2 middle row). In contrast, in veins sub-
mitted to high pressure for 7 days, immunostaining for alpha
smooth muscle actin, revealed a reduced number of SMCs in the
media layer and the redistribution of these cells in the intima layer
(Fig. 2 lower row). This change was largely prevented by the mesh
support (Fig. 2 lower row). Quantitative assessment of the intima
and media thickness after VGEL staining revealed that the
morphology of the vein grafts was unchanged in veins exposed to
7 mmHg. In contrast, the intima thickness was increased 3 fold in
vessels exposed for 7 days to 100 mmHg, whereas the media
thickness was decreased by 50% (Fig. 3A and B). The intima and the
media alteration were prevented in veins reinforced with the
external mesh (Fig. 3A and B). As a result, the mesh reduced by 50%
the intima-to-media ratio, compared to that of non-reinforced
veins (Fig. 3B).
The perimeters of both internal and external elastic laminae
were increased in veins exposed for 7 days to both 7 or 100 mmHg,
indicating a signiﬁcant outward remodelling (Fig. 3C and D). This
change was fully (7 mmHg) or partially (100 mmHg) prevented by
the mesh reinforcement (Fig. 3C and D). Further analysis revealed
that the alteration of the intima, media and internal elastic lamina,
but not that of the external elastic lamina, were already evident
Fig. 2. The external mesh reinforcement prevents most alteration of the vessel wall induced by high pressure, Upper panel: Masson’s trichrome staining differentiates SMCs (red)
and connective tissue (blue). In control veins, SMCs are equally distributed in 3 distinct layers of the vein. These layers were much reduced in veins exposed to 100 mmHg for 7
days, but not in veins exposed to the same conditions after the mesh wrapping. Middle panel: Antibodies against von Willebrand factor show the lining of endothelial cells at the
luminal surface of all vessels. Lower panel: Antibodies against alpha smooth muscle actin, together with a nuclear staining by DAPI, reveal an accumulation of SMCs in the intima
layer of the veins exposed to 100 mmHg. This alteration was prevented in veins with the external mesh. Insets are higher magniﬁcation views of the framed areas. L, lumen; M,
media. Bars represent 100 mm in ﬁgures and 400 mm in the insets. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of
this article.)
Table 1
Human primers used for the quantitative reverse transcription polymerase chain
reaction (RT-PCR).
Gene Sense primer (50e30) Antisense primer (50e30)
PAI-1 GGCTGGTGCTGGTGAATG ATCGGGCGTGGTGAACTC
TGFb2 GTGGAAACCCACAACGAAAT CACGTGCTGCTCCACTTTTA
MMP2 CAGAGCCACCCCTAAAGAGA TGTGAAAGGAGAAGAGCCTGA
MMP9 GCCACTTCCCCTTCATCTTC GTCGTCGGTGTCGTAGTTGG
TIMP1 TGACATCCGGTTCGTCTACA TGCAGTTTTCCAGCAATGAG
TIMP2 AAGCGGTCAGTGAGAAGGAA TCTCAGGCCCTTTGAACATC
Ephrin-B2 CTTTGGAGGGCCTGGATAAC CTGTTGCCGTCTGTGCTAGA
Eph-B4 CGCAGACCAAAGAGAGTGTG GGGACTACAAACCCCAATGA
Notch1 CACTGTGAGAACAACACGCC TGACATCGTGCTGGCAGTAG
Notch4 TACGACTGTGAGACCCCTCC TTTCTCACAGTGCCCGTTGT
eNOS GACGCTACGAGGAGTGGAAG CTGGGTGAGGAGCAGTGG
HO-1 AGGAGGTCATCCCCTACACA GGGGTAGAGCTGCTTGAACT
SM22a TTCCAGACTGTTGACCTCTTTG CAAAGCCATCAGGGTCCTC
Calponin GCTGTCAGCCGAGGTTAAGA CCCCTCGATCCACTCTCTC
GAPDH AACTTTGGTATCGTGGAAGG CAGTAGAGGCAGGGATGATGT
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Fig. 3. The external reinforcement prevents the thickening of the intima layer and the outward remodelling of veins, A: Representative histological sections stained for elastin show
a similar intima thickness in control, non perfused veins and in veins exposed to a low pressure perfusion (7 mmHg). In contrast, IH is seen in veins perfused at high pressure
(100 mmHg), and is largely decreased in the presence of the external mesh. M ¼ media, I ¼ intima and L ¼ lumen. Bar represents 100 mm. B: Morphometric measurements show
that high pressure perfusion induced IH and thinning of the media layer. IH was inhibited in the presence of the mesh, which also partially prevented the reduction of the media
layer. C: Representative histological sections stained for elastin show marked dilatation and wall thinning of veins exposed to high pressure for 7 days. These changes were
prevented by the mesh. L ¼ lumen. Bar represents 500 mm. D: Measurements show increased perimeter of both internal (IEL) and external elastic membranes (EEL) of veins perfused
at high pressure (100 mmHg). This change is partially prevented in the presence of the external mesh. E and F: The changes of intima, media, internal and external lamina were
already apparent after 3 days of perfusion. While the two former changes were already prevented by the mesh, the latter was not. Data represent mean þ SEM of 8e9 experiments.
#p < 0.05, ##p < 0.01 and ###p < 0.001 versus the non perfused segment (Ctrl); "p < 0.05,
""
p < 0.01 and
"""
p < 0.001 versus the respective 7 mmHg perfused veins *p < 0.05,
**p < 0.01 and ***p < 0.001 versus the non-reinforced veins (mesh).
after 3 days of perfusion (Fig. 3E and Suppl. Fig. 1). The mesh pre-
vented these early intima and media changes, but not the modest
outward remodelling (Fig. 3F and Suppl. Fig. 2).
3.2. Cellular and molecular changes
The media layer of control veins showed a minimal staining for
the cleaved form of caspase-3 (Fig. 4). In contrast, this staining was
markedly increased after either 3 or 7 days of perfusion at high
pressure (100 mmHg). The mesh reinforcement strongly dimin-
ished this alteration (Fig. 4). As compared to non perfused veins, the
levels of MMP-2 mRNA were decreased after 3 days of perfusion at
high pressure, and increased after 7 days (Fig. 5A). These alterations
were averted by the mesh, which also partially prevented the
elevation in the levels of pro- and mature-MMP-2 proteins (Fig. 5A
and B). The levels of the MMP-9 transcript were greatly induced
Fig. 3. (continued).
Fig. 4. The mesh reinforcement inhibits the cleavage of caspase-3 induced by exposure to high pressure, Top: Immunostaining revealed minimal cleaved caspase-3 (ClvCasp3) in
non perfused veins (Ctrl), and a sizable increase of the staining (brown) in veins perfused at high pressure for 3 or 7 days. Insets are higher magniﬁcation views of the framed areas.
L, lumen; M, media. Bar represent 100 mm. Bottom: Quantiﬁcation of ClvCasp3 staining demonstrates a 10- and 7-fold increase in apoptosis after 3 and 7 days of perfusion,
respectively. The external reinforcement markedly prevented this alteration. Data represent mean þ SEM of 5 experiments. #p < 0.05, ##p < 0.01 and ###p < 0.001 versus non-
perfused veins (Ctrl); **p < 0.01 and ***p < 0.001 versus non-reinforced veins. "p < 0.05 versus veins perfused for 3 days. (For interpretation of the references to colour in this ﬁgure
legend, the reader is referred to the web version of this article.)
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after 3 days of vein perfusion (Fig. 5C). The levels of the mature
MMP-9 protein were similarly regulated, whereas those of the pro-
MMP-9 proteinwere only increased after 7 days (Fig. 5D). Themesh
had little impact on the levels of MMP-9, at both mRNA and protein
levels. However, it impeded the up-regulation of mature MMP-9,
both after 3 and 7 days of perfusion (Fig. 5C and D). The mRNA
expression of the tissue inhibitor of metalloproteinases, TIMP-1,
was similarly enhanced in veins exposed to high pressure for
either 3 or 7 days, and was not affected by the mesh reinforcement
(Fig. 5E). The expression of the TIMP-2 transcript was markedly
Fig. 5. The external mesh reinforcement attenuates the increased expression of MMP-2 and MMP-9 induced by high pression, A: Compared to the control level (Ctrl), the MMP-2
transcript was decreased after a high pression perfusion for 3 days, and increased when the perfusion lasted 7 days. Both changes were prevented in the presence of the mesh. B:
Western blots demonstrate that the high pression perfusion increased both the proactive (middle panel) and active (right panel) forms of the MMP-2 protein. This effect was
prevented in reinforced veins. C and D: the MMP-9 transcript (C), as well as the pro- and active forms of the cognate protein (D) were up-regulated as a function of the duration of
the perfusion. These effects were partially prevented in reinforced veins. E: Veins exposed to arterial shear stress for 3 and 7 days featured increased expression of TIMP-1 mRNA,
which was not prevented by the external reinforcement. F and G: High pressure perfusion decreased the levels of the TIMP-2 transcript (F) and protein (G) after 3 days, 2 effects
which were partially prevented by the mesh. In contrast, the expression of the TIMP-2 protein (G) was increased after 7 days of perfusion, an effect which was not prevented by the
mesh. Data represent mean þ SEM of 8e9 experiments. #p < 0.05, ##p < 0.01 and ###p < 0.001 versus the non perfused control veins (Ctrl); *p < 0.05, **p < 0.01 and ***p < 0.001
versus the non-reinforced veins.
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decreased after both 3 and 7 days of perfusion at high pressure, and
the mesh had little effect on this regulation (Fig. 5F). The levels of
the cognate protein were also slightly decreased after 3 days of
perfusion, and the mesh counteracted this down-regulation.
However after 7 days, the high pressure perfusion resulted in a 6
fold increase in the TIMP-2 protein levels in both control and
reinforced veins (Fig. 5G). Compared to the levels observed in non
perfused controls, both PAI-1 transcript and protein levels were
elevated after 3 and 7 days of perfusion at high pressure (Fig. 6A
and B). The mesh reinforcement partially prevented the increase of
PAI-1 mRNA expression at 7 days (Fig. 6A), and fully normalized the
levels of the cognate protein both after 3 or 7 days of perfusion
(Fig. 6B). Immunohistochemistry further demonstrated an increase
in PAI-1 expression in the media layer, which was reduced in
reinforced veins (Fig. 6C). The expression of the TGFb2 transcript
was decreased after 3 days of perfusion, and up-regulated after 7
days and the mesh partially prevented these alterations (Fig. 6D).
The levels of the cognate proteinmarkedly decreased after 3 days of
perfusion at high pressure, an effect which was partly avoided upon
mesh reinforcement (Fig. 6E).
We then studied the expression of the venous Eph-B4 and the
arterial Ephrin-B2 markers and their respective transcription fac-
tors Notch 1 and 4, known to regulate vessel fate [25]. Compared to
controls, the levels of Notch 1, Notch 4, Ephrin-B2 and Eph-B4
mRNA were decreased after 3 and 7 days of perfusion at high
pressure (Fig. 7AeD). The mesh did not prevent this changes for
Notch 1 and Notch 4 (Fig. 7A and B), whereas it partially counter-
acted the down-regulation of Ephrin-B2 and Eph-B4, at both
transcript and protein levels (Fig. 7CeE). We next investigated the
regulation of the vasculoprotective genes endothelial nitric oxide
synthase (eNOS) and heme oxygenase-1 (HO-1), which have both
been shown to inhibit neointimal hyperplasia [26]. The expression
Fig. 6. The external mesh reinforcement differentially modulates the increased expression of plasminogen activator inhibitor and transforming growth factor induced by high
pressure, A and B: Compared to control levels (Ctrl), those of the PAI-1 transcript (A) and protein (B) were increased in veins perfused at high pressure for 3 and 7 days. A signiﬁcant
reduction of these changes was observed in reinforced veins. C: immunohistochemistry further revealed that PAI-1 mostly increased in the media layer. The insets show higher
magniﬁcations of the boxed areas. Bar represent 100 mm. D: Veins exposed to high pressure featured a down- and up-regulation in the levels of transforming growth factor beta
type II (TGFb2) mRNA after 3 and 7 days of perfusion, respectively. E: The cognate protein was decreased after 3, but not 7 days of perfusion. The mesh prevented most of the
transcript and protein alterations. Data represent mean þ SEM of 8e9 experiments. #p < 0.05, ##p < 0.01 and ###p < 0.001 versus the non perfused control veins; *p < 0.05 and
**p < 0.01 versus the non-reinforced segment.
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of endothelial nitric oxide synthase (eNOS) was also decreased after
7 days of perfusion at high pressure, and this down regulation was
not affected by the mesh reinforcement (Fig. 8A and B). In contrast,
the expression of the heme oxygenase-1 (HO-1) transcript was up
regulated after 3 and 7 days of perfusion at high pressure, an
alteration which was markedly reduced by the mesh (Fig. 8C).
Exposure of veins to high pressure perfusion dramatically reduced
the transcript levels of the contractile SMCs markers SM22a and
calponin, whether the mesh was present or not (Fig. 9A and B).
4. Discussion
We show that wrapping saphenous veins with a macroporous
tubular polyester mesh, markedly reduces the development of IH
and the thinning of the media layer, two alterations which are
otherwise observed after 3e7 days of a pulsatile perfusion
mimicking the conditions prevailing in the arterial compartment.
We further demonstrate that the structural alterations induced by
high pressure are associated with changes in SMCs survival, and in
the expression of several genes and proteins involved in the
development of IH [4], documenting that the mesh resulted in a
marked protection against most of these changes (Fig. 10).
Animal studies of venous bypass surgery have demonstrated
that the presence of a constrictive external support could efﬁciently
limit the dilation of venous walls, improving blood ﬂow, and that
the association of increased shear stress, decreased wall tension
and better size match between the host and the grafted vessels
prevent the development of IH [15e19]. Here, we show that a
Fig. 7. The external mesh reinforcement prevents the down-regulation of Ephrin-B2 and Eph-B4, A and B: The transcripts levels of Notch1 (A) and Notch4 (B) were decreased in
veins submitted to high pressure for 3 and 7 days. The mesh failed to prevent these down regulations. C and E: The transcript (C) and protein (E, upper panel) levels of Ephrin-B2
were signiﬁcantly reduced after a high pressure perfusion for 3 and 7 days. This down-regulation was prevented by the mesh only in veins perfused for 3 days. Insets show the box
area at higher magniﬁcations. L, lumen; M, media. Bar represents 100 mm. Data are mean þ SEM of 8e9 experiments. #p < 0.05 and ##p < 0.01 versus the non perfused veins (Ctrl);
*p < 0.05 and **p < 0.01 versus the non-reinforced veins. D and E: The expression of Eph-B4 also decreased, at both transcript (D) and protein levels (E, lower panel), after 3 and 7
days of high pressure perfusion. These changes were partially prevented by the mesh reinforcement in veins perfused for 7 days. Insets show higher magniﬁcations of the boxed
areas. L, lumen; M, media. Bar represent 100 mm. Data represent mean þ SEM of 8e9 experiments. #p < 0.05 and ##p < 0.01 versus non perfused veins (Ctrl); *p < 0.01 and
**p < 0.01 versus the non-reinforced veins.
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similar mesh is also efﬁcient in preventing the dilatation andmedia
remodelling of human great saphenous veins exposed ex vivo to
arterial conditions. Interestingly, this study demonstrates that IH
develops rapidly upon perfusion under an arterial regimen, even in
the absence of aggravating inﬂammatory and growth factors
released by circulating cells in vivo, thus supporting a major role for
haemodynamic forces in the development of IH. We conclude that,
by preserving the structure of the vein graft, the external support
increases shear stress and decreases wall tension, thereby pre-
venting IH.
Our study provides cellular and molecular evidence on how the
mechanical effects of the mesh reinforcement are translated into
protective tissue effects. First, the alterations in the organization of
the vein wall induced by high pressure perfusion are associated
with a marked increase in the apoptosis of SMCs within the media
layer. Disruption of the balance between SMCs proliferation and
apoptosis is a key event in the injury-induced IH [27]. Our data
support the view that this balance is mostly controlled by
apoptosis, whose importance in the thickening of the intima has so
far remained a matter of debate [28,29]. Second, our study shows
that, under conditions mimicking those of an arterial bed, there is a
rapid and marked decrease in SM22a and calponin, two markers of
contractile SMCs, consistent with a switch of these cells from a
contractile to a synthetic phenotype, as observed under several
pathological conditions [30,31], and after exposure to an arterial
environment [32]. We further observed a marked decrease in the
Fig. 8. The mesh reinforcement differentially affects the pressure-induced changes in endothelial nitric oxide synthase and heme oxygenase, A and B: High pressure perfusion down
regulated the levels of eNOS transcript (A) and protein (B). The presence of the external mesh reinforcement failed to prevent these changes. C: The transcript of HO-1 was increased
after 3 and 7 days of high pressure perfusion, two effects which were signiﬁcantly reduced in reinforced veins. Data represent mean þ SEM of 8e9 experiments. #p < 0.05,
##p < 0.01 and ###p < 0.001 versus non perfused controls (Ctrl); *p < 0.01 versus the non-reinforced veins.
Fig. 9. Early decrease of the contractile smooth muscle cells markers Smooth muscle 22 alpha (SM22a) and Calponin, A and B: A 3 and 7 day-long high pressure perfusion decreased
the transcripts of SM22a (A) and calponin (B). The presence of the mesh did not prevent these down-regulations. Data represent mean þ SEM of 8e9 experiments. ##p < 0.01 the
non perfused control veins (Ctrl).
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expression of Ephrin-B2 and Eph-B4, as previously reported [25],
but also of Notch 1 and Notch 4, consistent with a loss of differ-
entiation and higher proliferative phenotype of the “arterialised”
vein. Still, and in spite of its efﬁcient protection against the devel-
opment of IH, the mesh did not fully preserve the normal vein
phenotype, as indicated by the persistent down-regulation of eNOS,
a marker of endothelial function, which is consistent with a down-
regulation of the Notch/Ephrin pathway [33]. We further observed
that the mesh reinforcement prevented the over-expression of HO-
1, which counteracts cell growth in vascular diseases, and protects
against oxidative stress and intimal thickening [34,35]. Although
HO-1 has been demonstrated to be increased by shear stress and
pulsatile ﬂow [36], the exact mechanism underlying HO-1 regula-
tion remains to be elucidated. In our model, HO-1 is likely over-
expressed in response to SMCs proliferation and increased oxida-
tive stress, as a way to counteract the development of IH.
We also provide evidence that the external mesh prevents the
induction of both MMP-2 and MMP-9, which is observed under
high pressure perfusion [8]. Matrix metalloproteases play a crucial
role in the remodelling of the extracellular matrix (ECM) which, in
turn, contributes to the proliferation and migration of SMCs [37]. In
situ, the activity of MMP-2 and MMP-9 is modulated by tissue in-
hibitors of the TIMP family [37]. In veins exposed to arterial hae-
modynamic conditions, we observed that TIMP1 was rapidly up-
regulated with its MMP-9 substrate, whereas TIMP2 expression
was initially decreased and later increased with the continuation of
the perfusion. The data thus reveal a complex temporal regulation
of both MMPs and their regulators during the development of IH.
The mesh efﬁciently dampened these changes, consistent with a
protective effect on ECM remodelling. Accordingly, PAI-1 expres-
sion, a key regulator of ECM remodelling, as well as of SMCs
adhesion and migration [38], was found increased under arterial
conditions that trigger IH [20,21], and this alteration was fully
prevented by the mesh reinforcement.
Although the mechanisms whereby external mesh re-
inforcements protect veins exposed to arterial haemodynamic
conditions remain to be fully unravelled, our data clearly suggest
that external scaffolding may prevent IH in vein grafts. Several
clinical studies have already documented the usefulness of rigid
polytetraﬂuoroethylene reinforcement [15e19,39,40] or ProVena
mesh support [41,42], enabling the use of suboptimal autologous
ectatic or varicose veins in lower limb grafts. However, the only
published trial addressing the effectiveness of an external support
to improve healthy vein patency during coronary artery bypass
reported the thrombosis of all veins reinforced with an external
Dacron stent, or Extent. This dramatic outcomewas most likely due
to the rigidity and design of this external support, which probably
resulted in graft kinking and thrombosis [43]. Together with pre-
vious animal studies [15e19] and clinical evidence [41,42,44], our
data suggest that the ProVena, given its ﬂexible, honeycomb
structure, will not cause kinking and thrombosis and may reduce
the development of IH in vein graft bypass surgery. The majority of
Fig. 10. Schematic representation of the mechanisms involved in the mesh-dependent preservation of a vein graft structure. Vein submitted to an arterial pressure for 7 days
showed signiﬁcant IH and media thinning. These changes are associated with 1) increased SMCs apoptosis, 2) increased ECM degradation and ﬁbrosis, 3) altered endothelial
function, 4) loss of venous phenotype. The presence of a mesh limited the vein dilatation, prevented the development of IH, and preserved the architecture of the media layer by 1)
reducing SMCs apoptosis, 2) preventing the ECM degradation and the ﬁbrosis, 3) reducing the endothelial alterations, and 4) regulating the expression of key proteins involved in
the development of IH.
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bypasses are connected using end-to-side anastomosis, which
disrupt laminar ﬂow [3]. As a result, most graft stenoses due to IH
occur in the perianastomotic regions. This could not be tested in the
EVPS, since veins are attached in an end-to-end fashion, which
preserves a laminar ﬂow. Hopefully, future studies will demon-
strate that the ﬂexible structure of the ProVena mesh, which allows
complete mesh wrapping of the veins, including at the anastomosis
[44], will prove efﬁcient in reducing IH at these speciﬁcs sites.
5. Conclusions
In summary we provide morphological and molecular evidence
that an external mesh reinforcement is effective in preventing the
pathological alterations that saphenous veins face once exposed to
arterial haemodynamic conditions. Ex vivo, such reinforcement
prevented the dilatation of the vessel, decreased the development
of IH and preserved the architecture of the media layer by reducing
the apoptosis of SMCs and subsequent ﬁbrosis. At the molecular
level, the mesh prevented the up-regulation of matrix metal-
loproteinases (MMP-2, MMP-9) and plasminogen activator type I,
which are involved in the remodelling of the extracellular matrix.
Together with previous animal studies, our experimental, ex vivo
data on human veins now call for revisiting this efﬁcacy in a large
randomized multicenter clinical study, which could provide for a
proper in vivo comparison of reinforced and non-reinforced grafts.
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Abstract
The mainstay of contemporary therapies for extensive occlusive arterial disease is venous bypass graft. However, its durability is threatened
by intimal hyperplasia (IH) that eventually leads to vessel occlusion and graft failure. Mechanical forces, particularly low shear stress and high
wall tension, are thought to initiate and to sustain these cellular and molecular changes, but their exact contribution remains to be unraveled.
To selectively evaluate the role of pressure and shear stress on the biology of IH, an ex vivo perfusion system (EVPS) was created to perfuse
segments of human saphenous veins under arterial regimen (high shear stress and high pressure). Further technical innovations allowed the
simultaneous perfusion of two segments from the same vein, one reinforced with an external mesh. Veins were harvested using a no-touch
technique and immediately transferred to the laboratory for assembly in the EVPS. One segment of the freshly isolated vein was not perfused
(control, day 0). The two others segments were perfused for up to 7 days, one being completely sheltered with a 4 mm (diameter) external
mesh. The pressure, flow velocity, and pulse rate were continuously monitored and adjusted to mimic the hemodynamic conditions prevailing
in the femoral artery. Upon completion of the perfusion, veins were dismounted and used for histological and molecular analysis. Under ex vivo
conditions, high pressure perfusion (arterial, mean = 100 mm Hg) is sufficient to generate IH and remodeling of human veins. These alterations
are reduced in the presence of an external polyester mesh.
Video Link
The video component of this article can be found at http://www.jove.com/video/52079/
Introduction
Cardiovascular diseases are the leading cause of morbidity and mortality in Western countries1. Despite advances made in endovascular
treatments, bypass surgery remains the mainstay of contemporary therapies, thus over half a million vein grafts are performed annually in the
United States. However, despite decades of research, 30-60% of lower extremity vein grafts fail within the first years due to intimal hyperplasia
(IH)2. Mechanical forces, particularly low shear stress (SS) and high wall tension, are pivotal in the initiation and development of this hyperplastic
response3,4. To address this issue, an ex vivo veins perfusion system (EVPS) was generated to study, under strictly controlled hemodynamic
conditions (pressure and shear stress), the behavior of human saphenous veins. In this study, following insertion into the arterial-like circulation,
high pressure (mean = 100 mm Hg) was sufficient to stimulate proliferation and migration of smooth muscle cells into the intimal layer (IH)5.
Mammalian studies have suggested the use of external reinforcement as an efficient method to support the “arterialized vein” and counteract
the acute hemodynamic changes the vein faces once implanted into an arterial milieu. The mesh prevented over-distension, increased shear
stress, and reduced wall tension and consequently IH6-10. However, the underlying mechanisms and its applicability to human veins in improving
bypass patency have not been fully characterized. Our EVPS was used to compare, in condition mimicking the alterations a vein faces once
inserted into an arterial regimen (high shear stress and pressure), the behavior of human saphenous veins in the absence and presence of an
external macroporous polyester tubular mesh. By preventing pathological remodeling and IH, the mesh provided evidence of its potential clinical
efficiency11.
This study 1) introduces a model of ex vivo human saphenous veins perfusion under controlled pressure and shear stress 2) demonstrates that
external macro-porous polyester mesh reduces IH and provides crucial information for its potential clinical application.
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Protocol
The Ethical Committee of the University of Lausanne approved the experiments, which are in accordance with the principles outlined in the
Declaration of Helsinki of 1975, as revised in 1983 for the use of human tissues.
1. Human Great Saphenous Vein Harvest
1. Obtain surplus segments of non-varicose human saphenous veins from patients undergoing lower limb bypass surgery for ischemia. In the
operating room, disinfect the entire leg with an iodine solution and drape the patient to expose the leg from the groin to the foot.
2. Make a median incision from the groin to the knee (leaving the interrupted skin portion).
3. Harvest the great saphenous vein with a pedicle of surrounding tissue (no-touch technique). Secure side branches of the veins with 4-0 silk
ties. Immediately store a minimum of 9 cm long surplus segment of the greater saphenous vein, with an external diameter of 2.5-4 mm at 4
°C in a RPMI-1640 Glutamax medium, supplemented with 12.5% fetal calf serum and bring it to the laboratory.
2. EVPS Design
1. Assemble the general equipment shown in Figure 1. Autoclave all equipment and keep all components under sterile conditions. In addition,
ensure that the system is waterproof and does not leak chemicals into the medium. Use polymethacrylate methyl (PMMA-GS) for the cover.
Steel (X5 Cr Ni 18 10) and polyoxymethylene plastic (POM) as the vein support.
2. Design the perfusion chamber to the desired geometry to allow the placement of the vein and its connection. Make sure the depth (or radius
if using cylindrical construction) is at least 2.5 cm so it allows minimal flexion and dilatation of the vessel along with constant coverage by the
culture media (Figure 1). Sealing is a major issue and is the reason rectangular PMMA-GS construction is used.
3. Design the vein support to the desired geometry. To avoid vein kinking or over distension, allow length adjustment by pushing or pulling
(screw cannot be used to that purpose, as the vein would be twisted along with the screw).
NOTE: A full steel rod connected by 2 sliding L-shaped pieces that support the 2 vein cylinders (5 mm diameter to fit the vessel) and the vein
(Figure 1B and Figure 2) is used here.
4. Design the pressure column, such that the “resting pressure” applied to the system is: p = 0-10 = h x ρ x g, where p = pressure (N/m2, Pa) h =
height of fluid column (m) ρ = density of liquid (kg/m3) and g = the gravitational constant (9.81 m/sec2). Design four connection ducts, from top
to bottom: to apply pressure, for the outflow (from the vein), the inflow (to the vein) and to allow medium change.
5. Prepare the medium. Based on previous studies5,11-14, choose RPMI-1640, supplemented with Glutamax, 12.5% fetal calf serum, and 1%
antibiotic-antimycotic solution (10,000 U/ml penicillin G, plus 10 mg/ml streptomycin sulfate, plus 25 mg/ml amphotericin B, plus 0.5 μg/
ml: gentamycin). Shear stress (SS) is given by SS= 4 μQ/π*r3Q is the flow rate (ml/sec), r the radius (cm) of the vein segment, and μ is the
viscosity of the perfusion medium.
1. Modulate SS by adjusting the viscosity through addition of 70 kDa dextran. Measure the viscosity with a viscometer. Here, add 8% 70
kDa dextran to set SS to 9-15 dyn/cm2.
6. Set the gearing pump to induce a pulsatile cardioid signal of 60 pulses/min and constant amplitude generating a unidirectional flow of 150
± 15 ml/min, independent from the pressure applied in the system and controlled by a computer. Ensure that the driving software integrates
constant acquisition and monitoring of pressures, flow velocity, pulse rate, and signal. If desired, use a second pump (non synchronized) to
produce a non-laminar, turbulent flow.
3. EVPS Assembly (Figure 1)
1. Before starting, make sure all the equipment is sterile. Perform all the following steps under asepsis in a laminar flow hood.
2. Place the vein in a Petri dish filled with medium. Use a surgical blade and divide the vein into 3 equal segments.
3. Immediately rinse one segment in PBS. Divide the segment in 3 parts, fix one in formalin for morphometry. Freeze the other two for
quantitative transcript (RT-PCR) and protein (western blot) analysis. Consider these segments as a control, non-perfused vein.
4. Use the 2 remaining segments for perfusion.
1. Very gently inject medium into the vein and determine the normal flow direction; in presence of valves the vein is reversed.
2. Sealing the veins is of utmost importance to experimental success. Check for leaks through collaterals. Secure any leaks with 6-0 silk
sutures.
5. Connect the vein segment between the two metallic cylinders, one end at a time (2.3, Figure 1). Secure the cylinders with Ethibon 3-0 around
the indentations (Figure 1A and B).
1. Place the entire venous segment into the perfusion chamber previously filled with medium. Repeat the same procedure for the second
segment.
NOTE: Failure to properly seal the vein to the cylinder will be a source of leak, require reintervention, and significantly increase the risk
of infection and experimental failure.
6. To reinforce (mesh) the second segment, release the two cylinders (with the vein attached) from the L-shaped pieces (2.3 and Figure 1).
1. Be gentle and do not touch the vein with any instruments. Slide the mesh first on the cylinder then onto the vein. A push/pull jostling will
get the mesh on the vein.
2. Once the mesh covers the entire surface of the vein secure the jacketed vein to the cylinders with Ethibon 3-0.
3. Reassemble the vein/cylinder compound to the L-shaped support and transfer it to the perfusion chamber, previously filled with
medium.
7. Connect each metallic cylinder (in-and outflow) to a Y-splitter using peroxide-treated silicone tubing with an internal diameter of 3.2 mm.
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8. Connect the outflow splitter to a second Y-splitter using the same type of tubing. From this Y-splitter, use one tube to measure the perfusion
pressure through both vessels. Connect the other one back to the column to form a closed loop system (Figure 2).
9. Inside the incubator, use a long (one-meter length) tube to connect the pressure column to the pump head.
10. Complete the set up by connecting the pump head to the inflow Y-splitter with another long length tube (Figure 1).
4. Veins Perfusion
1. After the EVPS assembly has been completed, fill the column with medium (stay below the vein outflow duct to allow refilling). Add more
medium into the column until the system is full. Move all the system into the incubator maintained at 37 ± 0.1 °C with a pH kept constant at
7.40 ± 0.01 (using a CO2/pH algorithm based on the Henderson-Hasselbach equation).
2. Bring the gear pump head outside the incubator and connect it to the gear pump drive. Screw the rods to secure the assembly.
3. Switch on the pump power, make sure it is activated on the driving software and allow 5 min for the medium to be equally distributed in every
compartment.
4. To monitor the pressure, use an arterial line monitoring. Connect the EVPS pressure output (it corresponds to the arterial catheter) to the
pressure transducer linked to the computer.
1. Make sure the tube is entirely filled with medium and does not contain any bubbles. De-bubble the culture system through the “arterial
line” tube (Figure 2). Pay attention to the display and look for a pulsatile cardioid signal of 60 pulses/min of constant amplitude. At this
point, the average pressure is between 0-10 mm Hg. If the pressure is < 0 and the column progressively empties look for a leak (vein
collateral or inadequate seal between the vein and the tube).
5. Set the minimal pressure to 6 mm Hg for a venous test or at 90 mm Hg for an arterial test. Under these conditions, an air injector applies the
required pressure to the column and system.
6. Change the medium every 2 days by using the tube connected to the pressure column. To prevent pressure change damage, open the
column plug first.
5. Completion of the Perfusion
1. After 3 or 7 days of perfusion: take the EVPS out of the incubator and dismount the veins. Discard the 5 mm proximal and distal vein ends
attached to the equipment. Cut a central, 5 mm thick rings from the remaining segment and fix in formalin (morphometry). Freeze the
remaining fragments and reduce into powder for further molecular analyses.
Representative Results
The EVPS provides a valuable tool to independently assess the hemodynamic forces on human saphenous vein grafts remodeling and IH.
Figure 1 shows the perfusion chamber and the vein support. In Figures 1A and B, the vein support before (Figure 1A) and after (Figure 1B)
assembly, respectively, is pictured. It is composed (from the top to the bottom) of 1 plain stainless steel tube measuring 9 cm, which serves as
a support for 2 L-shaped pieces that can easily slide (from the left to the right) and provides a reliable technique to adjust the support size to the
vein. Each of these pieces holds a POM disc to fit a steel cylinder (vein connector) fixed in place by integrated screw (arrowhead). Figure 1C-D
shows the perfusion chamber alone (C) and after insertion of the vein support (D). On the perfusion chamber, depressions are designed to hold
the vein support in place (top) and to avoid kinking of the connecting tube coming in and out from the vein (bottom).
Figure 2 shows real time pictures (Figure 2A) and a schematic representation (Figure 2B) of the EVPS. The perfusion chamber, veins and its
supports, as well as the pressure column, are maintained in a controlled environment (temperature, CO2 and O2) whereas the pump, pressure
injector, and control devices all remain outside the incubator. The figure illustrates the gearing pump (1) that generates a pulsatile signal
controlled by a computer (2), which monitors the flow velocity (3), pressure (4), and controls the minimal diastolic pressure (5); two segments of
a same saphenous vein are connected in parallel to the perfusion pump inside separate perfusion chambers (6a and 6b) placed in a cell culture
incubator.
In Figure 3, histomorphometric analysis shows that external reinforcement prevents intimal hyperplasia and pathological media remodeling
otherwise observed after 7 days under high pressure (arterial regimen, mean = 100 mm Hg) perfusion. In Figure 3A, representative histological
sections stained for Hematoxylin-eosin (HE) reveals the lining of the lumen by nuclei of endothelial cells and the nuclei of SMCs in the media
layer in all conditions. Figures 3B-C shows representative Van Gieson Elastic Lamina (VGEL) stained sections. In Figure 3B, the intima is
thickened (IH) in veins perfused at high pressure (mean = 100 mm Hg) for 7 days compared to control non-perfused veins, a phenomenon
largely decreased in the presence of an external mesh. Figure 3C illustrates the pathological outward remodeling and media thinning in veins
subjected to 7 days of arterial pressure. This is largely prevented by the external reinforcement. Furthermore, in Figure 3D, Masson’s trichrome
staining (blue=connective tissue, red=muscle) associates this pathological remodeling with the persistence of only one of the three muscle layers
and accumulation of smooth muscle cells in the inner layer (intima). The external reinforcement preserves the distribution of the SMCs and
media structure.
Figure 4 illustrates a current clinical application of the external mesh. An illustrative example is provided by external reinforcement of an
aneurysmal arterio-venous fistula (hemodialysis access). Figure 4A shows a time-course representation of the vein reinforcement (from the
top to the bottom). First, the mesh was placed around a rigid tube while the vein’s extremity is fixed to a mandrel (upper panel). Then, the vein
was pulled through the tube thanks to the mandrel. Once the vein was in place, the tube was slowly retracted, leaving the mesh around the vein
(upper and middle panel). In this particular case, the procedure was repeated on both sides of the veins, and the veins segments and mesh
reinforcements were assembled by an end-to-end anastomosis (lower panel). Figure 4B provides a larger view of the arterio-venous end-to-side
anastomosis, showing that the mesh is wrapped around the anastomosis by tying it along the posterior wall of the artery.
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Figure 1. The vein support and perfusion chamber. A. The vein support is composed of 1 plain tube, 2 L-shaped pieces, discs and cylinders
(form the top to the bottom). B. The vein support once assembled. C. View of the perfusion chamber. D. The perfusion chamber is designed to
hold in place the vein support and allows its connection to the vein and connecting tubes.
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Figure 2. The ex vivo perfusion system. A. The completely assemble EVPS in the cell-culture incubator. B. Schematic representation. 1) the
pump generating a pulsatile cardioid wave; 2) the computer controlling the pressure, flow (type, rate and amplitude); 3) the flow meter; 4) the
pressure transducer – arterial line; 5) the pressure injector; 6) two segments of a very same saphenous vein are perfused without (6a) or with
external mesh reinforcement (6b).
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Figure 3. The external reinforcement prevents intimal hyperplasia. A. Representative histological sections stained with Hematoxylin-eosin
(HE). Bar represents 50 µm. B-C. Representative histological sections stained for elastin (VGEL). l = lumen m = media, IH = intimal hyperplasia.
Bar represents 50 µm. D. Representative histological sections stained with Masson’s trichrome. Bar represents 50 µm.
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Figure 4. External reinforcement of an aneurysmal fistula. A. Time-course photographs of vein reinforcement (from top to bottom). B. Larger
view of the arterio-venous end-to-side anastomosis.
Discussion
This study uncovers an ex vivo vein perfusion system (EVPS) to perform extensive hemodynamic studies in human veins. This system allows
saphenous veins perfusion under defined hemodynamic parameters in the absence of aggravating inflammatory and growth factors released
by circulating cells in vivo. Thus, it provides a better understanding of the underlying pathways involved in the control of IH in human veins
grafts5,11,12,15.
Reproducible and quantifiable hemodynamic perturbations are limited in vivo. Several complex murine microsurgical procedures have been
described. Using a bypass isograft model via interposition of a vena cava from a donor mouse into the right common carotid artery and the
additional creation of an outflow branch ligation, mid graft or common carotid stenosis, flow and SS acutely decreased and enhanced IH3.
Outward versus inward remodeling can further be interrogated using a mid-focal versus distal common carotid stenosis16. In large animals
(sheep, pig, and baboon), bypass grafts are technically easier and represent an attractive approach to test pre-clinical human sized devices such
as the mesh used in the present study8-10. However, its cost and the paucity of validated molecular tools limit the use of these strategies. Finally,
these flow manipulations constantly alter wall tension and fail to interrogate one single constituent. In addition, the intricate relationships between
the hemodynamics and the immune and endocrine systems further limit the analysis of a single actor.
Several issues arise with the use of the EVPS. 1) Low-grade bacterial contamination often accompanied human vein harvest and the ex-vivo
absence of circulating cells stand as an important cause of infection. This is mainly prevented by hand washing the pieces separately then
autoclaving all material prior to use. Furthermore the assembly is performed in less than 90 minutes and under rigorous asepsis. 2) Sealing
that endures repeated sterilization. For this reason, a rectangular PMMA-GS construction was used, avoiding the use of joints and limiting
deformation. 3) SS and wall tension are calculated at defined time points, based on the vessel lumen radius (histology), the flow and viscosity
being constant. The integration of a longitudinal imaging (high definition camera, laser or Doppler) that continuously monitors the vein diameter
and/or flow will provide more detailed information on local flow variations and allow cyclic strain calculations. 4) The two parallel vein segments
may have uncontrolled differences in their wall compliance and radius. Thus, we only compare segments from a same vein and assume that
under the same pressure, the flow rate pattern is similar in both segments.
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In this study, veins were submitted to pulsatile laminar flow; however, 50% of intimal hyperplastic lesions occur in the end-to-side perianastomotic
areas of the vein graft, where laminar flow is disrupted. Turbulent conditions can be modeled with the addition of a second pump, non-
synchronized with the first pump. Future studies will be performed to specifically assess the impact of laminar flow disruption on IH and the
potentially beneficial effect of mesh reinforcement. Interestingly, the flexible structure of the mesh allows circumferential wrapping at the
anastomosis sites, as already performed to repair aneurysmal fistulas17 (Figure 4). Thus, the mesh could prove useful to limit perianastomotic
dilatation, laminar flow disruption and consequently reduce IH at the anastomosis sites. This may be particularly beneficial in distal bypass graft,
frequently affected by diameter mismatch between the vein and the tibial or peroneal artery.
In summary, the setup shown here allows parallel perfusion of human veins, under identical hemodynamic conditions. These data demonstrate
that the use of an external macroporous tubular polyester mesh is an efficient method to limit the development of IH in vein grafts inserted into an
arterial environment11. This system can profit several areas of research. Especially, it emerges as a powerful tool to perform pre-clinical studies
testing the feasibility and efficiency of various approaches to reduce IH in human material, and is a valuable addition to in vivo animal models.
Other prosthetic supports or meshes coated with pharmaceutical agents will be evaluated using this method6-10. In addition, one could envision
to test locally applied pharmacological molecules to prevent IH in human tissue, under near physiological state. Gene therapy interventions are
also achievable, transducing a vein segment to overexpress or silence target genes of interest.
In conclusion, our system will increase our understanding of the hemodynamic contribution to human vein graft diseases. It provides an
innovative platform to test new therapeutic strategies and may arise as a “bench to beside translation tool.”
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Abstract
Venous bypass grafts often fail following arterial implantation due to excessive smooth mus-
cle cells (VSMC) proliferation and consequent intimal hyperplasia (IH). Intercellular commu-
nication mediated by Connexins (Cx) regulates differentiation, growth and proliferation in
various cell types. Microarray analysis of vein grafts in a model of bilateral rabbit jugular
vein graft revealed Cx43 as an early upregulated gene. Additional experiments conducted
using an ex-vivo human saphenous veins perfusion system (EVPS) confirmed that Cx43
was rapidly increased in human veins subjected ex-vivo to arterial hemodynamics. Cx43
knock-down by RNA interference, or adenoviral-mediated overexpression, respectively
inhibited or stimulated the proliferation of primary human VSMC in vitro. Furthermore, Cx
blockade with carbenoxolone or the specific Cx43 inhibitory peptide 43gap26 prevented the
burst in myointimal proliferation and IH formation in human saphenous veins. Our data dem-
onstrated that Cx43 controls proliferation and the formation of IH after arterial engraftment.
Introduction
Bypass of stenotic arteries with autologous saphenous vein is an established treatment for
ischemic vascular disease. However its long-term success is limited, with 30–50% of the saphe-
nous grafts failing within 5 years post implantation [1]. Vein graft failure is due to intimal
hyperplasia (IH), a process whereby the vein wall thickens and expands to adapt to the high
arterial pressure and flow.
Several studies suggest that intercellular signaling regulates VSMC’s phenotypic switch [2,
3] and proliferation [4–7]. However gap junction’s response to flow, pressure and their contri-
bution to IH remains poorly delineated. The direct intercellular exchange of small molecule
(<1kDa) through gap junctions is critical to integrate individual cells into coordinated
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multicellular units, allowing maintenance of cellular homeostasis and regulation of cellular
functions including proliferation, migration and differentiation [8–10]. Endothelial cells (EC)
predominantly express Cx37, Cx40 and some Cx43, whereas vascular smooth muscle cells
(VSMC) are mostly coupled by Cx43 and Cx45, albeit minimal levels of Cx37 and Cx40 have
been reported [8–10].
To determine the contribution of hemodynamic forces in the development of IH, we previ-
ously developed a model of bilateral rabbit carotid artery interposition grafts plus a unilateral
distal outflow ligation to model differential flow states [11, 12]. In this setting, we identified
divergent patterns of vein graft remodeling under low versus high flow and shear stress [12].
To further study the impact of hemodynamic forces after human vein arterial engraftment, we
developed an ex-vivo human vein perfusion system (EVPS) [13, 14] and observed a 7-day
high-pressure perfusion (mean = 100 mmHg) to be sufficient for IH formation. The VSMC
forming the media layer of the vessels are highly specialized contractile cells featuring a very
low proliferation rate under physiological conditions [15]. Following injury, VSMC integrate
signals that promote their phenotypic switch from a quiescent contractile to a proliferative and
motile state. The proliferation and migration of VSMC from the media toward the intimal
layer are keys component to IH.
The aim of this study was to characterize the regulation of vascular connexins flowing arte-
rial implantation of vein grafts. We observed that endothelial connexins Cx37 and Cx40 are
rapidly down-regulated while VSMC connexin Cx43 is strongly and rapidly up-regulated in
response to pulsatile arterial perfusion in rabbit vein grafts in-vivo and in human veins grafts
ex-vivo. We further demonstrate, using primary human VSMC, that Cx43 controlled prolifera-
tion and show for the first time that specific Cx43 blockade partially prevented IH formation in
human veins ex-vivo.
Materials and Methods
Animal vein graft
Male New Zealand White rabbits (3.0–3.5 kg; n = 56) were anesthetized through an intramus-
cular injection with ketamine hydrochloride (30.0 mg/kg). Anesthesia was maintained with
endotracheal intubation and continuous isoflurane inhalant anesthesia (2% during painful sti-
muli, and 1% at latent periods). Vein bypass grafts were constructed with an anastomotic cuff
technique as previously as described [11, 12]. Bilateral carotid artery interposition grafting
with jugular vein and unilateral distal carotid artery branch ligation were performed to create
two distinct flow states. Briefly, differential flow states between the right and left vein grafts
were accomplished by ligation of the internal carotid artery and three of the four primary
branches of the external carotid artery, resulting in an immediate six fold difference in mean
shear stress [11, 12]. Routine daily postoperative care and analgesia was provided, including
daily neurologic assessment up to day 5 post surgery to identify any or all of head tilt, ear
droop, or extremity weakness. Graft flow rates were determined at the time of implantation
and harvest with an ultrasonic flow meter (VisualSonics Inc, Toronto, Ontario, Canada). Vein
grafts harvest was performed under general anesthesia through an intramuscular injection with
ketamine hydrochloride (30.0 mg/kg). Then the recipient rabbit was whole-body blood flushed
with saline via intravascular access through the left ventricle, leading to exsanguination and
death. Vein grafts were harvested after implantation at 2 hours (0.08 days) (high-flow, n = 4;
low-flow, n = 4) and 1 day (high-flow, n = 5; low-flow, n = 4), 3 days (high-flow, n = 4; low-
flow, n = 5), 7 days (high-flow, n = 5; low-flow, n = 5), 14 days (high-flow, n = 4; low-flow,
n = 5), and 28 days (high-flow, n = 6; low-flow, n = 6). Normal rabbit jugular vein served as the
control (n = 5). The perianastomotic regions for each vein graft were removed, and the mid-
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portion of the graft was divided into two segments, one for histological and immunohisto-
chemical analyses and the other for total RNA extraction using the RNeasyMiniKit (Qiagen) as
previously described [12].
Microarray analysis
Microarray analysis was performed as previously described [12]. Briefly Complementary DNA
form rabbit vein was generated using Ovation Pico WT kit (NuGEN, San Carlos, Calif) and
labeled using GeneChip WT Terminal Labeling (Affymetrix, Santa Clara, Calif). Samples were
hybridized to a proprietary rabbit array (Affymetrix). The resulting expression data were nor-
malized with the Partek Genomics Suite (Partek, St. Louis, Mo).
Human saphenous veins culture
After informed consents, 27 surplus segments of non-varicose human saphenous veins were
obtained from 27 patients (15 men and 12 women) with a median age of 72 years (interquartile
range 51–82), who underwent lower limb bypass surgery for critical ischemia. A 7 to 9 cm long
segment of the greater saphenous vein, with an external diameter of 2.5–4 mm, was harvested
and immediately stored at 4°C in a RPMI-1640 Glutamax medium, supplemented with 12.5%
fetal calf serum (Life Technologies Europe B.V.). The segment was divided in 3 equal parts.
One part was immediately fixed in either formalin (one half) or rapidly frozen in liquid nitro-
gen (the other half). The two others parts from the same vein were perfused using an ex-vivo
perfusion system (EVPS) [13, 14, 16], with or without an external mesh reinforcement (Pro-
Vena, B.Braun Medical SA) to model and control (mesh) the development of IH as previously
described [13] (more details on the method can be found at: http://www.jove.com/video/
52079/procedure-for-human-saphenous-veins-ex-vivo-perfusion-external). A pulsatile, cardi-
oid signal at 60 pulses per minute with constant amplitude was setup up via the computer soft-
ware which independently pilots the gearing pump. The resulting flow was about 160
milliliters per minute. The conditions of the perfusion were set to obtain a shear stress (SS) of
9–15 dyn/cm2, as expected in the femoral artery [14], given by SS = 4 μQ/ π r3, where μ is the
viscosity of the perfusion medium set to was 3.73 10−2 dyn!s/cm2, as measured in a Coulter vis-
cometer (Coulter Electronics, High Wycombe, UK), Q the flow rate (mL/s), and r the radius
(cm) of the vein segment. Mean pressure (MP) = 100 mmHg, as given by MP = (systolic pres-
sure + 2 x diastolic pressure)/3. Upon completion of the perfusion period, the vein segments
were dismounted and the 5 mm proximal and distal ends, which attached the vessel to the per-
fusion equipment, were discarded.
Static vein cultures were performed as previously described [17]. Briefly, 5 mm segments of
vein were opened longitudinally and pinned on a layer of Sylgard 184 resin (Dow Corning,
Seneffe, Belgium) in a Pyrex dish and kept in culture for 10 days in RPMI-1640 Glutamax sup-
plemented with 10% FBS and and 1% antibiotic solution (10,000 U/mL penicillin G, 10,000 U/
mL streptomycin sulphate). 100 μMCarbenoxolone (Sigma-Aldrich), 200 μM of the Cx-
mimetic peptides 43Gap26 (VCYDKSFPISHVR, Tocris Bioscience Bristol, UK) and the control
scrambled peptide (PSFDSRHCIVKYV) (Severn Biotech, UK) were prepared in SMC culture
media. 5-mm segments of vein were harvested after culture. The vein segments were either fro-
zen for molecular analysis or fixed in 4% formalin and paraffin-embedded for histological
analysis.
Morphometry
Hematoxylin-eosin and Van Gieson-elastin (VGEL) stainings were used for histological and mor-
phometric analysis, respectively. All morphometric measurements were done by 2 independent
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researchers, one of them blind to the experimental groups using the Leica Qwin1 software
(Leica, Switzerland). Twenty-four measurements of the thickness of the intima and media layers
were made in each sample at a magnification of x100 as previously described [14, 16].
Cell culture
The human smooth muscle cells were prepared from explants culture, as previously described
[18–20]. Briefly, primary smooth muscle cells were cultured from human saphenous veins
from a similar cohort used for ex-vivo perfusion. Veins explants of 1–2 mm were plated, lumi-
nal side down, on the dry surface of a 24-well culture plate, previously coated with 1.5% Gelatin
type B (Sigma-Aldrich). Explants were gently covered with one drop of RPMI, 10%FBS
medium, and placed overnight in a 37°C, 5% CO2. The next day, culture medium was carefully
added to the wells, taking care not to detach the explants. VSMC were identified by immunos-
taining using antibodies to smooth muscle actin (abcam, ab5694) and desmin (Dako, M 0760).
Passages 1 to 4 were used for the experiments.
RNA interference
Smooth muscle cells were transiently transfected using lipofectamine RNAiMAX (Life Tech-
nologies Europe B.V.) and 30nM siRNA. Cx43 siRNAs 1 and 2 (s5758 and s5759) were pur-
chased from Ambion (Ambion, Life Technologies Europe B.V., Zug, Switzerland). Briefly,
confluent cells were transfected using antibiotics free Optimem medium (Life Technologies
Europe B.V.), according to the manufacturer’s indications. Cells were kept 48 hours in culture
before the experiments. The Allstars Negative Control siRNA (Qiagen, Hombrechtikon, Swit-
zerland) was used as a control. The efficiency of transfection was above 90% as evaluated using
the Thermo Scientific™ Dharmacon™ siGLO™ Green Transfection Indicator (Thermo Fisher
Scientific Inc. Waltham, MA, USA).
Adenoviral transfer
The Control Ad-GFP virus were generated as previously described [21, 22]. Ad-Cx43 was a
kind gift from Professor Viviana Berthoud and Eric Bayer (University of Chicago, Illinois, U.S.
A.). All viral vectors were amplified and purified by Vector Biolabs, (Philadelphia, PA, U.S.A.).
Human VSMC were infected overnight in complete medium and collected 48 hours later.
Quantitative real-time PCR
Quantitative real-time PCR analysis was performed on total RNA extracted from human
saphenous veins using the TriPure isolation reagent (Roche) as previously described [14, 20].
The primers used to amplify specific cDNAs are given in S1 Table, and were designed using the
free online software Primer3Plus (http://primer3plus.com/cgi-bin/dev/primer3plus.cgi) [23].
Levels of expression were determined relative to those of GAPDH, which were not significantly
altered by the experimental conditions tested here.
Western Blots
Segments of saphenous veins were reduced to powder in liquid nitrogen, and homogenized in
lysis buffer as published [23, 24]. Immunoblot analyses were performed as previously described
[16, 23, 25] using the following antibodies: rabbit polyclonal against Cx43 (Millipore) diluted
1:1000; rabbit polyclonal against Cx40 (InVitrogen) diluted 1:2000; rabbit polyclonal against
Cx37 (kindly provided by Pr. A. Simon [23]) diluted 1:2500; mouse monoclonal against α-
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Tubulin (Sigma-Aldrich), diluted 1:1000 and horseradish peroxidase-conjugated goat anti-rab-
bit or anti-mouse IgG (Sigma-Aldrich), diluted 1: 5000.
Immunohistochemistry and immunocytochemistry
The Proliferating Cell Nuclear Antigen (PCNA) and alpha smooth muscle actin (α-SMA)
immunostaining were performed on paraffin-embedded tissue slides using the monoclonal
mouse anti-human PCNA (Clone PC10 1/200; Dako Schweiz AG, Baar, Switzerland), and
anti-SMA (Abcam, ab5697, Lucerna chem. AG, Luzern, Switzerland) antibodies. Slides were
subjected to standard protocol of antigen retrieval prior to antibody incubation. PCNA staining
was revealed either using DAKO envisionTM+-HRP-DAB staining or using secondary biotin-
steptavidin antibodies coupled to AlexaFluor 594. The PCNA positive signal was evaluated
automatically using the ImageJ software on 10 slides per vein and 3 to 5 veins per conditions
[16]. PCNA/DAB+ signal were quantified as follows: images were converted into 16 bit and a
color threshholding based on red hue was applied to select only the brown staining. The
selected staining was processed into a binary image and the number of positive pixels deter-
mined. This signal was normalized to the total pixel number composing the vein section and
expressed as a PCNA positive pixels/total vein pixels ratio. PCNA fluorescent signal were
quantified as follows: images were converted to a 32 bit format and the signal to noise ratio was
determined by applying the Yen thresholding method. A binary image was then created and
the number PCNA+ nuclei automatically detected. Data were normalized to the number of
cells (nuclei imaged by DAPI staining) in each image. Cx immunostainings were performed
using frozen sections of unfixed veins as previously described [23], using the primary antibod-
ies used for Western blotting at a dilution of 1:100, except those against Connexin43 (Milli-
pore), which was diluted 1:200. Vein sections were rinsed in PBS, counterstained with 0,02%
Evans Blue and coverslipped. BrdU and Cx43 immunostaining were performed as previously
described [20, 26] on SMC grown on glass coverslips and fixed for 5 min in −20°C acetone, air-
dried, rinsed in PBS and permeabilized for 1 h in PBS supplemented with 2% BSA and 0.1%
Triton X-100 (full PBS). Brdu positive nuclei were automatically detected using the ImageJ
software and normalized to the total number of DAPI-positive nuclei.
Cell cycle analysis
To measure the cellular DNA content, transfected cells were kept under 0% FBS for 48 hours,
and then supplemented with 10 ng/mL Platelet-Derived Growth Factor (PDGF-BB, Pepro-
Tech) for an additional 24 hours. Adherent cells were collected by trypsinization. Cells were
pelleted, rand washed in PBS/EDTA and fixed in 70% ethanol overnight at 4°C. Cells were pel-
leted and resuspended 15 min at 37° in 1ml PBS 0.1% Triton X-100 with 0.1 mg RNase (Sigma-
Aldrich) and 0.2 mg propidium iodide as previously described [27]. Samples were analyzed on
BD FACS Scan. The percentage of cells in different phases was calculated using FlowJo soft-
ware (Tree Star, Inc).
Scratch wound assay
Two perpendicular scratch wounds were created on confluent cells using a sterile p200 pipette
tip. Repopulation of the wounded areas was recorded by phase-contrast microscopy connected
to a digital camera every 2 hours and for 24 hours. The size of the denuded area was deter-
mined at each time point from digital images using the ImageJ software. The area of each
experiment, measured immediately after the wounding was used to standardize quantitative
analysis.
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Statistical Analysis
All experiments were quantitatively analyzed and results shown as mean + SEM. One or two-
way analysis of variance (ANOVA) were performed to compare mean values between groups,
using post hoc t-tests with Bonferroni correction, as provided by the Statistical Package for the
Social Sciences (SPSS 17.0, Chicago, Ill., USA). Statistical significance was set at p< 0.05.
Ethics Statement
Written, informed consent was obtained from all vein donors who underwent lower limb
bypass surgery for critical ischemia. The study protocols for organ collection and use were
reviewed and approved by the Centre Hospitalier Universitaire Vaudois (CHUV) and the Can-
tonal Human Research Ethics Committee (http://www.cer-vd.ch/, no IRB number, Protocol
Number 170/02), and are in accordance with the principles outlined in the Declaration of Hel-
sinki of 1975, as revised in 1983 for the use of human tissues.
Rabbit care, surgery and euthanasia procedures were approved by the Institutional Animal
Care and Use Committee of the University of Florida (https://iacuc.ufl.edu) and conforms to
the Guide for the Care and Use of Laboratory Animals (NIH Publication, Revised 2011, Ani-
mal Welfare Assurance Number A3377-01).
Results
Arterial engraftment induces vein intimal hyperplasia and time-
dependent regulation of the vascular connexins
As previously described [11, 12, 28], bilateral rabbit vein grafting caused a robust hyperplastic
response beginning at 7 days after vein graft implantation, and progressing to 28 days. Micro-
array analysis of both vein grafts demonstrated that flow did not impact the gene expression of
Cx37 (GJA4), Cx40 (GJA5) and 43 (GJA1), as assessed by ANOVA for fixed effects with flow
and time as the two variables (Fig 1 and S1 Fig). Temporal changes in gene expression after
vein graft placement were then analyzed from 2 hours (0.08 days) following grafting and up to
28 days. At a p value< 0.05, 57 genes were differentially expressed over time (S1 Fig). Unsuper-
vised genes cluster analysis revealed that individual vein grafts cluster by time point rather
than by flow state, indicating time from implantation as the dominant effect on gene expres-
sion (S1A Fig). A supervised hierarchal clustering analysis using averaged expression data fur-
ther revealed that among the early upregulated genes (S1B Fig), Cx43 was the most
differentially expressed, with a fivefold upregulation 2 hours after implantation, which per-
sisted over time (Fig 1A and 1B). In the cluster of downregulated genes, despite an early down-
regulation, the Cx37 and Cx40 transcript levels did not significantly change over time (Fig 1A
and 1B).
Myointimal proliferation and Cx43 are increased in human veins
exposed to arterial hemodynamic
Using our validated ex-vivo vein perfusion model [13, 16], human saphenous veins grafts were
exposed to high-pressure (mean = 100mmHg) and high flow (180-200ml/min), mimicking the
femoral artery hemodynamic. As previously established [16], 3 and 7 days of arterial perfusion
resulted in neointima formation (Fig 2A upper panel and 2B) and reduced media thickness
(Fig 2A upper panel and 2C). VonWillebrand factor (vWF) immunostaining revealed intact
endothelial cells lining the lumen of native vein and vein subjected to a 3 or 7 days high pres-
sure pulsatile perfusion (Fig 2A, lower panel).
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Further analysis of cell growth dynamics, showed reduced media cellularity and a concomi-
tant increase in proliferative activity within the myointima after 3 and 7 days (Fig 3), as
assessed by PCNA immunostaining. The addition of an external reinforcement preserved the
structure but not the cellularity of the media layer, reduced the number of PCNA-positive
nuclei, and prevented the development of IH (Fig 3).
In human saphenous vein, Cx37 and Cx40 are specifically expressed in ECs, whereas Cx43 is
mainly expressed in VSMC [17, 29]. Both Cx37 and Cx40 transcripts (Fig 4A and 4C) and pro-
tein (Fig 4B and 4D) levels decreased after 3 and 7 days of arterial hemodynamic exposure. In
contrast, Cx43 mRNA (Fig 4E) and protein (Fig 4F) levels were both increased after 3 and 7 days.
External vein support did not prevent Cx37 mRNA (Fig 5A) and protein decrease (Fig 5B).
The external mesh had a tendency to reverse Cx40 mRNA (Fig 5B) and significantly prevented
Cx40 protein drop (Fig 5D). In contrast, the mesh support dampened Cx43 mRNA (Fig 5E)
and protein (Fig 5F) upregulation.
Further immunofluorescent staining of connexins after 7 days of perfusion confirmed that
endothelial Cx37 and 40 remained decreased in presence of the mesh, whereas Cx43 overex-
pression was attenuated (Fig 6).
Fig 1. Probe sets analysis demonstrate changes in Cx transcripts levels over time after rabbit vein graft. A) Supervised hierarchal clustering analysis
of selected time-dependent probe sets (false discovery rate = .05) reveals GJA1 (Cx43), GJA4 (Cx37) and GJA5 (Cx40) to cluster with differential expression
patterns. Mean expression data at each time point (expressed as day) and flow condition are presented across the x-axis, with red representing upregulation
and blue representing downregulation compared to normal vein. B)Mean expression fold change from baseline (normal vein) of Cx43 (top), Cx40 (middle)
and Cx37 (bottom) at each time point under high and low flow conditions. Dotted red line represents the mean value observed in control normal vein. Data
represent mean ± SEM of 5 experiments.
doi:10.1371/journal.pone.0138847.g001
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Cx43 controls smooth muscle cell proliferation
To determine the role of Cx43 in VSMC phenotypic switch, Cx43 was knocked-down in pri-
mary human VSMC using two distinct siRNAs, which both decreased Cx43 protein levels by
90% (Fig 7A). Loss of Cx43 (siCx431 and 2) did not alter VSMC migration, as compared to
VSMC transfected with a control siRNA (siCtrl) (Fig 7B and 7C). However, the absence of
Cx43 reduced by 40% the number of Brdu positive cells over a 24h treatment with 10 ng/mL
PDGF-BB (Fig 8A). Flow cytometry analysis of DNA content further revealed that the
absence of Cx43 arrested VSMC in G0/G1 cell cycle phase (76% vs 68%) (Fig 8B). Conversely,
the adenoviral-mediated overexpression of human Cx43, which resulted in a dose-dependent
increase in Cx43 protein levels (Fig 9A) at the cell-cell membrane contacts (Fig 9B), increased
VSMC proliferation by 30% over a period of 24 hours in presence of 10 ng/mL PDGF-BB
(Fig 9C and 9D).
Fig 2. Intimal hyperplasia formation in ex-vivo human vein perfusion.Human veins were subjected to arterial pressure and flow (mean pressure = 100,
high flow) for 3 and 7 days using an ex-vivo perfusion model. A)Representative Van Gieson Elastic Laminae staining (VGEL, upper panel) and vWf (green)
and nuclei (DAPI blue) (lower panel) staining. I: intimal hyperplasia; L: lumen; M: media; IEL: internal elastic lamina. Bar represents 100 μm. Data are
representative of 8–9 experiments. B-C)Morphometric measurements of human veins subjected to a 3- and 7-day pulsatile high pressure perfusion, with or
without external mesh reinforcement. Data represent mean ± SEM of 4–9 experiments. *p<0.05, **p<0.01 and ***p<0.001 versus the non-perfused veins
(ctrl). °°p<0.01 and °°°p<0.001 versus the unsupported vein segment.
doi:10.1371/journal.pone.0138847.g002
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Connexins blockade prevents intimal hyperplasia
The potential vasculoprotective effect of Cx43 blockade was then tested in human saphenous
vein, using the pan-Cx inhibitor carbenoxolone (100 μM) or the specific Cx43 inhibiting pep-
tide 43Gap26 (200 μM) [30, 31]. Both strategies reduced the development of IH (Fig 10) and
myointimal proliferation (PCNA staining) (Fig 10) observed after 10 days of static culture, sug-
gesting that Cx43 is the main Cx involved in VSMC proliferation and IH.
Discussion
The data here show that arterial engraftment rapidly increased rabbit Cx43 gene expression in-
vivo. Consistently, Cx43 transcript and protein levels were upregulated in human veins exposed
to arterial hemodynamics ex-vivo. Cx43 genetic inactivation or chemical inhibition reduced
VSMC proliferation in vitro and in vivo, reducing myointimal proliferation and IH formation.
Cx43 was rapidly and consistently increased in all our experimental models, which supports
findings from previous studies showing higher Cx43 levels in vascular occlusive disorders,
including rabbit iliac and rat carotid restenosis models [32, 33], or atherosclerotic lesion in rab-
bit aorta [34, 35]. We further observed that flow, which play a key role in intimal expansion
Fig 3. Growth dynamics in ex-vivo human vein perfusion.Human veins were subjected to arterial pressure and flow (mean pressure = 100, high flow) for
3 and 7 days using an ex-vivo perfusion model. A)Representative PCNA (red) and DAPI (blue) and smooth muscle actin (SMA; green). Arrowheads point to
PCNA positive nuclei. L: lumen, Bar represents 50 μm. Data are representative of 8–9 experiments. Square insets represent a 4 fold magnification of images.
Quantitative assessment of nuclei (DAPI) over section area (B) and PCNA positive nuclei over total DAPI positive nuclei (C). Data represent mean ± SEM of
4–9 experiments. *p<0.05 and ***p<0.001 versus the non-perfused veins (ctrl). °p<0.05 versus the unsupported vein segment.
doi:10.1371/journal.pone.0138847.g003
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and VSMC proliferation [12, 28], is not involved in Cx43 overexpression, in accordance with
our previous findings that Cx43 expression is increased in static human vein culture [17]. The
fact that Cx43 is upregulated both in vivo and ex-vivo implicate intrinsic factors in the Cx43
upregulation following vein grafting. Similarly, the contribution of bone marrow derived
Fig 4. Expression of endothelial Cx37 and 40 are decreased, while muscular Cx43 is increased following arterial engraftment of human vein.
Human veins were subjected to arterial pressure and flow for 3 and 7 days using an ex-vivo perfusion model. Levels of Cx37 transcript (A) and protein (B),
Cx40 transcript (C) and protein (D), and Cx43 transcript (E) and protein (F). Data are mean ± SEM of 4–8 experiments. *p<0.05, **p<0.01 and ***p<0.001
versus the native segment. °p<0.05 day 3 versus day 7.
doi:10.1371/journal.pone.0138847.g004
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Fig 5. Cx43 overexpression following arterial engraftment is dampened by the use of an external mesh support.Human veins were subjected to
arterial pressure and flow for 7 days in absence or presence of the external mesh support. Cx37 transcripts (A) and protein (B) levels remain low in presence
of the mesh. Cx40 transcript (C) and protein (D) levels tend to increase in presence of the mesh. Cx43 transcript (E) and protein (F) levels are decreased by
the external support. Data are mean ± SEM of 4–8 experiments. *p<0.05, **p<0.01, ***p<0.001 versus the native segment. °p<0.05 ctrl versus external
mesh.
doi:10.1371/journal.pone.0138847.g005
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progenitor cells homing to the sites of injury in vivo is expected to be negligible in our ex-vivo
perfusion system.
Given the rapidity of Cx43 overexpression following rabbit grafting we propose that Cx43 is
overexpressed in response to the early surgical stress, rather than flow per se. In line with this
hypothesis, cFOS and cJUN, which play a key role in cell proliferation [36], cluster with the
Cx43 gene GJA1 following rabbit grafting. Indeed, previous reports demonstrated that cJUN or
cFOS control Cx43 promoter activity through a functional AP1 site [37, 38], hence those
Fig 6. Expression pattern of endothelial Cx37 and 40 andmuscular Cx43 following arterial engraftment of human vein.Human veins were subjected
to arterial pressure and flow for 3 and 7 days using an ex-vivo perfusion model. Representative Cx37 (upper panel), Cx40 (middle panel) and Cx43 (lower
panel) immunostaining after 7 days of perfusion, with or without external mesh. Connexin stainings (green) were counterstained with Evans blue staining of
the elastic laminae (red). Data represent mean ± SEM of 8–9 experiments. Bar represents 50 μm. L: lumen; I: intimal hyperplasia; M: media. Data are
representative of 5 experiments. Square insets represent a 3 fold magnification of images.
doi:10.1371/journal.pone.0138847.g006
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Fig 7. Cx43 knock-down reduces hVSMC proliferation. Human primary VSMCwere transfected with a
control siRNA (siCtrl) or Cx43 siRNAs (siCx431 and siCx432). A)Representative Western blot analysis of the
Cx43 over tubulin levels (upper panel, n = 3) and immunofluorescence staining (lower panel, n = 3). B)
Human VSMCmigration was assessed using scratch wound assay. Representative images of wound
closure at 0, 12 and 24 hours after injury of VSMC transfected with a control siRNA (siCtrl) or two different
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factors may control Cx43 in response to grafting. On the other hand Cx43 overexpression is
partially prevented by external support, implying at least a partial regulation of Cx43 expres-
sion by hemodynamic sensitive pathways.
Although the exact mechanisms whereby arterial engraftment leads to Cx43 upregulation
remain to be fully unraveled, we observed a strong correlation between the amount of IH and
the levels of Cx43, suggesting a role of Cx43 in neointima formation. Conflicting data exist
regarding the role of Cx43 in VSMC proliferation and IH formation [2, 5, 7]. Our study clearly
supports the concept that Cx43 stimulates VSMC proliferation [2, 7]. Furthermore, both gen-
eral inhibition of intercellular communication using carbenoxolone or specific blockade of
Cx43-made gap junctions prevented myointimal proliferation and the development of IH in
human vein grafts, suggesting that Cx43-mediated intercellular communication plays a key
Cx43 siRNAs (siCx431 and siCx432). C)Representative wound closure kinetic (n = 3–4) in cells transfected
with the siCtrl (continuous line), siCx431 (dotted line) or siCx432 (dashed line).
doi:10.1371/journal.pone.0138847.g007
Fig 8. Cx43 knock-down does not affect human VSMCmigration. Primary hVSMCwere treated 24h with PDGF-BB, 48 hours after transfection with a
control (siCtrl) or Cx43 (siCx431 or 2) siRNAs. A) Representative immunofluorescence staining (left panel) and quantification of Brdu positive nuclei (right
panel). Nuclei were identified with DAPI. Data represent mean ±SEM of 5 experiments. **p<0.01 versus siCtrl. Bar represents 20 μm. B) Representative (left
panel) and quantification (right panel) of flow cytometry analysis of DNA content (propidium iodide staining). Data represent mean ±SEM of 4 experiments.
**p<0.01 versus siCtrl.
doi:10.1371/journal.pone.0138847.g008
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role in IH. The development of IH also involves VSMC migration from the media layer to the
neointima region. Cx43 knock-down did not impact VSMC migration in our experimental
model of wound healing, in contrast with studies showing that Cx43 participates in VSMC
transmigration when stimulated with angiotensin II [7] or PDGF [2]. This discrepancy is prob-
ably due to the differences between experimental designs and wound healing assay versus
transmigration assay. Studies performed in other cell types suggest an opposite role of Cx43 in
cell migration [39–41], suggesting a very complex role of Cx43, which clearly depends on the
model and cell type studied and warrants further pre-clinical studies before using Cx43-tar-
geted peptides in the treatment of pathologies.
Endothelial cells (EC) are highly sensitive to hemodynamic flow and the frictional forces
between blood and the endothelium [42]. Notably, the production of nitric oxide (NO) by EC
is a key factor in maintaining quiescent and contractile VSMC [43]. Our data indicate that
exposure to arterial hemodynamic rapidly decreases the expression of the major endothelial
connexins Cx37 and Cx40, both in-vivo and ex-vivo. Cx40 [24, 25] and Cx37 [44] are required
for proper eNOS expression and function. In line with these data, we previously demonstrated
that the expression of the endothelial NO synthase (eNOS) is strongly reduced upon arterial
Fig 9. Cx43 overexpression promotes SMC proliferation. hVSMCwere infected or not (NI) with a control adenovirus (Ad-GFP) or a human Cx43
adenovirus (Ad-Cx43) at various multiplicity of infection (MOI) as indicated. A and B)Representative Western blot analysis of the Cx43 over tubulin levels
and Cx43 immunofluorescent staining.C and D) Representative immunofluorescent images and quantification of Brdu incorporation during 24h in primary
hVSMC in presence of PDGF-BB. Nuclei were identified with DAPI. B) Bar represent 50 μm. C) Bar represent 25 μm. Data represent mean ±SEM of 5–6
experiments. **p<0.01 versus NI and ad-GFP.
doi:10.1371/journal.pone.0138847.g009
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implantation in the EVPS [16]. Thus, despite continuous endothelial coverage as demonstrated
by vWf immunostaining, it is likely that the vein graft endothelium is not fully functional when
placed in an arterial environment, as suggested by a previous report [45]. In line with this
hypothesis, a polymorphism in the Cx37 gene [46], as well as the loss of Cx37 (Cx37-/- mice)
[47] increase the risk of atherosclerosis, which share molecular events with IH, including endo-
thelial dysfunction and VSMC proliferation. Unfortunately external reinforcement using the
mesh barely improved the expression of these endothelial markers. The combined loss of
eNOS, endothelial Cx37 and Cx40, as well as other key endothelial genes likely precludes
proper NO production and facilitates IH development. External meshing did not restore the
expression of EC connexins Cx37 and 40. In sharp contrast, Cx43 levels, SMCs proliferation
Fig 10. Inhibition of Cx43-mediated intercellular communication alleviates the development of intimal hyperplasia in human veins. 5 mm segments
of opened vein were kept in static culture for 10 days in presence or not (ctrl), of 200 μM carbenoxolone or 200 μM 43Gap26 peptide or a respective scramble
peptide.A) Representative VGEL (upper panel), and PCNA (lower panel) stained sections showed decreased intimal thickness and cell proliferation in
presence of the Cx43 inhibitors. I = intima; M = media; IEL: internal elastic lamina. Bar represents 100 μm. Square insets in PCNA staining represent a 3 fold
magnification of images.B and C)Quantitative assessment of intima thickness (B) and PCNA positive area (C). Data represent mean ± SEM of 3–4
experiments. *p<0.05, versus ctrl.
doi:10.1371/journal.pone.0138847.g010
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and neointima formation were all severely blunted by the external scaffold, which we believe is
a viable approach to reduce vein graft failure.
This study highlights Cx43 as an early molecular marker of IH and demonstrates that the
development of pathological IH in human vein grafts requires Cx43. Further studies are
required to identify the signals passing through gap junctions mediating the increased VSMC
proliferation and we cannot exclude that hemi-channels also play a role in this process. Cx43 is
mostly expressed by VSMC. Thus, the development of Cx43-targeted pharmacological tools
provides an opportunity to manipulate VSMC proliferation while sparing EC connexins. Espe-
cially, topical delivery of mimetic peptides blocking Cx43 might provide an exciting strategy in
the prevention of IH.
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Preoperative dietary restriction reduces intimal
hyperplasia and protects from ischemia-reperfusion
injury
Christine R. Mauro, MD,a Ming Tao, MD,a Peng Yu, MD, PhD,a
J. Humberto Treviño-Villerreal, MD, PhD,b Alban Longchamp,a Bruce S. Kristal, PhD,c
C. Keith Ozaki, MD,a and James R. Mitchell, PhD,b Boston, Mass
Objective: Whereas chronic overnutrition is a risk factor for surgical complications, long-term dietary restriction (reduced
food intake without malnutrition) protects in preclinical models of surgical stress. Building on the emerging concept that
acute preoperative dietary perturbations can affect the body’s response to surgical stress, we hypothesized that short-term
high-fat diet (HFD) feeding before surgery is detrimental, whereas short-term nutrient/energy restriction before surgery
can reverse negative outcomes. We tested this hypothesis in two distinct murine models of vascular surgical injury,
ischemia-reperfusion (IR) and intimal hyperplasia (IH).
Methods: Short-term overnutrition was achieved by feeding mice a HFD consisting of 60% calories from fat for 2 weeks.
Short-term dietary restriction consisted of either 1 week of restricted access to a protein-free diet (protein/energy re-
striction) or 3 days of water-only fasting immediately before surgery; after surgery, all mice were given ad libitum access
to a complete diet. To assess the impact of preoperative nutrition on surgical outcome, mice were challenged in one of two
fundamentally distinct surgical injury models: IR injury to either kidney or liver, or a carotid focal stenosis model of IH.
Results: Three days of fasting or 1 week of preoperative protein/energy restriction attenuated IH development measured
28 days after focal carotid stenosis. One week of preoperative protein/energy restriction also reduced plasma urea,
creatinine, and damage to the corticomedullary junction after renal IR and decreased aspartate transaminase, alanine
transaminase, and hemorrhagic necrosis after hepatic IR. However, exposure to a HFD for 2 weeks before surgery had no
signiﬁcant impact on kidney or hepatic function after IR or IH after focal carotid stenosis.
Conclusions: Short-term dietary restriction immediately before surgery signiﬁcantly attenuated the vascular wall hyper-
plastic response and improved IR outcome. The ﬁndings suggest plasticity in the body’s response to these vascular surgical
injuries that can be manipulated by novel yet practical preoperative dietary interventions. (J Vasc Surg 2016;63:500-9.)
Clinical Relevance: In view of the high clinical complication rates in the setting of cardiovascular reconstructions (and their
pathophysiologic links to ischemia-reperfusion and intimal hyperplasia), short-term dietary restriction stands as a partic-
ularly attractive, pleiotropic strategy for this population to enhance patient outcomes. Whereas employment of rodent
models will be useful in reﬁning our understanding of the nutritional basis of protection and underlying molecular mech-
anisms, inevitablymulticenter randomized clinical trialswill be required todetermine efﬁcacy of such approaches in humans.
Contemporary surgical treatments for occlusive arterial
disease include endarterectomies and bypasses. These inter-
ventions carry high risk of complications during the
periprocedural period, including ischemia-reperfusion (IR)
injury. Furthermore, surgical treatments for occlusive arterial
disease suffer from high failure rates in the longer term
because of reocclusive vascular wall adaptations largely
from cell proliferation-driven intimal hyperplasia (IH).1
Although IR and IH occur on different time scales with
respect to the surgical procedure and by different molecular
mechanisms, they collectively lead to considerable morbidity
and mortality, with mitigation strategies currently largely
lacking for both.
Chronic overnutrition on calorie-dense foods and die-
tary restriction without malnutrition (DR, otherwise
known as calorie restriction) have opposite effects on risk
for cardiovascular disease and obesity-associated metabolic
dysfunction.2 Overnutrition is an accepted risk factor for
cardiovascular disease as well as for surgical complications.3
DR is best known for extending longevity and reducing
age-associated morbidity in multiple species,4,5 but it also
mitigates IR to heart and brain in animal models.6-8 The
wide-ranging beneﬁts of DR in experimental organisms
have led to prospective clinical trials to evaluate potential
beneﬁts in humans, including the recently completed
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Comprehensive Assessment of Long-term Effects of
Reducing Intake of Energy (CALERIE) trial.9 This phase
2 study used intensive dietary and behavioral interventions
in a highly motivated nonobese population to seek 25%
restriction for 2 years as measured by doubly labeled water
technique. However, sustained adherence to such regimens
in the general population is poor, probably because of a
combination of behavioral, physiologic, psychological,
and environmental (such as food availability) factors.10
Recently, we and others have shown that beneﬁts of
DR against surgical stress accrue rapidlydwithin days to
weeksdin rodents and humans.11-19 These studies demon-
strate plasticity in the mammalian response to surgical stress
with beneﬁcial outcomes readily achievable by brief preop-
erative dietary manipulations. However, it is not currently
known if such beneﬁts extend to other models of vascular
injury, such as IH. Similarly, whereas long-term overnutri-
tion is a demonstrated risk factor for surgery, it not known
how long it takes for the detrimental effects of high-fat diet
(HFD) feeding on surgical outcome to occur.
Here, to provide insight into the overall plasticity of the
mammalian response to acute changes in nutrition on resis-
tance to surgical stress, we tested the effects of 2 weeks of
overnutrition with or without brief periods of preoperative
DR on the response to two common forms of vascular sur-
gical trauma, IH and IR.
METHODS
Mice. Male F1 hybrids derived from C57BL/6 and
DBA2 strains purchased at the age of 6 weeks (Jackson
Laboratories, Bar Harbor, Me) and previously shown to
respond beneﬁcially to protein restriction19 were used in
both IR and IH models; C57BL6/J mice previously
shown to respond beneﬁcially to fasting17 and detrimen-
tally to long-term HFD feeding15 were used additionally in
the IH model. Animals were maintained under standard
laboratory conditions with ad libitum access to chow unless
otherwise noted. All experiments were approved by the
appropriate Institutional Animal Care and Use Committee.
Diets. In addition to unreﬁned chow pellets (PicoLab
Mouse Diet 20-5058; LabDiet, St. Louis, Mo) with 22% cal-
ories from fat, 55% from carbohydrate, and 23% from pro-
tein, three different diets composed of reﬁned ingredients
(lard and soybean oil for fat; sucrose, maltodextrin, and
corn starch for carbohydrate; hydrolyzed casein for protein)
were employed (Research Diets, New Brunswick, NJ). The
HFD D12492 consisted of 60% calories from fat, 20%
from protein, and 20% from carbohydrates and was delivered
in a soft pellet form. The control and protein-free diets were
both based on D12450BSpx and delivered in a ﬁnal 1% agar
form. The control diet consisted of 10% calories from fat,
70% from carbohydrate, and 20% from protein. The protein-
free diet consisted of 10% calories from fat and 90% from
carbohydrate and was made isocaloric to the control diet by
addition of sucrose.
IR models. Renal and hepatic IR injury was induced as
described previously.19 Brieﬂy, mice were anesthetized by
isoﬂurane inhalation (5% induction, 2% maintenance), and
body temperature was maintained on a water-circulating
heat pad. Preoperative blood glucose determinations were
performed on fresh blood with an Easy Check Diabetes
Meter Kit (Home Aide Diagnostics, Deerﬁeld Beach, Fla)
according to the manufacturer’s instructions. Ischemia was
induced after a midline abdominal incision. For renal IR,
the left renal pedicle was localized and the renal artery and
vein were occluded for 25 or 30 minutes with an atrau-
matic microvascular clamp (Roboz Surgical Instrument
Co, Gaithersburg, Md). The procedure was repeated
immediately on the right kidney. For hepatic IR, after
visualization of the liver hilum, an atraumatic clamp was
placed over the portal vein, hepatic artery, and bile duct to
the left and median hepatic lobes for 30 minutes. In this
model, 70% of the liver tissue becomes ischemic, and blood
outﬂow from the small intestine is preserved through the
right anterior and caudate liver lobes. After inspection for
signs of ischemia (purple color in kidney, pale color in
liver), the wound was covered with phosphate-buffered
saline-soaked gauze and the animal placed under a heat-
ing pad and an aluminum foil blanket to maintain body
temperature. After release of the clamp, restoration of
blood ﬂow was conﬁrmed by return of the ischemic organ
to normal color. Animals were returned to clean cages and
allowed ad libitum access to a complete diet after surgery.
Blood samples were collected from a superﬁcial nick to the
tail or terminally through the renal artery for analysis of
ischemic injury over a time course based on organ-speciﬁc
end points determined previously.17,19 Functional impair-
ment was assessed in the renal IR model by measurement
of serum urea or creatinine levels daily for up to 3 days after
IR with QuantiChrom assay kits (BioAssay Systems,
Hayward, Calif). Kidney damage was assessed by blind his-
tologic analysis of corticomedullary tubular necrosis from
serial 3-mm sections taken 100 mm apart from formalin-
ﬁxed, parafﬁn-embedded kidney samples stained with
hematoxylin and eosin (HE). Injury was assessed in the
hepatic IR model by measurement of levels of liver enzymes
alanine transaminase (ALT) and aspartate transaminase (AST)
in the serum for up to 24 hours after reperfusion by kinetic
analysis in a 96-well formatwith aBioTek IImicroplate reader
(BioTek, Winooski, Vt) and by histology from 3-mm sections
from formalin-ﬁxed, parafﬁn-embedded samples stained with
HE. Hepatic injury was scored in HE-stained sections in a
blind fashion by counting of the percentage necrotic area per
ﬁeld in 10 ﬁelds/section. All images were taken under the
same magniﬁcation and exposure settings.
IH model. IH was induced by our validated model of
low ﬂow in the mouse carotid artery.20 Brieﬂy, the left
common carotid artery was exposed and visualized through
a midline incision with use of a surgical microscope (OPMI-
MD; Carl Zeiss, Germany). A focal stenosis was created
approximately 1 mm proximal to the common carotid
bifurcation by tying of a 9-0 nylon suture around both the
artery and a blunt 35-gauge needle (external diameter of
0.14 mm, item No. NF 35 BL; World Precision In-
struments, Inc, Sarasota, Fla). After removal of the needle,
the vessel diameter was reduced by about 78%. Our previous
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studies have shown that this diameter reduction will produce
a reduction in luminal ﬂow of about 85%.20 Carotid
thrombosis was not noted in this model under normal chow
conditions. After creation of the focal stenosis, the surgical
incision was closed, and mice were allowed to recover; all
mice were returned to ad libitum feeding on a complete diet
after surgery. One month later, arterial morphology was
assessed on Masson trichrome-stained 6-mm sections up to
3mmdownstreamof the stenosis as previously described.20-23
Digitized images were taken and analyzed with a computer-
ized imaging system (Zeiss Axio A1 microscope, High Reso-
lution Camera, Vision 4.7 software for Windows; Carl
Zeiss). Morphometric analysis was performed by tracing the
interior surface of the lumen, the internal elastic lamina
Fig 1. Inﬂuence of short-term high-fat diet (HFD) on outcome of ischemia-reperfusion (IR) injury. Two-week
exposure to HFD did not worsen outcome of IR injury in male B6D2F1 mice. A, Experimental design. Mice were
fed a low-fat control diet (C) or HFD for 2 weeks before onset of renal or hepatic IR injury and then returned to the
low-fat control diet after surgery. Blood was drawn before injury or at the indicated times after reperfusion and analyzed
for markers of renal function (urea) or liver injury (alanine transaminase, ALT) as indicated. B,Outcome of 25 minutes
of bilateral renal IR injury as measured by changes in urea in serum before (time ¼ 0) and on the indicated day after IR
injury (n ¼ 5/group). C, Outcome of 30 minutes of hepatic IR injury as measured by the amount of the liver enzyme
ALT in serum before (time ¼ 0) and at the indicated time after reperfusion (n ¼ 5/group).
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Fig 2. Inﬂuence of short-term protein-free (PF) dietary restriction (DR) after high-fat diet (HFD) on outcome of
ischemia-reperfusion (IR) injury. A, Experimental design. Male B6D2F1 mice were fed HFD for 2 weeks followed by
1 week of low-fat control (C) vs low-fat PF diet before onset of renal or hepatic IR injury. All animals were returned to
the low-fat control diet after surgery. B, Outcome of 30 minutes of bilateral renal IR injury as measured by changes in
serum urea and creatinine on the indicated day after injury; n ¼ 5/group. The percentage of tubular epithelial cell
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(IEL), and the external elastic lamina (EEL). Areas were
calculated from the measured circumference assuming a
circular structure under in vivo conditions: luminal, intimal
(¼ IEL " luminal), and medial (¼ EEL " IEL).
Statistical analyses. All data are expressed as means 6
standard error of the mean. One- and two-way analysis of
variance followed by Holm-Sidak correction for all pairwise
multiple comparison procedures and unpaired two-tailed
Student t-test were performed with SigmaPlot v11.0
(Systat Software Inc, San Jose, Calif) or GraphPad Prism.
RESULTS
Short-term exposure to HFD does not signiﬁcantly
affect outcome of renal or hepatic IR injury. Long-term
exposure to HFD results in increased adiposity, systemic
inﬂammation, and metabolic derangements. We tested
the ability of short-term exposure to HFD to worsen
outcome against IR injury in kidney and liver. To this end,
6-week old F1 hybrid B6D2F1 males were given ad libitum
access to a reﬁned diet composed of 60% calories from fat
(HFD) or a control diet with 10% calories from fat (control
chow; Fig 1, A). Animals consumed less of the energy-
dense HFD but equal numbers of calories as animals on
the control chow, gained more weight, and had a signiﬁ-
cantly higher percentage body fat than animals on control
chow (Supplementary Fig 1, online only).
After 2 weeks on HFD or control chow, half of the
animals in each diet group were subject to renal IR and
the other half to hepatic IR. Serum drawn on days 1, 2,
and 3 after reperfusion (renal) or 3 and 24 hours after
reperfusion (hepatic) was used to monitor organ damage
and dysfunction.
Contrary to our initial hypothesis, there were no signif-
icant differences between HFD and control chow groups in
the damage suffered from 25 minutes of renal ischemia fol-
lowed by reperfusion (Fig 1, B). Similar results were seen
for hepatic IR injury with respect to release of ALT and
AST, markers of liver injury, in the serum (Fig 1, C;
Supplementary Fig 1, online only). We conclude that
although long-term HFD can worsen outcome of IR
injury, it does not do so in the short time of 2 weeks in
this relatively healthy hybrid strain of mice.
Short-term protein-free DR improves outcome of
renal and hepatic IR after HFD. We next tested the abil-
ity of short-term DR, which can lend protection against
ischemic injury in as little as 6 days,19 to protect against
ischemic injury to kidneys or liver within 1 week immedi-
ately before surgery. Because protein/essential amino acid
restriction and overall calorie restriction may each
contribute to DR beneﬁts,19,24 we employed a DR regimen
combining both protein and energy restriction by giving
mice limited access to a protein-free diet.
Mice were exposed to HFD for 2 weeks as in the pre-
vious arm of the experiment and then fed either a control
or protein-free diet for 1 week before induction of renal
or hepatic IR (Fig 2, A). Animals on the protein-free diet
consumed signiﬁcantly fewer calories than animals on the
control diet during the ﬁrst 6 days after the switch from
HFD. The protein-free group also had reduced blood
glucose levels and reduced body weights relative to animals
switched back to the control diet (Supplementary Fig 2,
online only).
After preconditioning, animals were subject to either
renal or hepatic IR. As we were predicting improvement
with dietary preconditioning, we lengthened the period
of renal ischemia from 25 to 30 minutes in this study
arm to increase the magnitude of damage against which
to measure protection. After bilateral renal IR, animals pre-
conditioned on a protein-free diet displayed better preser-
vation of renal function than those switched back to the
control diet before surgery as measured by renal functional
markers urea and creatinine in the serum (Fig 2, B; n ¼ 5/
group). Histologic analysis conﬁrmed that changes in
serum markers represented damage to the corticomedullary
junction typical of this injury and that tubular necrosis was
signiﬁcantly reduced by the protein-free diet before surgery
(Fig 2, B; n ¼ 3/group).
Mice on the protein-free diet subjected to hepatic IR
were also protected, displaying reduced ALT and AST 3
and 24 hours after injury (Fig 2, C; n ¼ 15/group). This
was conﬁrmed by histologic analysis of hemorrhagic necro-
sis, with signiﬁcant improvement in the preoperative
protein-free group (Fig 2, C; n ¼ 6/group).
We conclude that plasticity in the response to dietary
modulation of ischemic injury in young adult male mice al-
lows improvement in outcomes by short-term DR but not
worsening of outcomes by short-term exposure to HFD.
Fasting protects against IH after HFD or normal
chow. We next asked if short-term preoperative dietary
interventions could modulate a fundamentally different
outcome, IH, on hemodynamic changes in blood ﬂow in a
model of common carotid focal stenosis. Previously, we
necrosis in the cortex and at the cortical-medullary junction in serial sections 100 mm apart from each kidney
is quantitated at right; n ¼ 3/group. Below, Representative images of hematoxylin and eosin (HE)-stained kidney
sections from the indicated groups harvested 3 days after injury. The arrows point to tubular structures in which
cell death and disruption of normal structure are evident. G, Glomerulus; scale bar ¼ 20 mm. C, Outcome of
30 minutes of hepatic IR injury as measured by the amount of the liver enzymes alanine transaminase (ALT) and
aspartate transaminase (AST) in serum 3 and 24 hours after reperfusion; n ¼ 15/group. The average percentage
of necrosis in 10 microscopic ﬁelds per animal is quantitated at right; n ¼ 6/group. The asterisks indicate the signif-
icance of the difference between groups at the indicated time point according to an unpaired, two-tailed Student t-test;
*P < .05, ***P < .001. Below, Representative images of HE-stained liver sections from the indicated group harvested
24 hours after injury. The asterisk indicates the central vein associated with portal triads; eosinophilic regions are
characteristic of cell necrosis. Scale bar ¼ 100 mm.
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Fig 3. Inﬂuence of short-term high-fat diet (HFD) or fasting on intimal hyperplasia (IH). A, Experimental design. Male
C57BL/6Jmicewereexposed for2weeks toHFDor low-fat control diet (C) for the indicatedperiodwithorwithouta3-day
water-only fast immediately before focal stenosis. All mice were then returned to the control diet. Four weeks later, IH was
measured by histology. B andC, Intimal area, medial area, and intimal/medial area ratio at the indicated distance from the
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found that long-term HFD feeding before and 4 weeks
after focal stenosis exacerbates IH in C57Bl/6 mice by this
model.20
Here, we tested whether 2 weeks of HFD exposure
immediately before induction of focal stenosis had an effect
on development of IH and if this could be modulated by
DR. The ﬁrst DR regimen that we tested was 3 days of
water-only fasting, which we previously showed to protect
against both renal and hepatic IR in male C57Bl/6 mice.17
To test the effects of HFD with or without fasting on
development of IH, 6-week-old male C57Bl/6 mice
were exposed to HFD or control chow for 11 days and
then maintained for 3 more days, on the same diet or sub-
ject to 3 days of water-only fast (Fig 3, A; n ¼ 10/group).
Immediately after focal stenosis, all mice were given ad libi-
tum access to control chow for 4 weeks, and then the
amount of IH was determined by histology as previously
reported.20
Similar to IR injury, a 2-week preoperative HFD did
not signiﬁcantly affect the intimal hyperplastic response.
However, 3 days of fasting immediately before the proce-
dure signiﬁcantly reduced IH whether the mice were previ-
ously on the HFD (P < .001) or a control diet (P ¼ .002)
(Fig 3, B-D). In contrast, medial areas proximal to the focal
stenosis were not signiﬁcantly different between diet
groups; as a result, intimal/medial ratios resembled intimal
areas (Fig 3, B and C).
Short-term protein-free DR attenuates IH. Because
extended periods of fasting may not be feasible in clinical
practice, we also tested the ability of protein-free DR to
modulate IH (Fig 4, A). For these experiments, we used
B6D2F1 hybrid males shown to respond beneﬁcially to
protein restriction to rule out any potential artifacts asso-
ciated with particular inbred lines such as C57Bl/6J. We
found that 1 week of protein-free DR before focal stenosis
signiﬁcantly reduced IH at 28 days (Fig 4, B; n ¼ 10/
group). In contrast, medial areas proximal to the focal
stenosis were not signiﬁcantly different between diet
groups; as a result, intimal/medial ratios resembled intimal
areas (Fig 4, B).
We conclude that whereas short-term HFD exposure
did not worsen surgical outcome, two different short-
term dietary regimens (3 days of water-only fasting and
1 week of protein-free DR) protected from IR to kidney
and liver and reduced the intimal hyperplastic response to
hemodynamic perturbation on focal stenosis.
DISCUSSION
Although long-term dietary habits such as DR or
overnutrition can have beneﬁcial or detrimental effects,
respectively, on surgical outcome in experimental models,
the potential of acute changes in food intake in the days
leading up to a planned surgical procedure to alter surgi-
cal outcome has not been rigorously tested. On the basis
of emerging data on the ability of mammalian metabolism
and physiology to respond rapidly to changes in dietary
intake, we hypothesized that short-term overnutrition
would worsen surgical outcomes and that short-term
DR immediately before surgery would reverse these nega-
tive effects and improve outcomes. Furthermore, we hy-
pothesized that these effects would not be speciﬁc to IR
but generally applicable to different vascular surgical out-
comes, including development of IH. Whereas we found
no detrimental effects of short-term (2 weeks) HFD,
short-term DR markedly improved outcomes after two
distinct vascular surgery injuries, IR and hemodynamically
driven IH.
Long-term overnutrition resulting in obesity and type
2 diabetes is a risk factor for surgical complications. Excess
adiposity makes surgical procedures technically more chal-
lenging and is also associated with reduced insulin sensi-
tivity and increased systemic inﬂammation.25,26 Here we
examined a different clinical scenario, short-term overnutri-
tion, but found no detrimental effect on IR or focal
stenosiserelated surgical outcomes. Although 2 weeks of
HFD feeding signiﬁcantly increased adiposity, it did not in-
crease blood glucose levels. Hyperglycemia typically takes a
few weeks longer to develop in HFD-fed mice and corre-
lates with a reduction in insulin sensitivity and an increase
in systemic low-grade inﬂammation. Thus, one can specu-
late that the detrimental effects of long-term overnutrition
on surgery are likely to stem from perturbations in these
metabolic parameters rather than directly from the absolute
amount of adipose tissue. This position is supported by the
observation that obesity itself often does not correlate with
surgical outcome27; indeed, increased adiposity itself is not
mutually exclusive of a healthy metabolic proﬁle.28
Long-term DR is known to improve a variety of meta-
bolic end points as well as acute stress resistance but is
impractical in the clinical setting. Whereas longevity ben-
eﬁts in nonhuman primates on DR have been equivocal,
beneﬁts on health span (protection from age-related can-
cer, diabetes, and cardiovascular disease) are clear.5,29,30
Importantly, studies suggest that humans respond to
DR in beneﬁcial ways with respect to metabolic ﬁtness
(including improved glucose homeostasis, lipid proﬁles,
and cardiovascular performance).31,32
Although short-term DR has recently emerged as a
powerful mediator of beneﬁcial adaptive stress responses
including protection from surgical IR,14 the ability of
short-term DR to affect IH occurring as a result of focal
stenosis is remarkable, considering that the dietary inter-
vention occurred 4 weeks before outcome assessment.
Limited data on the half-life of the DR beneﬁts suggest
that such beneﬁts are short-lived after the return to ad
focal stenosis (n ¼ 10 mice/per group). P value indicates the signiﬁcance of the difference between intimal areas of the
indicated groups according to a two-way analysis of variance.Note the absence of differences betweenHFDand control diets
alone on intimal area.D,RepresentativeMasson trichrome-stained images under each dietary condition taken at 0.6- to 3.0-
mm distance proximal to a focal stenosis. The yellow line depicts internal elastic lamina. Scale bars ¼ 50 mm.
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Fig 4. Inﬂuence of short-term protein-free (PF) dietary restriction (DR) after high-fat diet (HFD) on intimal hy-
perplasia (IH). A, Experimental design. After 2 weeks on HFD, male B6D2F1 animals were exposed for 1 week to a
control diet with 18% calories from protein (C, n ¼ 10) or an isocaloric diet lacking protein (PF, n ¼ 10) before focal
stenosis. All mice were then returned to control chow. Four weeks later, IH was measured by histology. B, Intimal area,
medial area, and intimal/medial area ratio at the indicated distance from the focal stenosis. P value indicates the sig-
niﬁcance of the difference between intimal areas of the indicated groups according to a two-way analysis of variance.
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libitum feeding on a complete diet. For example, the ben-
eﬁts of 3 days of fasting on survival in the renal ischemia
model last approximately 3 days.17 Similarly, the beneﬁts
of long-term DR on gene expression proﬁles and longevity
are lost rapidly, within days to weeks.33 Most likely, the
beneﬁts of short-term DR against IH reﬂect modulation
of events occurring shortly after the change in hemody-
namic ﬂow that further affect later remodeling, rather
than the change in ﬂow itself, which remains perturbed
because of the focal stenosis throughout the experimental
period.
This study has a number of limitations. Because the na-
ture of the injuries encumbered by IR and focal stenosis
occur on very different time scales and with different causes,
we did not set out a priori to deﬁne underlying mechanisms
of protection. Thus, one limitation of this study is that mo-
lecular mechanisms of protection against IR and IH, and
whether they are shared, are not delineated. Furthermore,
in the case of IR, it is unknown if preconditioning affects
reperfusion injury to other organs, such as lung, outside of
the ischemic organ. A further limitation of this study is the
use of two different genetic strains, the inbred C57BL/6
strain and the hybrid B6D2F1 strain, preventing direct com-
parison of the result of fasting and protein restriction in the
IH model. Whereas such direct within-strain comparisons
are important in future studies designed to elucidate underly-
ing mechanisms, here they had the advantage of reducing the
risk of identifying strain-speciﬁc, diet-speciﬁc, or interaction-
speciﬁc effects with less likelihood of translating to humans.
What little is known about the mechanistic basis of pro-
tection by either long-term or short-term DR regimens
points to dampening of local or systemic inﬂammation and
upregulation of cell/organ autonomous stress resistance
mechanisms, including oxidative stress resistance.6,8,15,17
Teleologically, one can speculate that evolutionary selection
under the intense pressure of nutrient/energy restriction
yielded molecular pathways to maximize stress resistance un-
der starvation conditions.30 The amino acid starvation
response activated by the amino acid sensor and eIF2a
(eukaryotic translation initiation factor 2a) kinase GCN2
(general control nonderepressible 2) may be one such
pathway, implicating dietary protein sensing and transla-
tional control in stress protection.19 Interestingly, precondi-
tioning regimens leading to equivalent functional protection
against renal ischemic injury, including 3 days of water-only
fasting and 4 weeks of 30% DR, have divergent effects on
kidney gene expression with little overlap, consistent with
the possibility of multiple underlying mechanisms of protec-
tion.17 Further research in experimental models will be
required to deﬁne such molecular effectors, leading, it is
hoped, to the identiﬁcation of clinically relevant targets.
Despite the risk posed by chronic overnutrition and the
potential beneﬁcial effects of short-term protein or calorie
restriction before surgery, preoperative DR is rarely consid-
ered before surgery except in speciﬁc instances, for
example, in bariatric surgery in which the immediate goal
is to lose weight to facilitate the operation itself. The
only universal dietary recommendation before surgery is
overnight fasting to avoid aspiration of regurgitated solids
under anesthesia. In some cases, overnight fasting has
been replaced by carbohydrate energy-dense drinks up to
a few hours before surgery to reduce postoperative thirst,
hunger (well-being), and insulin resistance.34 Data pre-
sented here and elsewhere19,35 suggest that protein restric-
tion, rather than calorie restriction, is a major determinant
of short-term DR beneﬁts. By extension, preoperative car-
bohydrate loading may not be mutually exclusive with
short-term DR beneﬁts, whether in the form of water-
only fasting or brief protein restriction.
CONCLUSIONS
Whereas short-term overnutrition leading to increased
adiposity had no effect on outcome of IR or IH examined
here, protein/energy restriction imparted signiﬁcant beneﬁts
in these models, suggesting clinically relevant strategies to
enhance the mammalian response to injury. Clinical human
trials in this arena have documented feasibility and safety of
preoperative dietary interventions, including 2 weeks of
very low calorie diets or 3 days of reduced food intake fol-
lowed by 24 hours of water-only fasting immediately before
surgery.11,36 In view of the high clinical complication rates in
the setting of cardiovascular reconstructions (and their path-
ophysiologic links to IR and IH), short-term DR now stands
as a particularly attractive, pleiotropic strategy for this popu-
lation to enhance patient outcomes.37 Whereas employment
of rodent models will be useful in reﬁning our understanding
of the nutritional basis of protection, including duration and
severity of restriction, and underlying molecular mechanisms,
inevitably multicenter randomized clinical trials will be
required to determine safety and efﬁcacy of such approaches
in humans.
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Supplementary Fig 1 (online only). Characteristics of animals on short-term exposure to high-fat diet (HFD) vs
control low-fat diet (C). A, Food intake during a 2-week period (n ¼ 10/group) presented as average grams of
food eaten per gram of mouse. B, Calorie intake corrected for energy density of diet. C, Weight gain expressed as
a percentage of starting weight. D, Adiposity expressed as a percentage of total body weight. E, Blood glucose in the
fed state before harvest. F, Serum levels of creatinine at the indicated time after renal reperfusion (n ¼ 5/group). G,
Serum levels of aspartate transaminase (AST) at the indicated time after hepatic reperfusion (n ¼ 5/group). The
asterisks indicate the signiﬁcance of the difference between groups according to an unpaired, two-tailed Student
t-test; **P < .01, ***P < .001. IR, Ischemia-reperfusion.
Supplementary Fig 2 (online only). Characteristics of animals on short-term protein-free (PF) dietary restriction
(DR) after high-fat diet (HFD) exposure for 2 weeks. A,Daily food intake for 1 week before ischemia-reperfusion (IR)
after the switch from HFD to the indicated control (C) or PF diet; n ¼ 4 cages/group (20 mice/group). B, Total food
intake 1 week before IR. C, DR calculated as a percentage of average food eaten by animals on the control diet. D, E,
Blood glucose (D) and body weight (E) after 1 week on C or PF diet as indicated. The asterisks indicate the signiﬁcance
of the difference between groups according to an unpaired, two-tailed Student t-test; ***P < .001.
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